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Intracellular recordings were made from presumptive serotonergic neurones in the in
vitro slice preparation of the rat dorsal raphe nucleus confirming previous
observations that the membrane hyperpolarisation evoked by bath-application of 5-
HT is associated with a decrease in input resistance. The reversal level was
approximately -90 mV, a value close to that predicted for a potassium-mediated
event. The 5-HT-evoked hyperpolarisation was blocked by WAY-100635, a result
consistent with the response being mediated by the 5-HTia receptor subtype. WAY-
100635 alone was found to have no effect on membrane potential or input resistance
in this study and in this sense is silent. In addition, WAY-100635 did not block the
ai-adrenoreceptor-mediated membrane depolarisation and increase in input resistance
that follows bath-application of noradrenaline and phenylephrine.
The blockade of the 5-HTiA-evoked hyperpolarisation with WAY-100635 revealed a
5-HT-evoked depolarisation associated with an increase in cell excitability. In the
majority of cells tested there was no significant change in input resistance and I/V
analysis failed to show a point of intersection in the range -120 mV to -60 mV.
However, some cells did show a change in input resistance at approximately -50 mV.
The depolarising response was observed in the presence ofTTX showing it to be
independent of propagated action potentials and thus unlikely to involve a
transynaptic event.
In the presence ofWAY-100635, the 5-HT2 agonist DOI, evoked a depolarisation
with similar properties to that evoked by 5-HT. The more selective 5-HT2B/2C agonist
mCPP and the 5-HTib agonist CP 93129 had no effect in WAY-100635 treated cells.
The broad spectrum 5-HT receptor antagonist methysergide blocked the 5-HT-evoked
depolarisation in 6 of 8 cells as well as the depolarising action of DOI. The 5-HT2
antagonist ketanserin completely blocked the 5-HT-evoked depolarisation, as did the
5-HT2A selective antagonist MDL 100, 907. The 5-HT2C selective antagonist, SB
200646, partially blocked the response. The 5-HTia/ib antagonist pindolol did not
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block the depolarisation. These findings suggest that a 5-HT2a receptor subtype
mediates the 5-HT-evoked depolarisation.
5-HT receptor mediated modulation of the action potential and the
afterhyperpolarisation (AHP) were also investigated. Action potentials were
overshooting, of long duration and sensitive to block by TTX. The repolarising phase
of the action potential has a shoulder thought to be due to the activation of voltage-
sensitive calcium channels. Bath-application of TEA resulted in an action potential
of a much longer duration. Single action potentials were followed by an AHP that
reversed at approximately -90 mV, consistent with a potassium-mediated event. Two
components of the AHP were identified. TEA blocked a fast component that appears
as a continuation of the repolarising phase of the action potential, while apamin
blocked a slower component that normally decayed over 150 ms. These results
indicate the involvement of TEA-sensitive potassium channels in the early
component of the AHP and apamin-sensitive SK channels in the slower, late phase.
Firing frequency and adaptation were also investigated. In control cells a long
depolarising pulse generated a train of regularly spaced action potentials through the
whole of the pulse with no apparent accommodation. Following bath-application of
apamin a typical cell showed an increase in its firing rate and in addition displayed
prominent accommodation. Bath-application of TEA also increased firing frequency
and resulted in accommodation.
Bath-application of 5-HT led to a reduction in the shoulder of the action potential
and a decrease in the duration of the AHP. Additionally, an increase in spike
frequency was observed in response to a long depolarising current pulse. It has been
reported that 5-HTia receptors mediate an inhibition of voltage-sensitive calcium
channels. This supports the theory that 5-HTia receptor activation inhibits the influx
of calcium during the action potential thereby leading to the inhibition of the calcium
dependent phase of the AHP. In agreement with this WAY-10063 5 blocked the 5-
HT-evoked increase in spike frequency.
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In summary, 5-HT has an important role in the regulation of cell excitation in the
DRN. Excitability is predominantly regulated by a 5-htia-mediated
hyperpolarisation, which inhibits cell firing, and the 5-HT1A-mediated inhibition of
voltage-sensitive calcium channels, which have a role in the regulation of spike
width and the AHP. Significantly this study has shown that the hyperpolarisation is
blocked by the 5-HTia antagonist WAY-100635. Cell excitability is also regulated
by a 5-HT-evoked depolarisation. This is mediated by the 5-HT2A receptor indicating
a direct functional role for non-5-HTiA receptor subtypes in the DRN. The absence of
any significant resistance change associated with this depolarisation could indicate
that in the DRN 5-HT2A receptors either modulate separate potassium and sodium
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Serotonin or 5-hydroxytryptamine (5-HT) is an important chemical messenger in the
mammalian brain. It has proven to be involved in a number of different roles in the
central nervous system (CNS) and continues to hold important functional secrets. It
has been linked to many physiological and behavioural functions including
aggression, appetite, cognition, endocrine function, motor function and sleep. Many
drugs are thought to act through serotonergic mechanisms, including selective
serotonin uptake inhibitors (SSRI's) used to treat depression and atypical
antipsychotics. This multitude of different functions is possible due to the molecular
diversity of the serotonin receptor and the anatomy of the serotonergic system.
5-HT production is centred in the raphe nuclei, which are clusters of cell bodies
found in the brainstem. From the raphe nuclei projections are sent down the spinal
column and up to high centres within the brain, such as the hippocampus and cortex.
This makes the methods of control of the neuronal firing and so 5-HT release
important mechanisms for study. The dorsal raphe nucleus (DRN) region generally
has a constant tonic firing pattern and each action potential is accompanied by the
release of 5-HT. The rate of cell firing can shift up or down depending upon the
chemical environment of the cell that varies with different behavioural states. For
example, during rapid eye movement (REM) sleep the DRN region is quiet.
Receptor diversity allows 5-HT to have both excitatory and inhibitory actions even
on the same brain region and same type of cell. One early example of this was found
during intracellular studies of cortical pyramidal cells where 5-HT can be inhibitory
via binding to one receptor subtype and excitatory via binding to another receptor
subtype. This type of contradictory message has been found in a number of brain
regions including the pyramidal cells of the hippocampus and the dorsal root
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ganglion. Thus serotonin can act to both increase and decrease excitability in a single
cell within a network of cells. Serotonin appears to have a role in modulating cell
excitability throughout the CNS and in this way co-ordinates the activity of neurones
and networks within a given behavioural state. In the DRN 5-HT predominantly
causes a membrane hyperpolarisation via the 5-HT1A receptor subtype. Investigations
into a functional role for non-5-HTIA receptor subtypes have been hindered by the
lack of silent 5-HTIA antagonists. The use of the newly developed compound WAY-
100635, a selective 5-HT1A antagonist, allows the search for a multiplicity of actions
for 5-HT in the DRN.
Research Aims
Since it was first realised that the DRN was the largest site of serotonin producing
cells in the CNS the physiological importance of the DRN has been investigated
using a number of different techniques. Investigations using pharmacological,
biophysical and molecular techniques have led to a greater understanding of the role
of the DRN in the CNS. Biophysical investigations were limited at first due to the
problems of electrode impalement stability. The in vivo preparation (Aghajanian and
VanderMaelen 1982a) has largely been restricted to extracellullar investigations of
the pharmacological alterations of unit activity of neurones within the DRN
(Aghajanian et al 1970; Bramwell and Goyne 1973; Mosko and Jacobs 1977). With
the introduction of the in vitro slice preparation (Li and Mcllwain 1957) it became
possible to study specific brain regions using both extracellular and intracellular
electrodes. Some brain regions were found to lend themselves easily to this
technique, but it was not until Crunelli et al (1983) that the first stable intracellular
recordings were obtained from neurones in the DRN slice. The in vitro DRN slice
preparation has now become a useful tool for studying the properties of neurones in
this nucleus.
The actions of 5-HT in the DRN are mediated by the 5-HT1A receptor so use of the
silent 5-HT1A antagonist WAY-100635 allows the opportunity to more completely
study the actions of 5-HT in the DRN by selective blockade of the 5-HT,A receptor.
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These 5-HT-mediated actions include the effects of 5-HT on the action potential in
the DRN and any functional role for non-5-HT1A receptor mediated 5-HT effects. This
programme of research set out to investigate the following issues:
1) The characterisation of the 5-HTIA-evoked membrane hyperpolarisation in vitro
in the hippocampal and DRN brain slice using intracellular electrophysiology.
2) An investigation into the effects, if any, of the 5-HT1A antagonist WAY-100635
on the properties of hippocampal and DRN neurones.
3) The study of the mechanisms and pharmacology of non-5-HTIA mediated actions
of 5-HT in neurones of the DRN following pre-application ofWAY-100635.
Neuronal excitability in the DRN is regulated by a number of mechanisms including
the pacemaker potential, which in turn is made up of a number of different
conductances, and the relative position of the membrane potential to the firing
threshold. 5-HT is known to inhibit neuronal excitability indirectly via the 5-HTIA-
evoked hyperpolarisation. A more direct role for the regulation of firing by 5-HT
should also be investigated. For instance, does 5-HT released by a neurone with a
single action potential have a local feedback effect on that neurone's firing pattern.
This was investigated with the following studies:
1) The characterisation of the conductances involved in the pacemaker potential of
the DRN neurone with particular attention paid to spike width, and the AHP.
2) The observation of the actions of 5-HT on the spike width, AHP and the overall
firing pattern ofDRN neurones.
This chapter reviews the DRN and its anatomy and physiology. The introduction
then goes on to discuss the role of serotonin in the brain and its discovery and
production. Particular attention is paid to the actions of 5-HT released within the
DRN and there is reference to the 5-HT receptor subtypes found in the DRN. Finally,
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the introduction reviews the properties and pharmacological classification of each of
the 5-HT receptor subtypes.
The Dorsal Raphe Nuclei
The DRN is one of the clusters of serotonergic cell bodies that make up the raphe
nuclei. Dahlstrom and Fuxe first reported in 1965, using histochemical techniques,
that 5-HT containing neurones were present in the CNS. Serotonergic neurones have
now been found in many brain regions and several methods have been used to
characterise these cells. Histochemical studies show the largest cluster of 5-HT cells
is found in the brainstem and midbrain. These cells can be designated as nine distinct
cell groups, B1-B9, where each cell group corresponds generally to a different area of
innervation (Figure 1.0). For example, the medullary nuclei send projections mainly
in the caudal direction, where they seem to have roles in the regulation of
nocioceptive pathways within the spinal cord and motor control (Bowker et al 1983,
1987). The present study concentrated on the serotonergic neurones of the DRN (B7).
Anatomy
The largest group of 5-HT-containing cells in the brain is found in the DRN,
however, there are also non-serotonergic neurones present in the DRN. Thanks to the
use of a number of techniques, including autoradiography (Taber-Pierce et al 1976,
Bobillier et al 1976) and immunocytochemistry (Steinbusch 1981, Steindler et al
1983) the efferent projections of the DRN have been mapped to a number of higher
brain centres. Fibres arising from the DRN have fine axons with irregularly spaced
granular or fusiform varicosities that branch frequently (Kosofsky and Molliver 1987;
Mulligen and Tork 1988). The DRN innervates areas within the midbrain and
forebrain, especially the thalamus, amygdala, cerebral cortex, septum and lateral
habenula. The DRN has also been found to innervate more caudal structures such as
the locus coeruleus and the pontine and reticular nuclei (Taber-Pierce et al 1976). It
may be that these connections regulate the reciprocal firing rates of raphe and
reticular neurones during the sleep cycle.
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Figure 1.0. Schematic illustration of the major 5-HT pathways in the rat brain.
The cell groups B1-B9 represent those described by Dahlstrom & Fuxe (1964) and
correspond to the raphe nuclei (B1 - nucleus raphe pallidus; B2 - nucleus raphe
obscurus; B3 - nucleus raphe magnus; B4 - nucleus raphe obscurus, dorso lateral
part; B5 - median raphe nucleus caudal, part; B6 - dorsal raphe nucleus, caudal part;
B7 - dorsal raphe nucleus rostral, part; B8 - caudal linear nucleus and nucleus raphe
pontis; B9 - nucleus raphe pontis and supralemniscal region). Projections form B1 -
B3 descend to innervate the spinal cord, whilst B5 - B9 innervate the forebrain.
(Adapted from Cooper et ah, The Biochemical Basis ofNeuropharmacology 1982).
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Physiology
Much of the work increasing the understanding of the physiology of the DRN has
been carried out by observing single unit activity of the brain serotonergic neurones
of conscious freely moving cats. This allows the neuronal activity of the DRN to be
followed over long periods of time, from hours to weeks, in an animal capable of
living a normal life. The raphe firing rate has been widely observed to vary with sleep
and is almost completely suppressed during REM sleep in the cat (Adrien and
Lanfumey 1986, Trulson 1985). This shows that the raphe firing is related to the state
of the organism. During periods ofwakefulness the raphe has a slow and regular
rhythmic discharge (2-10 spikes/s). The rate of discharge decreases with drowsiness
and again with each stage of progressively deeper sleep, such as slow-wave sleep and
paradoxical sleep. These observations suggest that the DRN has a role in regulating
an animal's level of general arousal. The depression of the raphe firing may be
controlled by the level of activity in the brain structures mediating CNS motor
control. REM sleep is associated with centrally induced atonia leading to a decrease
in input to the raphe from the centres for motor control and therefore a decrease in
raphe activity.
The regulation of the spontaneous firing activity of the DRN is in part down to the
intrinsic nature of the DRN neurone and in part due to the influence of transmitter
released from inside or outside the DRN. Noradrenaline release increases the activity
of the DRN via the a,-adrenoceptor (Baraban and Aghajanian 1980a). The DRN also
regulates itself via the release of 5-HT, which takes the form of auto-inhibition by
decreasing firing activity (Aghajanian and VanderMaelen 1982). Activation of the
auto-inhibition mechanism has a number of physiological and behavioural effects.
These effects include changes in locomotive behaviour (Hillegaart 1990; Higgins and
Elliot 1991), a decrease in body temperature (Higgins et al 1988; Hillegaart 1991)
and blood pressure (Connor and Higgins 1990; Valenta and Singer 1990) and an
increase in food consumption (Bendotti and Samanin 1986; Hutson et al 1986). This
implies that the DRN has more roles than simply regulating arousal. The regulation
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of the spontaneous activity is an important mechanism for study and will be
discussed further in later chapters.
Serotonin
Discovery
Serotonin was first described as a naturally occurring compound in the blood where it
was thought to be an endogenous serum factor causing vasoconstriction (Stevens and
Lee 1884; Brodie 1900). The compound was purified from serum and characterised as
5-hydroxytryptamine (5-HT) (Rapport et al 1948, Rapport 1949). Another substance,
named enteramine, was found in the enterochromaffin cells of the gut where it was
characterised as causing smooth muscle contraction (Vialli and Erspamer 1933).
When enteramine was later purified it was found to be identical to 5-HT (Erspamer
and Asero 1952).
The presence of 5-HT in the mammalian brain was established following the
development of a 5-HT sensitive bioassay (Twarog and Page 1953). This bioassay
was based on the observation that 5-HT excited the heart in some molluscs (Erspamer
and Ghiretti 1951) and takes the form of an isolated heart from Venus mercenaria.
Once 5-HT could be extracted from mammalian tissues and quantified it was realised
that 5-HT was distributed heterogeneously throughout the canine brain (Amin et al
1954) making it apparent that it may act as a chemical messenger (Woolley and Shaw
1954a).
With the elucidation of the chemical structure of 5-HT it became obvious that a
number of other compounds had structural similarities. These included alkaloids, such
as the ergot derivatives, methysergide and lysergic acid diethylamide (LSD), which
were observed in vivo to antagonise the contractile effects of 5-HT on vascular
smooth muscle (Shaw and Woolley 1953). Several of these compounds had been
observed to have actions on brain function and behaviour in man where they can
cause "mental aberrations"; these included hallucinations and a transitory change in
mental state resembling schizophrenia (Woolley and Shaw 1954a). As a consequence
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of these observations it was proposed that 5-HT may be involved in the regulation of
a normal mental state and that disruption of its actions lead to abnormal mental states
such as schizophrenia (Woolley and Shaw 1954a).
Biosynthesis
5-HT is synthesised from the precursor amino acid tryptophan by enzymatic action.
Tryptophan is found in the diet but this is largely metabolised in the gut before
reaching the bloodstream. In the first stage of the synthesis of 5-HT tryptophan is
converted to 5-hydroxytryptophan (5-HTP) by the enzyme tryptophan hydroxylase by
hydroxylation of its indole ring (Joh et al 1975). This process is found in chromaffin
cells and neurones, but not in platelets. 5-HTP is then decarboxylated by the enzyme
L-amino acid decarboxylase to give 5-HT (Clark et al 1954).
Storage and Release
Prior to release 5-HT is stored in vesicles at the nerve terminal with its specific 5-HT
binding protein (Tamir and Gershon 1979). Release into the synaptic cleft is stimulus-
evoked and mediated by calcium-dependent exocytosis (Elks et al 1979). Once
stimulated 5-HT is then rapidly removed from the synaptic cleft by an active uptake
mechanism (Shaskan and Snyder 1970) which takes the form of a Na"-dependent
transporter protein (Blakely et al 1991).
Degradation
Following uptake into the cell 5-HT is degraded by a process of oxidative
deamination resulting in an aldehyde, this is catalysed by the enzyme monoamine
oxidase (MAO) (Weissbach et al 1961) found on the outer membrane of the synaptic
terminal mitochondria (Schnaitman and Greenawalt 1968). This is followed by
oxidation to 5-hydroxyindoleacetic acid (5-HIAA) by an NAD+-sensitive aldehyde
dehydrogenase (Duncan and Sourkes 1974). 5-HIAA is then removed from the body
by excretion in the urine and is a marker for 5-HT production in the body.
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Serotonin and the DRN
To evaluate the role of 5-HT release on DRN excitability, animals were pre-treated
with the 5-HT synthesis inhibitor p-chlorophenlyalanine (p-CPA) (Koe and
Wiessman 1966). When administered alone p-CPA results in a depletion of brain 5-
HT, but does not affect the DRN firing rate (Aghajanian et al 1970). Treatment with
monoamine oxidase inhibitor's (MAOI's), such as paragyline, were also looked at.
This resulted in an increase in extracellular 5-HT and a decrease in firing in the DRN.
This suggests extracellular accumulation of 5-HT sets off a negative feedback loop on
5-HT containing cells. Pre-treatment with p-CPA prevents the inhibitory effects of
MAOI's. This suggested the theory that 5-HT release has an autoregulatory role in
DRN firing regulation.
Regulation of Firing in the DRN
Early histochemical studies showed the presence of noradrenergic inputs into the
DRN (Loizou 1969, Roizen and Jacobowitz 1976). Later studies using electron
microscopic radiography gave a more detailed picture and showed noradrenergic
inputs terminating on 5-HT cells with the formation of synaptic machinery (Baraban
and Aghajanian 1981). Baraban and Aghajanian (1980a) also found that
noradrenaline increases the firing rate of serotonergic neurones in the DRN which
could indicate that noradrenaline increases 5-HT release in the DRN.
Retrograde labelling showed that the DRN received innervation from the substantia
nigra, medial preoptic nucleus and the lateral habenula (Aghajanian and Wang 1977).
Stimulation of the substantia nigra was shown to depress the frequency ofDRN firing
activity (Stern et al 1979a). Stern et al also showed that single unit activity in the
DRN was suppressed following stimulation of the lateral habenula. Stimulation of the
lateral habenula also resulted in a reduction in the release of labelled [3H] 5-HT from
the substantia nigra and caudate nucleus. Local application of picrotoxin (a GABA
antagonist) in the DRN antagonised the inhibition of 5-HT release (Reisine et al
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1982). This was suggestive of a negative feedback loop regulating DRN firing
activity involving one or more afferent inputs.
The feedback loop was thought to be a local effect following the work of Haigler and
Aghajanian (1974). In this study they showed that the application of 5-HT and LSD
to the DRN could still cause a decrease in baseline firing rates following transection
of the brain between the diencephalon and the mesencephelon. This did not eliminate
the brainstem as a site of the feedback mechanism. Work performed with the aromatic
amino acid decarboxylase inhibitor R04-4602 did. This compound leads to the
depletion of 5-HT in the cells of the DRN. Pre-treatment with R04-4602 was found to
increase accumulation of 5-HTP in the perykarya of the DRN cell bodies and its
projections (Carlsson and Lindqvist 1970). Gallager and Aghajanian (1976) showed
that a reduction ofDRN firing was seen following L-tryptophan treatment. This led to
the idea that the local release of 5-HT in the extracellular fluid inhibited DRN firing.
Thus adding support to the observations that 5-HT and LSD could inhibit firing
following R04-4602 treatment, and that 5-HT was released following DRN
depolarisation with potassium chloride (Henry et al 1982). The most direct route for
the feedback loop was thought to be via 5-HT axon collaterals. Antidromic
stimulation of the DRN was shown to cause a period of post-stimulus inhibition in the
amygdala (Wang and Aghajanian 1977). This inhibition is still present following
transection of the frontal afferent pathways (Wang and Aghajanian 1977) and
following the destruction of noradrenergic pathways by 6-hydroxydopamine. It is
lost, however, following the destruction of 5-HT pathways by 5, 7-DHT, confirming
that local release of 5-HT suppressed DRN firing is probably due to the interaction of
the transmitter with a receptor. In the DRN the 5-HT1A receptor is now thought to act
as a somatodendritic autoreceptor, which acts to control the release of 5-HT onto
postsynaptic sites by inhibiting cell firing.
The Somatodendritic Autoreceptor
Serotonergic neurones of the DRN are inhibited by bath-application of 5-HT leading
to the 5-HTia receptor, which mediates this inhibition, being termed the
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somatodendritic autoreceptor. Activation of the somatodendritic autoreceptor was
found to trigger a number of changes in the cell including a reduction of 5-HT
synthesis and release and electrical activity (de Montigny and Blier 1992). As with all
5-HT1A receptors activation leads to an opening of K+ channels resulting in a
membrane hyperpolarisation and decrease in input resistance (Aghajanian and
Lakoski 1984). Some differences have been observed in each brain region expressing
the 5-HT1A receptor in the ability of agonists and antagonists to effect these K+
channels which could suggest the molecular organisation of the "5-HTIA-G protein-K
channel" complex might show regional differences (Corradetti et al 1996). For
example, differences in the nature of the coupled G-protein and the ratio of the
5-HT,a receptor binding protein and it corresponding G-proteins might explain why
some drugs act as full agonists in the DRN, but as partial agonists in other areas, e.g.
the hippocampus (Hamon et al 1990). The 5-HTIA receptor has been found to have
different functions in different regions of the brain. In the DRN the 5-HT,A receptor
acts as a somatodendritic autoreceptor, but is a postsynaptic receptor in the
hippocampus. There is some evidence to show that these 5-HTIA receptor types are
different. This followed from the work with pindolol and (-)-pindolol, P-adrenoceptor
antagonists with high affinity for the 5-HT)A receptor subtype. Some studies have
reported, using electrophysiological techniques, that these compounds block the
action of 5-HT at the 5-HT1A autoreceptor but have no effect at the postsynaptic 5-
HT1a receptor (Artigas et al 1996; Romero et al 1996). However, there is also much
conflicting data to suggest that pindolol shows no preference for 5-HT,A receptors and
that these different 5-HT1A receptor types are, at the pharmacologically identifiable
level, identical.
The Pacemaker Potential
DRN neurones show a repeating cycle ofmembrane potential changes that take place
during the generation of spontaneous action potentials; this is the pacemaker
potential (Burlhis and Aghajanian 1987). The pacemaker potential is made up of four
repeating stages:
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1) a rapid depolarisation and an all-or-nothing action potential;
2) the action potential repolarises and then overshoots to give a long lasting AHP of
5-20 mV that gradually returns to the resting membrane potential, taking
approximately 200 ms;
3) the AHP leads to de-inactivation of IA, which slows the return of the AHP to the
baseline membrane potential;
4) the AHP decays so the cell returns to resting membrane values. The
hyperpolarisation of the AHP de-inactivates a low threshold calcium spike (or
pre-potential), a slow depolarising potential. This leads to the activation of
sodium channels and the next action potential.
This regular firing pattern has been given the term pacemaker activity. Several
stages, each mediated by different ion channel conductances, are involved in the
generation of the pacemaker potential. Each of these stages may be mediated by
external influences such as the presence of neurotransmitter in the extracellular fluid.
The ion channel conductances involved in the pacemaker potential include:
Sodium - The membrane potential undergoes a rapid depolarisation due to the
activation of a TTX-sensitive sodium conductance. This leads to the generation of an
all-or-nothing action potential.
Calcium - A broad action potential is generated with an extended shoulder due to
the activation of a high-threshold calcium conductance (Burlhis and Aghajanian
1987) allowing the influx of calcium into the cell. This slows the repolarisation of the
cell until it is overcome by the activation of the voltage-activated potassium current.
Both the high threshold calcium channels and low threshold calcium channels are
voltage-activated. 5-HT may have a role in the regulation of the high threshold
calcium conductance through the 5-HT1A receptor.
Potassium - The cell repolarises and then overshoots the resting membrane
potential to give an AHP. This is due to the activation of calcium-activated potassium
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channels (VanderMaelen and Aghajanian 1982b; Aghajanian 1985) and regulates the
interspike interval, the greater the AHP the greater the interspike interval and the
slower the firing frequency. A third potassium conductance inhibits the cell's ability
to generate an action potential. This is the voltage-gated transient outward current, IA,
and has a role in the regulation of the interspike interval. At the end of the action
potential IA channels are inactivated, however, they have been de-inactivated by the
membrane hyperpolarisation of the AHP. As the cell depolarises towards the next
action potential the IA channels open. This IA current almost cancels the spike
stimulus current, delaying depolarisation. However, this is overcome, resulting in the
small depolarisation due to the activation of low threshold T-type calcium channels
so the cell reaches firing threshold and the generation of an action potential.
Excitation in the DRN
It is well established that the neurones of the DRN respond to exogenously applied 5-
HT by a membrane hyperpolarisation and a decrease in input resistance (Aghajanian
and VanderMaelen 1982b) and that it is mediated by the 5-HT1A autoreceptor
(Sprouse and Aghajanian 1987). Activation of this receptor leads to inhibition of cell
firing and the action of 5-HT on this site is mimicked by the action potential coded
release of endogenous 5-HT in the nucleus in vivo (Wang and Aghajanian 1977;
Yoshimura et al 1985). However, it is also known that there are a number of
receptors other than the 5-HTIA receptor found in the DRN and that throughout the
CNS a multiplicity of 5-HT-evoked actions can coexist within the same neurone.
In the DRN a membrane depolarisation follows bath-application of noradrenaline
increasing the firing rate of neurones of the DRN (Baraban and Aghajanian 1980a).
However, there are a number of examples of 5-HT-evoking a membrane
depolarisation associated with an increase in cell excitability. There are many
examples of 5-HT having both an inhibitory and excitatory action on neurones of the
same cell population. In the medial pontine reticular formation 5-HT acts on 5-HT,
and 5-HT2 receptors by evoking a membrane hyperpolarisation and depolarisation
respectively, due to opposing actions on different potassium conductances. This is
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also seen in the nucleus prepositus hypoglossi and in the cerebrocortical neurones
(Araneda and Andrade 1991; Davies et al 1987). In the hippocampus the 5-HT,A
receptor mediates the hyperpolarisation but the 5-HT-evoked depolarisation is
mediated by 5-HT4-like receptors (Andrade and Nicoll 1987, Araneda and Andrade
1991; Colino and Halliwell 1987), these effects are again due to opposing actions on
different potassium conductances.
Electrophysiology of the DRN
An early study by Aghajanian and Haigler (1974) used extracellular recording
techniques in vivo to look at firing rates in neurones of the DRN. They found DR
cells to fire with a regular rate of 0.5-2 Hz., the action potentials had a positive-
negative waveform and that firing was inhibited by administration of LSD. Later
studies by Aghajanian and VanderMaelen (1982) used intracellular recording
methods in vivo to characterise the membrane properties of the cells. The action
potentials were of a long duration with amplitudes in the range 62-80 mV and the
cells input resistances ranged from 30-70 Mfi. The action potential was followed by
a large post spike hyperpolarisation (approximately 6 mV) and this together with a
gradual interspike depolarisation was termed the "pacemaker potential", these were
thought to be regulatory factors in determining raphe spike firing pattern.
Later studies performed in vitro by Crunelli et al (1983) made intracellular
recordings showing a spontaneous rhythmic pattern made up of single action
potentials occurring at 0.25-5 Hz. The action potential was followed by a long lasting
AHP with the input resistance in the range 100-320 MQ, higher than in vivo. Trulson
et al (1982) showed that the raphe cell maintained its own rhythmic firing pattern
indicating that the DR cells had an intrinsic pacemaker activity.
Serotonergic neurones in the DRN hyperpolarise following exposure to 5-HT due to
binding with the 5-HTIA receptor. This is accompanied by a decrease in cell input
resistance and results in a decrease in cell firing and 5-HT release (Aghajanian and
VanderMaelen 1982). This is due to the opening of potassium channels in the cell
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membrane (Aghajanian and Lakoski 1984) which are inwardly rectifying (Williams et
al 1988). Similar findings have been observed in the acutely isolated (Penington et al
1993b) and microcultured (Johnson 1994) DRN neurones, which also shows that
autoreceptor inhibition is independent of any input in the DRN. These effects are
mimicked by the 5-HT,A agonists 8-OH-DPAT and ipsapirone where neurones also
hyperpolarise and show a decrease in input resistance indicating the effect is due to
binding with the 5-HT)A receptor (Sprouse and Aghajanian 1987).
The 5-HT1a receptor is also coupled to calcium channels. Whole cell recordings in
acutely isolated DRN neurones have shown that 5-HT decreases high-threshold
calcium currents (HVA) and that this is mimicked by 8-OH-DPAT (Penington and
Kelly 1990). This calcium current is insensitive to L-type channel blockers but is
partially sensitive to ru-conotoxin, an N-type channel blocker (Penington et al 1991).
5-HT Receptors in the DRN
The 5-HT1A-evoked membrane hyperpolarisation was one of the first to be identified
and characterised in the DRN. This characterisation was aided by the development of
the selective 5-HT,A agonist 8-OH-DPAT which, when bath-applied, mimicked the
response of 5-HT (Sprouse and Aghajanian 1987). It is known that a number of 5-HT
receptor subtypes exist in the DRN but the search for electrophysiologically
identifiable responses mediated by non-5-HT,A receptors has proven difficult. There
are low levels of a number of 5-HT receptors including 5-HT1B, 5-ht1F, 5-HT2A, 5-ht5B
and 5-HT7 found in the DRN. 5-HT10 receptor mRNA has been reported in the raphe
nuclei (Voigt et al 1991). There are reports of 5-ht,F receptor mRNA being
concentrated in the DRN (Adham et al 1993b). The 5-HT2A receptor has been found
to mediate neuroexcitation in the raphe cell body (Roberts and Davies 1989). The 5-
ht5B receptor has been detected in the DRN (Erlander et al 1993). Autoradiography
has revealed a low density of 5-HT7 receptor sites in the DRN (Waeber and
Moskowitz 1995). Although the levels of expression of these receptors is low it does
not rule out the physiological significance of any functional effects of 5-HT binding.
However, it may be that these receptors will only be electrophysiologically
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observable following the blockade of the dominant and highly expressed 5-HTIA
receptor. The study of this has so far been difficult because of the lack of a truly
silent and selective 5-HTIA antagonist.
Classification of the 5-HT Receptor Family
5-HT exerts its neurotransmitter actions via specific interactions with cell surface
receptors. Currently seven families of 5-HT receptors have been identified, made up
of a total of fourteen different subtypes. Early work characterised each of the receptor
subtypes using pharmacological tools. The receptors can be activated by 5-HT and a
range of different compounds or agonists. Differences in receptor protein structure
give each receptor different binding affinities for various compounds. This allows
receptor classification by its binding profile, which also allows any 5-HT-evoked
responses to be classified to a receptor once its pharmacological profile has been
established. Gaddum and Picarelli (1957) were the first to differentiate between 5-HT
binding sites in the gut. They proposed that there were two receptor subtypes, the M
(morphine) and D (dibenzyline) receptors and named them after the compounds found
to block their activation. The D receptor was found predominantly in smooth muscle
and the M receptor was found more commonly on nerve ganglia and fibres. The M
receptor is now classified as the 5-HT3 receptor and the D receptor is classified the
5-HT2A receptor.
Molecular cloning has allowed a new way to classify receptors based in part on the
pharmacological characteristics but also on molecular structure and second messenger
system (Hoyer et al 1994). The International Union of Pharmacology (IUPHAR)
decided that the nomenclature system of the 5-HT receptors should be based on
operational (pharmacological), transductional (functional) and structural
characteristics. This included the 5-HTID, 5-ht, E and 5-ht1F receptors as part of the 5-
HT, receptor family (Amlaiky et al 1992) and recognised the 5-HT4 receptor as a
separate receptor class (Dumis et al 1988a, b). 5-HT, became the 5-HT,A, 5-HTIB, 5-
HT1D, 5-htIE and 5-htIF receptors. The 5-HTlc receptor was renamed the 5-HT2C
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receptor and the 5-HT2 family came to include the 5-HT2B receptor (Humphrey et al
1993). New receptor subtypes have been discovered and termed 5-ht5, 5-ht6 and 5-HT7
(Hoyer et al 1994; Martin and Humphrey 1994). Receptors can now be expressed in
cell lines making them more easily classified (Figure 1.1). Table 1.0 shows a
summary of the current classification of the serotonin receptor subtypes.
The 5-HT., Family
The 5-HT, receptor family is made up of five different receptor subtypes defined by
their structural characteristics where each receptor subtype has a single protein
structure varying in size from 374 to 421 amino acids with an overall sequence
homology of 40% (Hoyer et al 1994). All five subtypes are transmembrane G-protein
coupled receptors (via G, and G0). These receptors are all classified as negatively
linked to adenylyl cyclase. They can only be selectively labelled to a limited extent in
the brain using techniques such as autoradiography, but identification has proven
difficult pharmacologically due to the lack of truly selective antagonists. The 5-ht1E
and 5-htIF receptors do not have functional correlates in native tissue and so retain a
lower case appellation. Table 1.1 shows a summary of the ligands selective for the 5-
HT, subtypes.
The 5-HT1A Receptor
The 5-HTia receptor is commonly linked via a pertussis toxin-sensitive G-protein to
the inhibition of adenylyl cyclase (Albert et al 1990; Fargin et al 1988, 1989,1991).
There are also reports that the 5-HT,A receptor is positively coupled to adenylyl
cyclase resulting in cAMP accumulation (Shenker et al 1983, 1985, 1987) although it
has been suggested that the 5-HT7 subtype may mediate this response (Tsou et al
1994). There are also reports that 5-HT1A receptor activation leads to an inhibition of
the carbachol-stimulated accumulation of inositol phosphates (Claustre et al 1989).
The 5-HT1A receptor is made up of seven hydrophobic, transmembrane regions (each
of approximately 25 amino acid residues) that are arranged as a-helices characteristic
of all G-protein coupled receptors. Fargin et al (1988) (Figure 1.2) first described an











































Figure 1.1. Dendrogram of vertebrate and invertebrate 5-HT receptors.
From the branches of the dendrogram its is possible to deduce the evolutionary age
and relationship of the individual G-protein linked receptor subtype. The scale bar
indicates the percentage divergence (4%) along each branch. The signal transduction
mechanism of each receptor is also shown (+PLC - stimulation of phospholipase C;
+AC and -AC - stimulation and inhibition of adenylyl cyclase, respectively; ? -
signal transduction pathway unknown), h - human; r - rat; Dro - Drosophila
melanogaster; Lym - Lymnea stagnalis\ AP - Aplysia California. Adapted from
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Table1.1.Ligandsselectiveforth5-HTir ceptorubtyp . AdaptedfromH y retl(1994).
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Several agonists show selectivity for the 5-HT1A subtype, e.g. 8-OH-DPAT,
buspirone, isapirone (partial agonists), DP-5-CT (an agonist) and MDL 72832
(Richardson and Hoyer 1990). Developing a selective and silent antagonist has
proven more difficult. Several antagonists have been characterised e.g. NAN-190,
BMY 7378 and WAY-100135, but all have partial agonist activity at the 5-HT1A
receptor in the DRN. The only selective and high affinity silent antagonist available is
WAY-100635 (Fletcher et al 1993)
Electrophysiology
Activation of the 5-HT1A receptor is inhibitory, principally causing neurones to
display membrane hyperpolarisation making cells less likely to fire an action
potential. This is accompanied by a decrease in cell input resistance (Aghajanian and
Lakoski 1984) due to the opening of inwardly rectifying potassium channels (IK(IR))
(Williams et al 1988) and is independent of voltage changes. 5-HTIA activation
inhibits a number of calcium channel currents (N-, and L-type) in the DRN neurone
cell bodies (Penington et al 1991). The inhibition is mediated directly through G-
protein interaction and is also voltage and temperature sensitive (McAllister-Williams
and Kelly 1995).
Distribution
The 5-HT1A receptor is widely distributed in the CNS. It is found to a large extent in
the hippocampus, septum, amygdala and the raphe nuclei, especially the DRN
(Marcinkiewicz et al 1984; Radja et al 1991). The cell body in the DRN has been
shown to express high levels of 5-HT]A receptors (Verge et al 1985). Destruction of
some brain areas using kainic acid results in a selective degeneration of pyramidal
cells with a loss of the 5-HT1A receptor binding sites (Hall et al 1985) suggesting
cortical receptors are postsynaptic.
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Figure 1.2. Diagram of transmembrane topology of the rat 5-HTiA receptor.
Amino acid residues that are conserved in all known G-protein coupled 5-HT
receptors are indicated by squares. Site directed mutagenesis studies have shown that
several of these and other residues within the seven putative transmembrane
segments contribute to ligand binding (for review Branchek 1993). Consensus sites
for phosphorylation by protein kinase C (PKC) and A-glycosylation (Y) are marked.
Adapted from Boess and Martin (1994).
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Function
Many of the brain regions that express the 5-HT,A receptor are thought to be involved
in the modulation of mood and emotion and make up the limbic system. The
predominance of 5-HTIA receptors in the limbic system, the neocortex, hypothalamus
and the substantia gelantinosa, suggests the actions that 5-HT and the 5-HT receptor
ligands have on mood could be through this receptor (Iverson 1984). Its distribution
is also suggestive of 5-HT having a role in the regulatory mechanisms of the
hypothalamus and in the regulation of propioception and the integrative functions of
the neocortex. Following activation of the 5-HT1A receptor subtype, with low doses of
8-OH-DPAT, a behavioural syndrome is induced; this is characterised by flat body
posturing, reciprocal forepaw treading and head weaving (Tricklebank 1985). In the
DRN, an important site for the release of 5-HT, the 5-HTIA receptor acts as an
autoreceptor by inhibiting the further release of 5-HT.
Clinical Pharmacology
Agonists such as 8-OH-DPAT, gepirone, buspirone and ipsapirone have anxiolytic
effects in animal models of anxiety (Traber and Glaser 1987). Blockade of the 5-HTIA
autoreceptor in rodents has little effect on extra-neuronal 5-HT levels alone, but does
potentiate the increase observed following SSRI administration (Hoyer et al 1993).
This may mean that the desensitisation of the 5-HTIA autoreceptor can explain why
SSRI's only raise the levels of 5-HT in the synaptic cleft following chronic
administration (Hoyer et al 1993). Co-administration of SSRI's with the 5-HTIA
receptor antagonist pindolol is said to enhance therapeutic efficacy and shorten onset
of the action of the SSRI (Blier and de Montigny 1994).
The 5-HT1B and 5-HT1D Receptors
The 5-HT,B receptor was first described pharmacologically in the rat brain. However,
a corresponding binding site could not be detected in the human brain by
autoradiography with 5-HTIB receptor ligands (Hoyer et al 1986a). Later, a
pharmacologically distinct receptor class was discovered in non-rodents that was
termed the 5-HTID receptor (Heuring and Peroutka 1987; Hoyer & Middlemiss 1989).
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These two sites were noted to have the same distribution (Pazos and Palacios 1985;
Waeber et al 1988a). Weinshank et al (1992) then demonstrated that the human 5-
HT1D receptor was made up of two subtypes, encoded by different genes but sharing
77% homology. These receptor subtypes were termed the 5-HT1Daand 5-HT1Dp
receptors but were indistinguishable pharmacologically. However, it is now thought
that the 5-HT1Dp receptor is truly a species variant of the 5-HTIB receptor and that the
5-HT1Da has been renamed the 5-HT1D receptor (Hartig et al 1996; Barnes and Sharp
1999).
The 5-HT1B Receptor
The 5-HTib receptor is negatively coupled to adenylyl cyclase (Bouhelal et al 1988).
There are few selective ligands for the 5-HT1B receptor, however, there are some
useful compounds available such as CP 93129 (Macor et al 1990), RU 24969 (Hamon
et al 1986) and CGS 12066 (Schoeffter and Hoyer 1989b). There are also some
antagonists for the 5-HTIB receptor subtype including SE 242289 (Roberts et al
1997).
In the rat CNS the 5-HT1B receptor is concentrated in the substantia nigra, globus
pallidus, dorsal subiculum and superior colliculi (Segu et al 1991; Boulenquez et al
1992; Palacios et al 1992) and to a lesser extent in the raphe nucleus, striatum and
hippocampus (Voigt et al 1991). Lesion experiments performed in the rat have shown
that 5-HT,b receptors may be localised on the terminals of the striatal intrinsic
neurones, which innervate the substantia nigra pars reticulata. This was because
destruction of caudate neurones resulted in a significant decrease in binding in the
substantia nigra pars reticulata (Hamon et al 1990b). It was also known that lesions of
the dopaminergic neurones in the substantia nigra pars compacta do not lead to a
decrease in 5-HT10 receptor binding sites. Taken together this points to the 5-HT1B
receptors being localised in the cells controlling activity of the basal ganglia, but not
the dopaminergic cells. There is evidence that the 5-HT1B receptor acts as an
autoreceptor on the serotonergic neurone's nerve terminal. The 5-HT,B receptor also
acts as a terminal heteroreceptor in controlling the release of other neurotransmitters
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such as acetylcholine and glutamate (Engel et al 1986; Middlemiss 1986; Limberger
et al 1991; Maura and Raiteri 1986; Raiteri et al 1986.)-
Functional correlates of the 5-HTm receptor subtype have been found in vascular
tissue, but there has been little success in attributing any behavioural effects to the 5-
HT,b receptor. This is partly due to the lack of selective antagonists and partly due to
the failure of the few antagonists available to penetrate the brain. The development of
a gene knockout mouse lacking the 5-HT1B receptor has had more success (Saudou et
al 1994). The 5-HT1B receptor knockout mouse is more aggressive than the wild type
in the isolation induced aggression test. This is suggestive of the 5-HT,B receptor
being involved in the modulation of aggressive behaviour. Administration of the 5-
HT1B receptor agonist RU 24969 results in hyperlocomotion in the rat; this effect is
antagonised by propanolol (Lucki 1992). The 5-HT,B receptor seems to have a role in
penile erection (Berendsen and Broekkamp 1987) and in hypophagia (Kennett and
Curzon 1988a).
The 5-HT1D Receptor
The activation of the 5-HT)D receptor (formerly the 5-HTDa receptor) was originally
thought to lead to inhibition of the forskolin-stimulated adenylyl cyclase activity
(Waeber et al 1989d) however it is now believed that the receptor detected in these
studies was the species equivalent of the 5-HTlB receptor. No second messenger has
been conclusively attributed to the 5-HTlD receptor expressed in native tissue. The
drug profiles of the 5-HT,B and the 5-HTlD receptors are very similar. There have
been a number of 5-HTlB/lD agonists characterised SKF 99101H, GR 46611 and L-
694, 247 (Skingle et al 1993; Flagan et al 1995; Glennon et al 1996). There is also a
5-HT1B/1Dreceptor selective antagonist GR 127935 (Skingle et al 1993) and a 5-HT1D
selective compound (Price et al 1997).
The 5-HT1D receptor subtype has been found in many non-rodent species including
guinea pig, rabbit, dog, pig, calf and human (Heuring and Peroutka 1987; Waeber et
al 1988a; Hoyer and Schoeffter 1988; Flerrick-Davies and Titeler 1988; Beer et al
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1992; Maura et al 1993). High densities of the 5-HTID receptor are found in the
substantia nigra, basal ganglia and nigrostriatal pathway and low densities in the
hippocampus, raphe and cortex (Waeber et al 1989a). The 5-HT1D receptor subtype
was first identified as mediating the inhibition of 5-HT release from cortical nerve
terminals in the guinea pig (Middlemiss et al 1988) with similar findings in the pig
and rabbit (Schlicker et al 1989; Limberger et al 1991). This is suggestive of the 5-HT
terminal autoreceptor being of the 5-HT1D receptor subtype in the pig, rabbit, guinea
pig and human brain. The 5-HT1D receptor functions as a heteroreceptor where 5-HT
can inhibit release of glutamate from non-serotonergic cells in rat cerebellar
synaptosomes and acetycholine from guinea pig hippocampal synaptosomes (Raiteri
et al 1986; Harel-Dupas et al 1991). It is now thought that there are only low levels of
the 5-HTid receptor found in the brain among higher levels of the 5-HTIB receptor so
drugs that can distinguish between the two receptors must be used to conclusively
attribute any responses to the 5-HT1D receptor.
The 5-ht1E Receptor
The 5-ht,E receptor is negatively coupled to adenylyl cyclase and is linked to a G-
protein. There are no known selective agonists or antagonists. The 5-htlE receptor was
first identified in man as a [3H]-5-HT binding site in homogenates of the frontal
cortex after blocking the 5-HT,Aand 5-HTlD receptors with 5-CT (Leonhardt et al
1989). Human brain binding studies have reported the 5-ht1E subtype (representing up
to 60% of 5-HT, binding) to be concentrated in the caudate putaman with lower levels
in the amygdala, frontal cortex and globus pallidus (Hoyer et al 1993). The function
of the 5-htIE receptor is currently unknown.
The 5-ht1F Receptor
The 5-ht,F receptor is closely related to the 5-ht,E receptor with 70% sequence
homology. It mediates the inhibition of forskolin-stimulated adenylyl cyclase activity
(Amlaiky et al 1992). There is one selective agonist, LY 334370 (Adham et al 1996),
which is claimed to block the effects of trigeminal stimulation suggesting 5-ht1F may
have a role in neurogenic inflammation and migraine (Phebus et al 1996). There are
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no selective antagonists. The function of the 5-ht1F receptor is not yet clear but its
distribution suggests it may act as an autorecepetor (Adham et al 1993b). From
looking at the distribution of 5-ht1F mRNA it seems to be concentrated in the dorsal
raphe, hippocampus and cortex of the rat and also, to a lesser extent, in the striatum,
thalamus and hypothalmus of the mouse (Adham et al 1993b; Amlaiky et al 1992).
The 5-HT2 Family
The 5-HT2 receptor family consists of three different receptor subtypes. Each of the
subtypes has been cloned and found to be a G-protein-linked single protein molecule,
which is of a similar size and sequence homology. Receptor activation leads to an
increase in phosphoinositide metabolism leading to the production of ionsitol
phosphates and DAG and increasing intracellular calcium. The 5-HT2A receptor has,
until recently, been called the 5-HT2 receptor. 5-FlT2C was originally classified as part
of the 5-HT, group when it was termed the 5-HTlc receptor, but has now been
reclassified due to its close relationship to the 5-HT2A receptor following cloning and
sequencing. The 5-HT2B receptor has only recently been cloned and identified. Table
1.2 shows a summary of the ligands selective for the 5-HT2 receptor subtype.
The 5-HT2A Receptor
The first cloned cDNA sequence encoding for the complete 5-HT2A receptor was
taken from a rat brain library (Pritchett et al 1988). It was isolated by its similarity to
the rat 5-HT2C receptor gene with which it has 70% homology in its protein sequence.
The 5-HT2A receptor has been observed in a number of brain regions, including the rat
cortex, aortic smooth muscle and human platelets (Conn and Sanders-Bush 1984,
1985; Roth et al 1984; De Chaffoy et al 1985; Doyle et al 1986). The receptors are
coupled to phospholipase C, ionsitol phospholipid hydrolysis and Ca2+ mobilisation.
There are a large number of agonists, most, however have little 5-HT2A/B/c selectivity
and have not yet been fully characterised. These include compounds such as LSD,
DOM and DOI (all of which have hallucinogenic properties). There is still no ideal












































Table1.2.Ligandsselectiveforth5-HT2r c ptorubtype. AdaptedfromH y retl(1994).
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ketanserin, with 70-fold selectivity over the 5-HT2B/c subtypes. Spiperone is also
useful with its 80-fold lower affinity for the 5-HTIA subtype over the 5-HT2A receptor
and 100-fold selectivity for the 5-HT2A receptor over the 5-HT2B/2C receptor. The more
recently developed compound MDL 100, 907 may be more useful with its 100-fold
selectivity for the 5-HT2A receptor over the 5-HT2C receptor.
The 5-HT2a receptor is widely distributed in the periphery (Bradley et al 1986a). It
mediates a number of effects including the contractile response in many smooth
muscle preparations, inducing the contractile response in bronchial, uterine and
urinary smooth muscle and makes up part of the contractile response to 5-HT in the
guinea pig ileum. It also has a role in platelet aggregation and in capillary
permeability. It is found in the CNS where it has been implicated in a number of
behavioural effects in the rodent (head twitch and wet-dog shake). At the cellular
level the 5-HT2A receptor mediates neuronal depolarisation (rat facial motorneurone,
rat spinal neurone and cat preganglionic sympathetic neurones). Neurones possessing
the 5-HT2A receptor are found in some areas of the cortex (Pazos and Palacios 1985,
Pazos et al, 1987b).
In the neocortex, for example, it is found in laminae I and IV in the rat and laminae
III and V in the human. Binding sites are also found in the claustrum, which is
connected to the visual system, the limbic system especially the olfactory nuclei and
parts of the basal ganglia. It is found to a lesser extent in the caudate-putamen and
DRN (Pazos et al 1984). Cortical [3H] ketanserin binding sites have been seen to
decrease in the senile dementia of Alzheimer's disease paralleling the loss of intrinsic
somatostatin-containing cells in the cortex.
The 5-HT2A receptor is now thought to have a wide range of functions within the CNS
especially in neuroendocrine systems. It mediates neuroexcitation in guinea pig
cortical pyramidal neurones (Davies et al 1987), in the rat raphe cell body (Roberts
and Davies 1989), and the rat nucleus accumbens neurones (North and Uchimura
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1989). The discriminative stimuli and learning behaviour properties of LSD and
DOM seem to be mediated by the 5-HT2A receptor (this may also involve the a,-
adrenoceptor) (Tricklebank 1985, 1987). It plays a part in the 5-HT mediated
inhibition of the release of glutamate from the rat cerebellum (Maura et al 1988). It
has many neuroendocrine effects including regulation of the release of (3-endorphin,
corticosterone and luteinizing hormone in the rat and prolactin release in the rhesus
monkey (Koenig et al 1987; Lenahan et al 1987; Heninger et al 1987). The 5-HT
induced release of adrenaline from the adrenal medulla also appears to be mediated
through the 5-HT2A receptor (Humphrey and Feniuk 1987).
The 5-HT2B Receptor
The 5-HT2B receptor was first identified following the screening of a genomic DNA
library (Foguet et al 1992b). It was described as a G-protein-coupled receptor that
was similar to both 5-HT2Aand 5-HT2C (62% and 65% homology respectively). The 5-
HT2B receptor has been cloned in the mouse, rat and human (Loric et al 1992; Kursar
et al 1992; Schmuck et al 1994). It is linked to phospholipase C activation (Foguet et
al 1992b).
Agonists available for the 5-HT2B receptor include mCPP (a partial agonist) (Kennett
et al 1988a, b). Other full agonists are a-methyl 5-HT, 5-methoxytryptamine (which
is 25 and 400-fold more selective over the 5HT2A and 5HT2C receptors) and BW
723C86 (100 and 10-fold more selective over the 5-HT2A and 5-HT2C receptors
respectively). Many in vitro studies have used the a2-adrenergic receptor antagonists
yohimbime and rauwolscine which have high affinity for the 5-HT2B receptor and
low affinity for 5-HT2A and 5-HT2c receptor sites. More recently the compounds SB
200646 and SB 206553 have been shown to be antagonists 100-fold more selective
for 5-HT2B/2C receptors over 5-HT2A receptors (Forbes et al 1993).
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The 5-HT2B receptor has been found in the rat stomach, especially the fundus strip
where it mediates contraction (Baxter et al 1995). It is also in the gut, heart, kidney
and lung (Foguet et al 1992b; Duxon et al 1997). It is involved in endothelium-
dependent relaxation of the rat and cat jugular veins and the pig pulmonary artery
following nitric oxide release (Ellis et al 1995). There is also the suggestion of a role
in development following the observation that receptor mRNA is expressed in high
amounts in the foetal small and large intestine at El3-16, after which levels decline
(Fiorica-Howells and Gershon 1995). The 5-HT2B receptor is found to some extent in
the brain in particular the amygdala, septum, hypothalmus and cerebellum. It has also
been suggested that the 5-HT2B receptor has a role in the precipitation of migraine
(Kalkman 1994). Finally, 5-HT2B agonists have been shown to have some anxiolytic
properties (Kennett et al 1996).
The 5-HT2C Receptor
The 5-HT2C receptor gene contains introns that allow for postranscriptional
modification and so different receptor variants, although none have yet been reported
physiologically (Burns et al 1997). There are seven functional correlates presently
recognised that cannot be distinguished by pharmacological profiles. When expressed
in cell lines each isoform has different second messenger affinity. Receptor activation
leads to an increase in phospholipase C activation and inositol phosphate
accumulation in common with the other 5-ElT2 receptors.
A commonly used agonist is mCPP, this is a partial agonist with 10-fold selectivity
for 5-HT2C over 5-FIT2B receptors (Kennett 1993). A more selective compound
developed recently is the agonist MK 212, which is 25-fold more selective for the 5-
HT2Creceptor over the 5-FIT2B receptor (Kennett 1993). Most 5-HT2 receptor
antagonists are non-selective for the 5-HT2C receptor, but the more modern
compounds are better. The antagonists SB 200646 and SB 206553 are 50 and 100-
fold more selective for 5-HT2C receptors over 5-HT2B receptors (Kennett et al 1994).
The highly selective compound SB 242084 also has a high affinity for 5-HT2C
receptors and is 100-fold selective over other receptors (Kennett et al 1994). RS
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102221, which is similarly potent at 5-HT2C receptors (Bonhaus et al 1997), should
also help in elucidating the role of this receptor subtype.
Autoradiographic studies using [3H] LSD, [3H] 5-HT and [3H] mesulergine have
identified high densities for 5-HT2C receptors in the choroid plexus (Meibach et al
1980; Pazos et al 1984). There are 5-HT2C receptor rich sites in the epithelial cells of
the choroid plexus (Yagaloff and Hartig 1985) and on the cerebral ventricles where it
may regulate the composition and volume of cerebral spinal fluid (Pazos et al 1984).
It is found to a lesser extent in the limbic system and brain regions involved with
motor behaviour (Pazos and Palacios 1985). 5-HT2C receptor sites are common in the
human basal forebrain, in particular the globus pallidus and substantia nigra (Pazos et
al 1987a). 5-HT2C receptor transcripts are common in the rat olfactory nucleus,
cingulate cortex, lateral habenula and subthalamic nucleus (Mengod et al 1990a).
5-HT2C receptors are thought to have a role in various functions including locomotion,
feeding and anorexia nervosa, cerebrospinal fluid production, adrenocorticotrophic
release, migraine, obsessive compulsive disorders and anxiety (Kennett and Curzon
1988b; Kennett et al 1989; Brewerton et al 1988; Fozard and Gray 1989; Curzon and
Kennett 1990; Lucki 1992). These findings, based on animal models and human
volunteers using non-selective compounds such as mCPP, TFMPP and MK 212, may
be inconclusive. Other 5-HT2C receptor mediated effects are in penile erection, in the
mediation of the loss of behaviours involved in social interaction, in the suppression
of the consumption of hypertonic saline and the suppression of periaqueductal grey-
induced aversion (Kalkman and Fozard 1991b; Koek et al 1992). The mutant gene
knockout mouse which lacks the 5-HT2C receptor is overweight compared to the wild
type due to a lack of control of feeding behaviour (Tecott et al 1995). It is also prone




Gaddum and Picarelli (1957) first described the 5-HT, receptor when they
characterised the M receptor in the guinea pig ileum. Uniquely, the 5-HT, receptor is
a ligand-gated cation channel (Derkach et al 1989). Three observations against the
involvement of a G-protein are firstly, that the time course of electrophysiological
changes are very rapid. Secondly, responses to 5-HT can be recorded for long periods
of time from buffer-irrigated membrane patches (Derkach et al 1989) and finally, that
neither the 5-HT3-evoked currents nor the binding characteristics of radioligands are
affected by treatment with G-protein activators or inhibitors (Derkach et al 1989;
Kilpatrick et al 1987).
The number of 5-HT3 agonists available is limited. The more widely used are 2-
methyl-5-hydroxytryptamine, phenylbiguanide and chlorophenylbiguanide; the latter
having the highest affinity (Fozard 1990; Kilpatrick et al 1990a; Tadipatri et al 1992).
Unfortunately, all these compounds are partial agonists making them less functionally
active than the high affinity would suggest (Ireland and Tyers 1987; Kilpatrick et al
1990a; Sepulveda et al 1991). There are many highly potent and selective 5-HT3
receptor antagonists available including ondansteron, MDL 72222; granisetron and
BRL 46470 (Butler et al 1988; Fozard 1984a; Sanger and Nelson 1989; Kilpatrick et
al 1990a).
5-HTj receptors are found in neurones of both the central (Yakel and Jackson 1988;
Waeber et al 1988b) and the peripheral (Fozard 1984a; Wallis 1989) nervous systems
and a number of neuronally derived cell lines, such as NIE-115, NCB-20,
NG 108-15 and NI8 cells (Peters and Lambert 1989; Peters et al 1991). The highest
density of receptors is found in the discrete nuclei of the lower brainstem, including
the dorsal vagal complex and spinal trigeminal nucleus, the area postrema, the
nucleus tractus soliarius and the substantia gelatinosa (Flamon et al 1989; Pratt et al
1990). In lower densities the 5-HT3 receptor is found in the cortex and the limbic
system, including the hippocampus and amygdala (Kilpatrick et al 1987; Waeber et al
1988b; Palacios et al 1991).
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5-HT3 receptor activation triggers a rapid depolarisation due to a transient inward
current generated by the opening of a cation-selective channel (Peters et al 1991). The
response is fast to desensitise and resensitises (Yakel et al 1991). The depolarising
action of 5-HT3 activation is due to the movement ofNa+ and K7 ions through the cell
membrane (Peters et al 1991). The cellular depolarisation results in an increase in
cystolic Ca2+ ion concentration due to Ca2+ ion influx, which can then change the
activity of the cell. Table 1.3 is a summary of the ligands selective for the 5-HT3 and
5-HT4 receptor.
The 5-HT4 Receptor
The 5-HT4 receptor was first identified as a receptor that stimulated the activity of
adenylyl cyclase in mouse colliculi and guinea pig hippocampal membranes (Dumis
et al 1988a,b). It has been cloned from a rat brain cDNA library and can exist as two
C-terminal splice variants, one of 407 amino acids termed the 5-HT4L (long) receptor
and the other with 387 amino acids the 5-HT4S (short) receptor (Gerald et al 1995). It
is linked to adenylyl cyclases via the Gs G-protein, which leads to the accumulation
ofcAMP.
Early studies used the benzamides for their 5-HT4 agonist activity (Table 1.3). These
include renzapride, cisapride and zacopride (Bockaert et al 1992). Later the
benzimidazolones were found with higher affinities, these include BIMU8 and
BIMU1 (Bockaert et al 1992). However, all these compounds also have high affinities
for the 5-HT, receptor. There are several selective and potent antagonists at the 5-HT4
receptor. These are GR 113808 (3000-fold more selective for 5-HT4 over 5-HT3), RS
23597-190 (125-fold more selective over 5-HT3), SB 207266 (3000-fold more
selective) and SB 204070 (5000-fold more selective) (Grossman et al 1993a,b;
Bockaert et al 1992; Wardle et al 1993).
The 5-HT4 receptor has been found in a wide variety of tissues both in the periphery
and the CNS. Centrally, 5-HT4 receptors appear to be located on the nerve cell where






























Table1.3.Ligandsselectiveforth5-HT3d- 4r ceptor. AdaptedfromH y retl(1994).
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cAMP (Fagni et al 1992). In the pyramidal cells of the rat hippocampus the 5-HT4
receptor mediates a depolarisation with an increase in input resistance due to the
closure of potassium channels, it also mediates a decrease in the calcium-evoked
potassium conductance of the afterhyperpolarisation (Chaput et al 1990). This
increases neuronal excitation and may have a role in the regulation of
neurotransmitter release and enhance synaptic transmission (Fagni et al 1992;
Bockaert et al 1992). The areas of highest density for 5-HT4 receptor in the brain are
the structures of the limbic region, including the olfactory tubercles, nucleus
accumbens, corpus striatum, globus pallidus and substantia nigra. It has also been
found in the hippocampus and cortex (Grossman et al 1993b; Brown et al 1993;
Monferini et al 1993).
The 5-ht5 Family
The 5-ht5 receptor family is made up of two receptor subtypes. The two receptors
have been cloned and exhibit 88% homology for each other, but are not closely
related to any other 5-HT receptor families (Plassat et al 1992; Matthes et al 1993;
Erlander et al 1993). They were termed the 5-ht5A and 5-ht5B receptors and retain a
lower case appellation due to the lack of any functional responses, however their
mRNA's have been found in man (Grailhe et al 1995).
A few non-selective compounds have been found to have high binding affinities for
the 5-ht5 receptors. These include 5-carboxyamidotryptamine, LSD and ergotamine.
Little is known about the localisation, but mRNA has been found in the cortex,
hippocampus, habenula, olfactory bulb and the granular layer of the cerebellum
(Plassat et al 1992). Studies using 5-ht5A receptor antibodies have identified receptor
expression on glial cells expressing the cloned 5-ht5A receptor and have found the
receptor to be negatively coupled to adenylyl cyclase via the Gs G-protein (Carson et
al 1995). The 5-ht5A receptor may act as a terminal autoreceptor in the mouse frontal
cortex (Pineyro et al 1995). Little is known about the 5-ht5B receptor.
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The 5-ht6 Receptor
The 5-ht6 receptor has been identified as a G-protein coupled receptor positively
linked to adenylyl cyclase (Monsma et al 1993; Ruat et al 1993a). The 5-HT, agonists
5-CT and 8-OH-DPAT have low affinity for the 5-ht6 receptor. Pharmacologically,
the antagonist methiothepin has the highest affinity for the receptor. Other non¬
selective antagonists also have some affinity for the receptor; these include
metergoline, mianserin and ritanserin. Many antipsychotic and antidepressant drugs
have a high affinity for the 5-ht6 receptor (e.g. clozapine, amitriptyline and loxepine)
where they act as antagonists. Little is known about the distribution of the 5-ht6
receptor. However, immunocytochemistry has shown that in the hippocampus and
striatum 5-HT6 receptor-like immunoreactivity was associated with dendritic
processes synapsing with unlabelled axon terminals (Gerald et al 1997). Also mRNA
coding for the 5-ht6 receptor has been located in the brain at many sites including the
striatum, olfactory tubercle, cerebral cortex and hippocampus. There is no evidence
for the presence of the 5-ht6 receptor in the periphery.
The 5-HT7 Receptor
The 5-HT7 receptor has been cloned from the rat, mouse, guinea pig and human (Bard
et al 1993; Lovenberg et al 1993a; Plassat et al 1993; Ruat et al 1993b; Meyerhof et al
1993; Shen et al 1993). The 5-HT7receptor gene codes for a protein with 448, 404
and 435 amino acids (Ruat et al 1993b; Shen et al 1993; Lovenberg et al 1993b),
where the differences are due to the presence of introns in the coding region. It is
positively linked to adenylyl cyclase via the Gs G-protein. There are no selective
agonists or antagonists yet known. It has high affinity to the 5-HT, agonists 5-CT, 5-
MeOT and 8-OH-DPAT and the 5-HT2 agonists LSD and DOI. The antagonists
ritanserin, metergoline, methysergide and mesulergine have a high affinity at the 5-
HT7 receptor.In the CNS 5-HT7 may mediate phase advancement of neuronal activity
in the suprachiasmatic nucleus and may control the circadian rhythm of rats. The 5-
HT7 receptor seems to be highly expressed in the rat hypothalamus and thalamus and
other forebrain regions, and to a lesser extent, in the DRN and the CA3 region of the
hippocampus (Lovenberg et al 1993a). 5-HT7-like responses have been characterised
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in many smooth muscle preparations, including the 5-HT-induced relaxation of the
rabbit femoral vein, cat saphenous vein, cynomolgous monkey and dog jugular vein
(Eglen et al 1997).
5-HT1A Receptor Antagonism in the DRN
Early work with 5-HT, involving binding studies and electrophysiological and
biochemical investigations, indicated that a number of compounds previously
characterised as antagonists at other receptors also had 5-ETT antagonist activity. This
includes the dopamine antagonist spiperone (found to be antagonistic to 5-HT, and 5-
HT2 receptors) and a number of the f-adrenergic antagonists including propanolol,
penbutolol and pindolol (found to act at 5-HT,A receptors). More recently developed
compounds, such as methiothepin, metergoline and methysergide, had high affinities
at the 5-HT,a receptor but also bound to a number of 5-HT and monoamine
receptors. Later compounds, such as NAN-190 and WAY-100135, were more
selective but were found to have partial agonist activity at the DRN 5-HT,A site
(Hodgkiss et al 1992; Fletcher et al 1993). A more recently developed compound is
claimed to be both selective and silent, the phenylpiperazine WAY-100635 (Fletcher
et al 1996). This compound has a high affinity for the 5-HT,A receptor and is said to
be selective over a number of 5-HT receptors, ion channels and re-uptake sites.
WAY-100635 - a silent 5-HT1A antagonist
The lack of truly silent 5-HT,A antagonists has hindered the search for
electrophysiologically observable responses due to binding to non-5-HTIA receptors
subtypes found in the DRN. The most recently developed 5-HTIA antagonist is
WAY-100635 which has been reported as a selective 5-HTIA antagonist (Fletcher et
al 1996). WAY-100635 can displace specific binding of the 5-HT,A radioligand [h-
3J8-OH-DPAT to rat hippocampal membranes with a pIC(50) of 8.87 repressing a
100-fold selectivity relative to binding to other 5-HT receptor subtypes and major
neurotransmitter receptors (Forster et al 1995). Corradetti et al (1996) have reported,
using extracellular techniques, that WAY-100635 has no partial agonist activity at
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the 5-HTia receptor in the DRN neurone. They also investigated the pyramidal cells
of the CA1 region of the hippocampus intracellularly, where it has no partial agonist
activity and blocks the 5-HTIA-evoked hyperpolarisation. WAY-100635 has no
partial agonist activity in many physiological and behavioural models including the
isolated guinea pig ileum preparation and the 8-OH-DPAT induced behaviour
syndrome (Forster et al 1995). WAY-100635 also antagonises the decrease in the
amplitude of the NMDA receptor-mediated component of the EPSP's induced by 5-
HT (Corradetti et al 1998) and blocks the 5-HT and 5-HT]A agonist induced
inhibition of cell firing in the DRN (Craven et al 1994; Fletcher et al 1993; Forster et
al 1995). WAY-100635 application can lead to an increase in the firing rate of
serotonergic cells of the DRN in the anaesthetised cat (Fornal et al 1994), increasing
5-HT release. WAY-100635 reverses the partial agonist activity of pindolol in the
DRN, where pindolol inhibits cell firing, and in the frontal cortex, where pindolol
reduced 5-HT release (Clifford et al 1998). WAY-100635 shows competitive
antagonism with 8-OH-DPAT in the guinea pig DRN (Mundey et al 1996). This
study also showed that WAY-100635 application in vivo can increase neuronal
firing. Mundey et al concluded that this is probably because of the blockade of a 5-
HT1A-mediated inhibitor tone acting on serotonergic neurones resulting in an increase
in 5-HT release and 5-HT2 receptor-mediated effects. WAY-100635 has been widely
used as an in vivo radioligand (Hume et al 1994) and has been shown to have




Chapter 2 will describe the experimental methods used to set up and conduct the
experiments performed throughout this research programme. The chapter will also
report the biophysical properties of the neurones studied in this thesis and compare
each property with that reported in the literature.
Chapter 3 will cover the characterisation of the 5-HT1A receptor-mediated
hyperpolarisation in the DRN and hippocampus. It will then report the investigation
into the blockade of the 5-HT1A receptor-mediated hyperpolarisation with WAY-
100635 in the DRN and hippocampus. Chapter 3 will go on to characterise the actions
ofWAY-100635 in the DRN and hippocampus. Finally, this chapter will report the
additional actions of 5-HT in the DRN and hippocampus as revealed by WAY-
100635.
Chapter 4 will report the pharmacological characterisation of the 5-HT-evoked
depolarisation in the DRN using both agonists and antagonists.
Chapter 5 covers the characterisation of the action potential, AHP and firing pattern
of the neurones of the DRN. This chapter then goes on to discuss the actions of 5-HT
on the action potential, AHP and firing pattern of the neurones of the DRN.
Chapter 6 will discuss each issue of the thesis as highlighted in the previous chapters






This chapter will discuss the methodology used throughout the experimental
programme. This will include information on the setting up of the DRN slice
preparation and brain slice chamber. Reference will also be made to the storage and
preparation of drugs, the basis of recording from neurones and the methods of data
analysis. The chapter will also state the methods of visual identification with the
microscope and electrophysiological methods used to identify serotonergic neurones
in the DRN. The chapter will then go on to discuss the biophysical membrane
properties as determined from the neurones used throughout the study and makes
comparisons for each property with those described in the literature.
Experimental Techniques
DRN and Hippocampal Slice Preparation
To prepare the DRN slice male Wistar rats (3-6 weeks old) were decapitated and the
brain quickly removed and cooled to 4°C in oxygenated (95% O2, 5% CO2) artificial
cerebrospinal fluid (aCSF). The cortex was reflected back and two coronal cuts were
made, one at the rostral end of the thalamus and the other at the rostral end of the
cerebellum. Two parasagital cuts were then made between 3 and 4 mm from the
midline to give a small block of tissue. This block of tissue was then transferred to
the chuck of a vibrotome slicer (Campden Instruments) using a strip of filter paper
(Whatman). The tissue block was fixed to the chuck with cyanoacrylate glue with the
distal cut surface uppermost. The chuck was then transferred to the bath of the
vibratome containing oxygenated aCSF at 4°C. The aCSF contained (in mM) NaCl
126, KC1 6.25, Mg S04 1, CaCl2 2.5, NaH2P04 1.25,NaHC03 26 and glucose 10.
Transverse sections were cut dorso-ventrally to a thickness of 450 pm. Sections
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where the cerebral aqueduct retained its integrity and the medial longitudinal
fasiculus could be observed were selected for the recording chamber (Figure 2.0).
To prepare the hippocampal slice the brain was removed as described previously
then the brain was hemisected and the rostral and caudal ends removed from each
lobe. The lateral surface of the remaining tissue was then removed to give a flat
surface. This block of tissue was then transferred to the chuck of a vibratome with
the cut surface facing down. Each lobe was cut into brain slices to a thickness of 400
pm. The hippocampus was removed form the rest of the brain and the CA3 region
cut off with a scalpel to prevent feedback from the CA3 region resulting in less
excitable cells.
The selected slices were transferred to the recording chamber using a fine spatula.
The slices were supported on a fine nylon mesh and superfused from below with
aCSF, which had been warmed to 34°C and was flowing at approximately 0.8 ml per
minute. Above the slices flowed a warmed (34°C) moist atmosphere of 95% O2 and
5% CO2, which had been bubbled through the water bath of the chamber and acted as
the main supply of oxygen. The entire procedure, from decapitation to placement of
the slice in the recording chamber, took from 5 to 9 minutes. The slice was allowed
to recover and equilibrate in the aCSF for 1 hour prior to starting recording. The
recording chamber was adapted from the Haas bath (Haas et al 1979) (Figure 2.1).
The chamber is made up of a thermostatically controlled heated water bath arranged
below the incubation chamber. Artificial CSF, which had been gassed with 95% O2,
5% CO2, is gravity fed via polypropylene tubing through the water bath and into the
well of the incubation chamber. As the well overflows the fluid is channelled through
the nylon mesh below the slice to a tissue wick that syphons the aCSF into a
collecting funnel. An adjustable membrane flow regulator positioned between the
aCSF reservoir and the input port of the recording chamber regulates the flow rate.
The slice rests at the interface between the aCSF and a warmed humidified
atmosphere of 95% O2 and 5% CO2. The gas mixture is gently bubbled through the




Figure 2.0. Diagram of the DRN slice.
Schematic diagram of the mesencephalic area routinely taken for the DR slice and
selected for the recording chamber.
Aq Cerebral aqueduct
CG Central grey
CGD Central grey dorsalis
CGM Central grey medialis
DpWh Deep white layer superior coliculus
DR Dorsal raphe
InG Intermediate grey layer superior coliculus
InWh Intermediate white layer superior coliculus
Me5 Mesencephalic trigeminal nerve coliculus
mlf Median longitudinal fasiculus
xscp Dessucation superior cerebrallar peduncle
43
TS J AgCl pellet K
Figure 2.1. The Recording Chamber (modified from Haas et al 1979).
The tissue preparation (TS) was placed on the nylon netting (J) and perfused by
oxygenated aCSF. The aCSF was introduced into the chamber at port A, it was
warmed as it passed through the water bath and entered the incubation well at B. The
water bath was heated with a thermopad (G) (Minco, Cavel Components Ltd. U.S.A.)
the temperature of which was thermostatically regulated with reference to probe H.
The aCSF flowed through the netting and underneath the tissue, and was siphoned
into a collecting funnel (F) by a tissue wick. An O2/CO2 (95: 5 %) gas mixture was
bubbled from a sintered glass tube (C) through warmed distilled water and entered the
incubation chamber via port D. On entering the chamber the warmed, humidified gas
was deflected across the preparation by a baffle (K). A hole in the baffle allowed
access to the slice with microelectrodes and helped to prevent the slice from being
dehydrated by exposure to dry air. Dotted lines represent fluid levels.
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Drug Administration
Drugs were made up as concentrated stock solutions in distilled deionised water and
frozen until needed. The drugs were thawed and diluted in oxygenated aCSF to the
required concentration immediately prior to the start of drug administration. The
diluted drug was then superfused under the slice by switching a stopcock from a
reservoir containing control aCSF to a reservoir containing drug aCSF. Stock
solutions were made up in mM concentrations with a dilution factor of 1 to 1000. See
Table 2.0 for a summary of the compounds used in the research programme.
Visual Identification of Serotonergic Neurones
Serotonergic neurones tend to be arranged in four distinct areas in the DRN as
labelled DR in Figure 2.0. The largest cluster of cells is located ventromedially
within the isthmus of the DRN. Two smaller clusters are found either side of the
midline and the smallest cluster is found in the midline in the most dorsal aspect of
the DRN. The electrode was placed in the areas of high cell density and was moved
slowly through the slice until a cell was impaled. Following impalement, the cell was
first allowed to stabilise before a control application of 5-HT was given. One of the
major characteristics of serotonergic cells in the DRN is a 5-HT-evoked
hyperpolarisation and associated decrease in cell input resistance (Aghajanian and
VanderMaelen 1982b). Following the identification of the membrane properties of a
cell being recorded its response to bath-application of 5-HT was tested to confirm its
serotonergic nature.
Intracellular Recording Technique
Intracellular electrodes were made from borosilicate glass capillary tubing (Kwick
fil, GC 120-1 OF, Clark Electromedical Instruments) on a horizontal puller (P-97
Flaming Brown Micropipette Puller, Sutter Instruments Co.). The electrodes were
filled with 2M KC1 and had resistances in the range 50-100 MQ. The tip of the
electrode was placed on the surface of the slice in the area of the medial DRN under
microscopic control (Wild M5 stereomicroscope). The electrode was then stepped
through the slice in 2 pm steps using an Inchworm microdrive (Burleigh
Instruments) until a cell was penetrated. Potentials were recorded with respect to a.
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Substance Source Concentration
Apamin Sigma 100 nM
CP 93129 Tocris 10 pM
DOI RBI 10 pM
5-HT Sigma 100 pM
Ketanserin RBI 100 nM
mCPP Tocris 100 pM
MDL 100, 907 Gift from Merrel Dow 100 pM
Methysergide RBI 30 pM, 100 pM
Noradrenaline RBI 10 pM
Phenylephrine RBI 10 pM
Pindolol Tocris 1 mM
SB 200646 Gift from Tom Blackburn to JSK 1 mM
TEA Sigma 3 mM
TTX Sigma 3 pM
WAY-10063 5 Gift from Wyeth to JSK 100 nM -100 pM
Table 2.0. Summary of the compounds used throughout this research.
silver/silver chloride pellet placed against the tissue paper wick in the outflow of the
recording chamber. Recordings were made using a high input impedence DC
preamplifier (Axoclamp 2A, Axon Instrument Inc.) with an active bridge facility to
enable simultaneous current injection and voltage recording through a single
microelectrode (Figure 2.2). The voltage response to a rectangular current pulse
gives an indication of the resistance of the microelectrode according to Ohm's law:
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Figure 2.2. Electrical recording apparatus.
Electrotonic potentials were recorded with respect to a silver/silver chloride
reference ground attached to a the outflow of the recording chamber. Signals were
amplified using an Axoclamp 2A preamplifier via a 0.1 current gain headstage.
Hyperpolarising and depolarising current steps were applied to the cell, which were
generated via a stimulating pulse from the EPC software, reaching the preamplifier
via a 1401 interface. The EPC software regulated the timing and duration of all
current steps. The decay of the electrode discharging was continuously monitored on
the slave scope in discontinuous current clamp (DCC). Voltage responses were
amplified by a 1-20 variable gain, second stage amplifier before being recorded on a
digital tape recorder. Waveforms were monitored on an oscilloscope (Gould) to
ensure that no attenuation of the responses occurred during recording.
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Re = Ve/I0
Where Re = electrode resistance
Ve = voltage drop recorded across the electrode
I0 = amplitude ofthe test current pulse
The resistance of the microelectrode was compensated for using the active bridge
mode. The microelectrode's resistance changed when resting against a cell as
indicated by a voltage deflection in response to a repetitive (1 Hz.) current step. The
capacitance neutraliser on the preamplifier compensated for the capacitance of the
microelectrode. Over compensating for the microelectrode capacitance caused it to
oscillate or "buzz" allowing the microelectrode to move into the cell. Recordings
were made from cells showing a membrane potential of -55 mV or less on the
voltage monitor. The absolute membrane potential was calculated when the electrode
was withdrawn at the end of the experiment. If a residual voltage was seen on
withdrawal it was subtracted from the measured cell voltage of each current step
Current Clamp Recordings
In current clamp mode the current injected into the cell is kept constant (clamped)
and the voltage response of the cell is measured. The bridge balanced mode of the
Axoclamp was used for all current clamp experiments. In this mode not only can the
voltage of the microelectrode be sampled continuously, current can also be passed
continuously along the electrode from a constant current source.
When current flow (I0) is passed along the microelectrode there is an associated
voltage drop (Ve) along it which is dependent on the microelectrode's resistance (Re).
By bridge balancing for the microelectrode resistance the voltage drop is removed
from the potential measurement to give the cell's membrane potential. The
capacitance currents of the microelectrode and the cell membrane were reduced by
optimal negative capacity compensation. To set the negative capacity value the
Axoclamp was set to discontinuous current clamp (DCC) mode where the
microelectrode was used to pass current and record voltage. It has a 30% duty cycle
48
where current is injected for 30% of the time and voltage measured for 70% of the
time. The voltage source, V0, is in series with the resistors Rq (100 MQ for the O.lx
headstage) and Re acts as a current source when the switch SI is closed (Figure 2.3).
Under steady state conditions the voltage measured at the amplifier (Al) output is the
sum of Re.I0 and the membrane potential (Vm). In order to sample the true membrane
voltage Ve must be eliminated from the voltage records. When the switch S1 is
opened after 30% of the cycle period current flow stops and Ve decays to Vm.
Closure of the switch S2 allows the new membrane potential to be sampled at A2,
this is held until another sample of Vm is made. In this way the membrane potential
can be measured independently of the voltage drop across the microelectrode. The
time rise and decay of the voltage change observed on the voltage monitor is
dependent on the capacitance of both the amplifier and the microelectrode, but this
can be optimised by negative capacitance compensation. This involves the injection
of current into the headstage to offset the current required to charge the capacitors.
Over-compensation can be seen as an overshoot in the voltage response across the
microelectrode and under compensation by a failure to return to 0 mV before the
sample cycle repeat. Once the microelectrode has been properly compensated the
Axoclamp is returned to bridge balance mode for the remainder of the experiment.
The electrode resistance is now compensated for using bridge balance control.
The neuronal input resistance was indicated by the size of the steady state voltage
deflection recorded in response to the injected hyperpolarising current steps. This is
calculated from:
R,n = VJIo
A more accurate measurement of resistance was obtained from the slope of the I/V
relationship generated from voltage responses to a series of current steps of varying
amplitudes. When during drug application the resting membrane potential was seen
to change, a constant DC current of the opposite polarity was applied to the cell to













Figure 2.3. Circuit diagram for the axoclamp in discontinuous current clamp.
Current I0 was injected for 30% of the cycle time and voltage measured for 70% of
the cycle time. Due to the high input impedence of the preamplifier A1 the current
was injected into the cell. During the voltage sampling phase switch SI changes to the
zero volts position, this allowed the voltage drop across the electrode to decay to zero
as measured by the differential amplifier A3. Hence when the sample and the hold
device, switch S2, capacitor and amplifier A2, measured the membrane potential this
value was independent of the voltage drop across the microelectrode.
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compensate for any voltage-dependent changes in the cell membrane so only the
absolute affect of the drug would be examined.
Data Analysis
Data was collected and analysed using the CED Electrophysiology Package software.
Data was played from the DAT recorder into the CED software, which generated
traces of the current and voltage pulses. The voltage traces were first averaged by the
CED software to give a series of traces. The current and voltage is measured at the
same position in each trace. These values are then plotted by the CED software to
generate the I/V plot. Least squares linear regression analysis is then performed on
the I/V plot to calculate the input resistance. Reversal potentials where there is no net
change between two I/V plots is the point at which the plots cross and can give an
indication of the ion channel mediating the change. The membrane potential, input
resistance and time constant was taken from each cell. The mean and standard
deviation were calculated for each of the cell membrane parameters and have been
written in the form mean ± standard deviation throughout the thesis, as calculated by
the Microsoft Excel97 statistical analysis facility. Where data was tested for
significance the t-test was used to a 95% confidence interval, as performed by the
Microsoft Excel97 statistical analysis facility.
Biophysical Properties of Serotonergic Neurones
The initial experiments on the DRN performed in vivo used both intracellular and
extracellular techniques to characterise the neurones of the DRN. The first study,
using extracellular recording techniques in vivo, looked at firing rates and found
DRN cells to fire with a regular rate of 0.5-2 Hz, the action potentials had a positive-
negative waveform, and firing was inhibited by administration of LSD (Aghajanian
and Haigler 1974). Later studies, using intracellular recording methods in vivo,
characterised the membrane properties of the cells. The action potentials were of
long duration with amplitudes in the range 62-80 mV and the cells input resistances
ranged from 30-70 Mfi (Aghajanian and VanderMaelen 1982b). A large post spike
hyperpolarisation (approximately 6 mV) was observed and this together with a
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gradual interspike depolarisation was termed the "pacemaker potential", these were
thought to be regulatory factors in determining raphe spike firing pattern.
Later it was shown that intracellular recordings could be obtained in vitro (Crunelli et
al 1983). Again a spontaneous rhythmic pattern was observed made up of single
action potentials occurring at 0.25-5 Hz. The action potential was followed by a long
lasting AHP and the input resistance was found to be in the range 100-320 MQ,
higher than in vivo. Trulson et al (1982) also showed that the raphe cell maintained
its own rhythmic firing pattern in vitro thus indicating that the DR cells have an
intrinsic pacemaker activity. It was also observed that the neuronal population of the
DR region was not homogenous and occasionally a second cell type was impaled
(Crunelli et al 1983; VanderMaelen and Aghajanian 1983). These cells had a much
faster firing rate (>10 Hz), shorter duration action potentials (approximately 1 ms)
and a short duration AHP, but were not responsive to 5-HT.
The remainder of this chapter will present the membrane properties of the neurones
studied in this thesis and compare each property with those described in the literature
(giving confirmation that the experimental technique used during the research is
correct).
Passive Membrane Properties
Stable intracellular recordings were made from 102 dorsal raphe neurones. The
neurones all had overshooting action potentials and resting membrane potentials
ranging from -58 to -69 mV with a mean value of -63.5 ±4.1 mV. Of those impaled
60% appeared spontaneously active initially, but only 5% remained spontaneously
active during prolonged periods of recording.
Current-Voltage relationship
The most accurate calculation of the cell input resistance (Rm) is drawn from the
slope of the current-voltage (I/V) relationship of the cell. This was carried out by
injecting a series of rectangular hyperpolarising current steps of varying amplitudes
into the cell and measuring the cell's voltage output. A typical example is shown in
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Figure 2.4. The resting membrane potential was -64 mV and hyperpolarising current
steps, with increments of 0.025 nA, were used to evoke electrotonic potentials
(Figures 2.4A). The I/V relationship in the hyperpolarising direction was linear in the
range -110 mV to -50 mV and in this cell showed an input resistance of 316.6 MQ
over this range (Figure 2.4B). Membrane voltage responses to hyperpolarising
current commands showed a linear relationship. No inward rectification was
observed in voltage deflections as negative as -130 mV. The current-voltage
relationships in the linear portion of the curve from the population of neurones gave
an apparent mean input resistance of 263.5 ± 58.3 MQ, and ranged from 147.1 to
334.9 MQ (n=102). The high input resistances of the DRN neurones are due to the
small size of each individual neurone and allows cells to show a marked voltage
response to even very small synaptic inputs. The cells had a linear I/V relationship in
the hyperpolarising direction and did not show rectification in hyperpolarising
current steps.
Time Constant
The membrane time course of the potential change (tm) resulting from rectangular
current pulses was measured at the resting membrane potential using small
hyperpolarising current pulses (approximately 0.05 nA). By using small
hyperpolarising current pulses to determine xm alterations in the charging curve due
to the activation of voltage-activated channels were minimised. In all cells studied
the charging curve could be fitted by a single exponential curve. The exponential
change in membrane potential had a time constant of32.75±8.6ms (n=102).
The passive membrane properties of the DR neurones in the present study were in
agreement with those reported by Crunelli et al (1983) who also worked with the in
vitro slice preparation. The neuronal input resistance values reported by Crunelli et al
were twice those found during the in vivo work of Aghajanian and VanderMaelen
(1982). Aghajanian and VanderMaelen also found low input resistance values for DR
neurones in the in vitro slice preparation. More recent studies performed in vitro
agree with the input resistances from the present study, a typical example is from the
work ofCorradetti et al (1998) who report a high input resistance for DR neurones of
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Figure 2.4. Typical electrophysiological characteristics of a DRN neurone.
A. Voltage traces (upper record) are recorded intracellularly from DR neurones in
response to graded depolarising and hyperpolarising current steps (lower record).
The resting membrane potential was -64 mV and hyperpolarising and depolarising
current steps, at increments of 0.025 nA, were used to evoke electrotonic potentials.
B. The I/V relationship of the traces displayed was linear and in this cell showed an
input resistance of 316.6 MQ (as measured by linear regression over the range -110
mV to -50 mV). No rectification was seen with voltage deflections in the
hyperpolarising range to approximately -130 mV.
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of 270 MQ. The difference between the input resistance values reported from in vitro
and in vivo investigations is probably accounted for in part by the removal of tonic
synaptic inputs from areas of the brain that regulates the activity of the DR neurones.
There is also a case for the discrepancy simply being due to the removal of axons and
dendrites which occurs during slice preparation.
Synaptic Potentials
In a number of the cells studied (53 of 89 cells) spontaneous depolarising
postsynaptic potentials (PSP's) could be observed with 2M KC1 filled electrodes.
The depolarising PSP's typically had a fast onset and showed a gradual decay back
to the resting membrane potential. These depolarising PSP's were not observed with
3M K acetate filled electrodes (n=14), which would imply that they were reversed
IPSP's due to the change in Cf driving force associated with KC1 filled electrodes.
TTX treatment abolished these depolarising PSP's implying they result from activity
dependent transmitter release. These potentials can be inhibited by manually
hyperpolarising the membrane potential. This spontaneous activity was often lost
over time, but could be evoked by manually depolarising the membrane potential by
injecting positive current through the recording electrode. A quiet cell could be
driven to fire action potentials rhythmically in a similar manner to those seen
spontaneously by the addition of the a i-adrenoceptor agonist, phenylephrine, to the
bath-aCSF. These observations are in agreement with those made by Baraban and
Aghajanian (1980a) who showed that ai-adrenoceptor antagonists suppress neuronal
firing and Heym et al (1981) who described the effects of adrenergic drugs on unit
activity in the freely moving cat.
Active Membrane Properties
Action Potential
A large number of neurones (60%) were seen to be spontaneously active with a
rhythmical action potential firing rate of approximately 2 Hz. Manual
hyperpolarisation of these cells inhibited action potential generation and did not
reveal any excitatory synaptic events that may have accounted for the spontaneous
activity. The generation of spontaneous action potentials is due to the inherent
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membrane properties of the DRN neurone. Cell viability was in part determined by
the ability of the neurone to produce an overshooting action potential. Cells unable to
evoke an overshooting action potential were assumed to have suffered damage
during the electrode impalement.
A typical action potential in a DRN cell consisted of a rapid overshooting rising
phase where the time from spike onset to peak amplitude of 118 mV was 3 ms
(Figure 2.5). The falling phase is broad and slow with a marked shoulder due to the
activation of a calcium current. The repolarisation undershoots the resting membrane
potential producing a transient AHP of 15 mV that persists for 100 ms before the cell
returns to its resting potential.
Actions of TTX
TTX is a sodium channel blocker and can block the action potential in the DRN. In a
typical cell a short (2 ms) depolarising pulse generated an overshooting action
potential which reached a maximum of +40 mV after 2 ms (Figure 2.6A). Following
the addition ofTTX (3 pM) the same depolarising pulse no longer generated an
action potential. This confirms the involvement of TTX-sensitive sodium channels in
the first stage of the action potential.
TTX also causes a membrane hyperpolarisation accompanied with a slight increase
in input resistance. In Figure 2.6B TTX (3 pM) evoked a hyperpolarisation from a
resting membrane potential of -58 mV to -64 mV, with a slight increase in input
resistance from 205.8 MQ to 225.9 MQ. This could be due to a direct action on the
activity of sodium channels. It could also be due to the loss of tonic synaptic input
following the abolition of the action potential. The reversal level is not indicative of
any known ion channel. This implies it is unlikely that the change in membrane
properties is mediated simply by modulation of an ion channel. It is more likely to be
the result of either a combination of both possibilities or because of the blockade of
synaptic activity involving multiple ionic mechanisms. The inhibition of a tonic














Figure 2.5. The action potential in a typical DRN neurone.
A. A typical action potential evoked following a short, 3 ms, positive current pulse,
250 pA, in a cell with resting membrane potential of -63 mV. The action potential
consists of a rapid overshooting rising phase where the time from spike onset to peak
amplitude of 118 mV is approximately 4 ms. The falling phase is broad and slow
with a marked shoulder due to the activation of a calcium current. The repolarisation
overshoots the resting membrane potential producing a transient AHP of 14 mV.
B. The same action potential on a slower time base shows that the AHP persists for
100 ms before the cell returns to it resting potential.
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100 pA
Figure 2.6. The action of TTX in a DRN neurone.
A. The cell can no longer generate an action potential following the injection of a
short (2 ms) depolarising current step, 0.1 nA, while in the presence of TTX (3 pM).
B. I /V plot showing the action ofTTX (3 pM). The cell hyperpolarises from a
resting membrane potential of -58 mV to -64 mV, with a slight increase in input
resistance from 205.8 MQ to 225.9 MQ.
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changes seen with TTX. This again implies that the regulation of the activity of the
DRN is due to a number of mechanisms.
These findings concur with those made in other intracellular studies performed in
vitro in the DRN slice. The DRN neurone has been shown to have an action
potential, generated following the activation of sodium channels, with a broad
shoulder followed by a large AHP which decays slowly during the interspike interval
(Crunelli et al 1983; VanderMaelen and Aghajanian 1982a).
Afterhyperpolarisation
Following the generation of an action potential the cell repolarises past its resting
membrane potential level to give an AHP (Figure 2.6). From observing a number of
cells the peak amplitude of the AHP was found to be 11.4 ± 2.3 mV (n=14).
Effect of membrane potential on the AHP
The ionic nature of the AHP was investigated by changing the membrane potential of
the cell and looking for a reversal potential. This was performed by injecting a
known positive current into the cell to change the membrane potential and measuring
any effect on the size of the AHP. When at its resting membrane potential a cell
generated a broad action potential followed by an AHP of 10 mV (Figure 2.7A).
When the same cell was hyperpolarised to a membrane potential of -90 mV the AHP
was no longer observed (Figure 2.7B). When the cell was further hyperpolarised to
-100 mV the AHP inverted showing reversed polarity (Figure 2.7C). The AHP has
been shown to reverse at -90 mV as would be expected for a potassium-mediated
event suggesting the involvement of a potassium current. This observation was made
in a further three cells where the AHP reversed at approximately -90mV in all cells
tested (-89 mV ± 1.2 mV).
VanderMaelen and Aghajanian (1983) reported AHP's in the range 10-20 mV,
lasting for 200-800 ms. A number of studies have shown that a calcium-activated
potassium current underlies the AHP in the DRN, consistent with the AHP reversing











Figure 2.7. The AHP reverses at -90 mV.
Intracellular recording made from a typical cell showing an action potential
generated by injecting a short (3 ms) positive current pulse of 50 pA.
A. When at its resting membrane potential, -65 mV, the cell generates a broad action
potential followed by an AHP of 10 mV.
B. When the cell is hyperpolarised to a membrane potential of -90 mV the AHP is no
longer observed.
C. The cell is further hyperpolarised to -100 mV and the AHP is now inverted.
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VanderMaelen and Aghajanian 1982b; Aghajanian 1985). However, the AHP may
be mediated by different potassium conductances. Evidence for multiple components
to the AHP was first uncovered in the experiments on the hippocampus of
Pennefather et al (1985), Fowler et al (1985) and Lancaster and Adams (1986). In the
hippocampus for example, the AHP is made up of three components termed the fast,





The DRN contains the largest cluster of serotonergic neurones in the rat brain.
However, the DRN also contains non-serotonergic neurones. This makes it important
to be able to identify serotonergic neurones by their electrophysiological and
pharmacological characteristics. The most commonly found 5-HT-evoked response
that is electrophysiologically observable in the DRN is a membrane
hyperpolarisation. This is associated with a decrease in cell input resistance,
consistent with ion channel opening, and reverses at the predicted equilibrium
potential for a potassium mediated event. This was first characterised in vitro by
Aghajanian and VanderMaelen (1982b) who also discovered that iontophoretically
applied 5-HT inhibited the cell firing induced by iontophoretically applied
noradrenaline. The same result was obtained with the 5-HT agonist LSD.
The 5-HT-evoked hyperpolarisation was one of the first to be identified and
characterised, this characterisation was aided by the development of the selective 5-
HTia agonist 8-OH-DPAT. It is now thought that the 5-HT-evoked hyperpolarisation
is mediated by the 5-HTia receptor (Sprouse and Aghajanian 1987). However,
although there is known to be a number of 5-HT receptor subtypes reported in the
DRN, the search for electrophysiological identifiable responses mediated by non-5-
HTia receptors has proven difficult. This is because of the lack of a truly silent and
selective 5-HTia antagonist. Early work with 5-HT involving binding studies and
electrophysiological and biochemical investigations indicated that a number of
compounds previously characterised as antagonists at other non-5-HT receptors also
had 5-HT antagonist activity. A more recently developed compound is claimed to be
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both selective and silent, the phenylpiperazine WAY-10063 5. Forster et al (1995)
found that WAY-100635 blocked the inhibitory action of 8-OH-DPAT on DRN
neuronal cell firing in the anaesthetised rat. In the hippocampus WAY-100635 has
been found to prevent the 5-HT-evoked hyperpolarisation (Corradetti et al 1996) and
has been found to increase DRN neuronal activity and 5-HT release in behaving cats
(Fornal et al 1994) and in anaesthetised rats (Fletcher et al 1993).
This chapter will present data from both the DRN and the hippocampus
characterising the 5-HTiA-mediated hyperpolarisation, the actions of the 5-HTiA
antagonist WAY-100635 and the blockade of the 5-HTiA-mediated hyperpolarisation
by WAY-100635. This will allow comparison between the DRN and hippocampus
where some studies have suggested differences in the 5-HTiA receptor in the two
brain regions (Artigas et al 1996). This chapter will then discuss the actions of 5-HT
as revealed by the 5-HTiA antagonist WAY-100635 in the in vitro slice preparation
in the DRN neuronal cell.
Results
Study of WAY-100635 in the DRN
The 5-HTiA-evoked hyperpolarisation in the DRN
All healthy DRN cells impaled responded to 5-HT superfusion with a membrane
hyperpolarisation and an associated decrease in cell input resistance. In one cell the
addition of 5-HT (100 pM) to the bath-aCSF evoked a membrane hyperpolarisation
from a resting membrane potential of -58 mV to -73 mV with 5-HT, a peak
amplitude of 15 mV (Figure 3.OA). This was accompanied by a decrease in the cell
input resistance from a resting value of 354.9 MQ to 114.9 MQ (Figure 3.OB). On
washout the cell recovered to a membrane potential of -58 mV and cell input
resistance of 349.3 MQ. Further analysis involving the generation of current-voltage
(I/V) plots in the absence and presence of 5-HT showed a point of intersection at -87
mV. A value close to the predicted reversal potential for potassium mediated events
as calculated from the Nernst equation, suggesting that the 5-HT-evoked
hyperpolarisation was mediated by a potassium conductance.
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Figure 3.0. A 5-HT-evoked hyperpolarisation in the DRN.
A. Voltage traces of a cell before, during and after bath-application of 5-HT.
B. Current-voltage relationships were obtained by measuring at the point t after
injecting a series of depolarising and hyperpolarising current pulses in the cell. The
cell had a resting membrane potential of -58 mV and an input resistance of 354.9 Mft
(circles). Following bath-application of 5-HT (100 pM) the cell hyperpolarised to -73
mV (squares). This was accompanied by a decrease in input resistance to a value of
114.9 MQ. The control and 5-HT I/V relationships intersected at -87 mV. The 5-HT
was washed out and the cell returned to its resting membrane potential of -58 mV and
resting input resistance of 349.3 MQ (triangles).
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In 32 similar experiments 5-HT (100 pM) caused a 7.0 ± 2.3 mV hyperpolarisation
from a resting value of -63.5 ± 4.1 mV to a peak of -70.5 ± 3.9 mV. This was
accompanied with a reduction in cell input resistance from 263.5 ± 58.3 MQ to 197.9
± 52.5 MQ. Statistical analysis using the t-test showed with a confidence interval of
95% that both the resting membrane potential and the input resistance are
significantly altered by 5-HT. The reversal potential was observed to be -89 ± 1.3
mV, approximately the reversal potential for a potassium conductance.
Blockade by WAY-100635 in the DRN
The action of 5-HT on DRN neurones was investigated in the presence ofWAY-
100635. Prior to WAY-100635 application a typical cell, with a resting membrane
potential of -63 mV and an input resistance of 354.5 MQ, responded to bath-applied
5-HT (100 pM) with a control membrane hyperpolarisation (Figure 3.1A). In this
case the cell hyperpolarised to -72 mV with an associated decrease in input resistance
to 263.1 MQ. Following bath-application of WAY-100635 (100 nM) for 15 minutes
subsequent 5-HT (100 pM) applications did not evoke the 5-HTia receptor-mediated
hyperpolarisation. The 5-HTiA-evoked response was still blocked following WAY-
100635 washout of up to one hour. Application ofWAY-100635 (100 nM) for only
15 mins blocked the 5-HT (100 pM) evoked hyperpolarisation in a further 5 cells.
The selectivity of WAY-100635 in the DRN
Whether WAY-100635 had ai-adrenorecptor antagonist activity was also
investigated. WAY-100635 did not block the depolarisation associated with bath-
applied phenylephrine and noradrenaline. In a typical cell where pre-treatment with
WAY-100635 (100 nM) blocked the 5-HTiA-mediated hyperpolarisation, bath-
application of phenylephrine (10 pM) evoked a membrane depolarisation from a
resting membrane potential of -64 mV to -59 mV, a change of approximately 5 mV
(Figure 3.2A). This was accompanied by an increase in cell input resistance from
147.1 MQ to 173.4 MQ. The I/V plots reversed at approximately -94 mV a value
consistent with the event being mediated by a potassium channel. Similarly in a


















Figure 3.1. WAY-100635 blocked the 5-HT-evoked hyperpolarisation in the
DRN.
A. I/V plots obtained from a DRN neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM). The DRN neurone hyperpolarised from a resting
membrane potential of -63 mV to -72 mV, a change of approximately 9 mV. This was
accompanied by a decrease in cell input resistance from 354.5 MQ to 263.1 MQ.
B. Application ofWAY-100635 (100 nM) for 15 mins completely abolished the
hyperpolarisation, where the cell had a membrane potential of -64 mV and cell input






































Figure 3.2. WAY-100635 does not act at the ai-adrenoreceptor in the DRN.
A. I/V plots obtained from a DR neurone pre-applied with WAY-100635 before
(circles) and after (squares) bath-application of phenylephrine (10 pM). The DRN
neurone depolarised from a resting membrane potential of -64 mV to -59 mV, a
change of approximately 5 mV. This was accompanied by an increase in cell input
resistance from 147.1 MQ to 173.4 MQ. The I/V plots reversed at approximately
-94 mV.
B. I/V plots obtained from a DR neurone pre-applied with WAY-100635 before
(circles) and after (squares) bath-application of noradrenaline (10 pM). The DR
neurone depolarised from a resting membrane potential of -65 mV to -58 mV, a
change of approximately 7 mV. This was accompanied by an increase in cell input
resistance from 147.4 MQ to 182.6 MQ. The I/V plots reversed at approximately
-90 mV.
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hyperpolarisation following continued exposure to WAY-100635 (100 nM), bath-
application of noradrenaline (10 pM) evoked a membrane depolarisation from a
resting membrane potential of -65 mV to -58 mV, a change of approximately 7 mV
(Figure 3.2B). The noradrenaline-evoked depolarisation was accompanied by an
increase in cell input resistance from 147.4 MQ to 182.6 MQ. The I/V plots reversed
at approximately -90 mV, again close to that for a potassium-mediated event. Both
phenylephrine and noradrenaline evoke a membrane depolarisation in the DRN via
the aj-adrenorecptor so ifWAY-100635 does not block the depolarisation it may not
have antagonist activity at the a i-adrenoceptor.
WAY-100635 is silent in the DRN
WAY-100635 (lOOnM) was applied for up to 45 minutes and was found to have no
effect on resting membrane potential or input resistance (n=35). Prior to WAY-
100635 application the membrane potential was -63 ±3.5 mV, with an input
resistance of 263.1 ± 80.2 MQ. Following WAY-100635 (100 nM) application the
membrane potential stayed constant at -63 ±3.1 mV, as did the input resistance at
258.9 ± 79.2 MQ within the first 45 minutes ofWAY-100635 application. Statistical
analysis using t-tests show that the membrane potential and input resistance stay the
same with application ofWAY-100635 for up to 45 minutes. This suggests WAY-
100635 has no partial agonist activity.
However, there were some examples ofWAY-100635 having a slight effect on the
resting membrane potential and input resistance following long term exposure.
Following bath-application ofWAY-100635 (100 nM) for long time periods (up to
90 mins) some cells did show a slight depolarisation (n=8 of 35). This is illustrated in
a typical cell in Figure 3.3. The cell demonstrates a slight depolarisation in
membrane potential from a resting membrane potential of -66 mV to -63 mV, there
was also a slight increase in input resistance from 290.2 MQ to 310.5 MQ. This
depolarising membrane drift may represent WAY-100635 having some ion channel
blocking effect that can only be observed following a long application. It seems
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Figure 3.3. Long term application of WAY-100635 in the DRN.
A plot showing the change in membrane potential (closed circles) and input resistance
(open circles) during a prolonged application ofWAY-100635 (100 nM). Membrane
potential and input resistance were measured every 5 mins. Following bath-
application ofWAY-100635 (solid bar) the resting membrane potential was observed
to slowly drift in the depolarising direction from an initial value of -66 mV to -63 mV
after 90 mins. The input resistance also increased slightly from a value of 290.2
to 310.5 MQ.
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receptor as this would be observed as a hyperpolarisation. Also the concentration of
WAY-100635 in the chamber is high enough to block the 5-HT-evoked
hyperpolarisation after 15 mins exposure, so it seems unlikely that WAY-100635
would take over one hour to show agonist activity.
Additional actions of 5-HT revealed by WAY-100635
A 5-HT-evoked depolarisation in the DRN
In a cell illustrated in Figure 3.4 a short application ofWAY-100635 (15 mins, 100
nM) blocked the 5-HTiA-mediated hyperpolarisation (Figure 3.4A). This 5-HT-
evoked depolarisation was observed in a further 28 cells (n=29 of 35). However a
long application ofWAY-100635 (35 mins, 100 nM) revealed a 5-HT (100 pM)
evoked depolarisation (Figure 3.4B) showing that 5-HT can have multiple actions in
the DRN.
A typical example of the 5-HT-evoked depolarisation is shown in Figure 3.5 which
shows the voltage responses to injected current pulses in a typical neurone, resulting
in the generation of a series of voltage deflections or steps. The resting membrane
potential was indicated in the upper part of the step and the height of the step gives
an indication of cell input resistance. Figure 3.5A shows a 5-HTiA-evoked
hyperpolarisation. The resting membrane potential was -63 mV. The membrane
potential can be seen to move in a hyperpolarising direction with 5-HT (100 pM) and
reaches -71 mV, a change of 8 mV. The cell input resistance decreases following the
application of 5-HT. A more accurate measurement of the input resistance can be
obtained by measuring the voltage responses to a series of graded hyperpolarising
current steps and can be displayed as I/V plots. Figure 3.5B shows a 5-HT-evoked
depolarisation in the same cell following exposure to WAY-100635 (100 nM, 35
mins). The resting membrane potential is -64 mV. The membrane potential can be
seen to move in a depolarising direction with 5-HT (100 pM) and reaches -60 mV, a










































Figure 3.4. A 5-HT-evoked depolarisation with WAY-100635 in the DRN.
A. Following a short application ofWAY-100635 (100 nM) for 15 mins the 5-HT
(100 pM) evoked hyperpolarisation is blocked.
B. Following a long application ofWAY-100635 (100 nM) for 30 mins a 5-HT (100
pM) evoked depolarisation was observed. The cell depolarised from -67 mV to -61









Figure 3.5. Chart recording of the two 5-HT-evoked actions.
Current pulses of 250 pA and 500 ms duration were injected into a neurone every
second and the voltage responses were recorded intracellularly.
A. The chart recording showed a 5-HTiA-evoked hyperpolarisation. The resting
membrane potential was -63 mV. The membrane potential moved in a hyperpolarising
direction when 5-HT (100 pM) was added to the bath of aCSF (solid bar) and reaches
-71 mV, a change of 8 mV. The voltage response decreased in height in the presence
of 5-HT indicating a decrease in cell input resistance. A more accurate measurement
of the input resistance was obtained by measuring the voltage responses to a series of
graded hyperpolarising and depolarising current steps. The series of voltage steps can
be displayed in I/V plots for analysis.
B. The chart recording showed a 5-HT-evoked depolarisation in a cell pre-applied
with WAY-100635 (100 nM) (dashed bar). The resting membrane potential was -64
mV. The membrane potential moved in a depolarising direction with 5-HT (100 pM)
(solid bar) and reached -60 mV, a change of 4 mV. The cell input resistance decreased
slightly following the application of 5-HT.
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I/V plots from another DRN neurone are displayed in Figure 3.6 that shows the action
of bath-applied 5-HT before and after application of WAY-100635. In control
conditions the neurone exhibited a 5-HT (100 pM) evoked hyperpolarisation from a
resting membrane potential of -64 mV to -75 mV, a change of 11 mV (Figure 3.6A).
This was accompanied by a decrease in cell input resistance from 334.9 MO to 157.4
MQ. The I/V plots intersected at -87 mV. Following bath-application ofWAY-
100635 (100 nM) the neurone displayed a 5-HT (100 pM) evoked depolarisation
from a resting membrane potential of -65 mV to -60 mV, a change of approximately
5 mV (Figure 3.6B). This was accompanied by a decrease in cell input resistance
from 308.5 MQ to 272.2 MQ, measured over the linear portion of the I/V plot in the
range -90 mV to -120 mV. The I/V plots did not intersect over the measured range. In
addition, many cells showing the 5-HT (100 pM) evoked depolarisation was
associated had an increase cell excitability as seen by an increase in firing rate (n=15
of 29).
Using all the cases where WAY-100635 (100 nM) uncovered a slow 5-HT (100 pM)
evoked depolarisation the mean depolarisation was 4 mV ± 1.2 mV, from a resting
value of -64 ± 2.7 mV to -60 ± 2.3 mV with 5-HT (n=29 of 35). Statistical analysis
using the t-test showed with a confidence interval of 95% that the resting membrane
potential change is significantly different from the membrane potential with 5-HT.
Overall, the depolarisation was accompanied by a slight decrease in cell input
resistance from 261.6 MQ ± 58.9 MQ to 241.4 MQ ± 50.2 MQ, also further I/V plot
analysis showed the 5-HT response did not reverse in the range -100 mV to -70 mV
(n=29). However, I/V analysis revealed three distinct populations of cells. In one cell
population the input resistance before (250.1 ± 10.5 MQ) and after 5-HT (100 pM)
(238.2 ± 9.3 MQ) showed no change (n=9 of 29). In some cells the input resistance
increased from 248.3 ± 37.9 MQ before 5-HT (100 pM) to 272.8 ± 39.1 MQ in the
presence of 5-HT (100 pM) (n=14 of 29). A small number of cells showed a slight
decrease in input resistance of 273.5 MQ ± 56.6 MQ to 238.6 MQ ± 47.6 MQ with
73
Current pA
Figure 3.6. 5-HT evoked a depolarisation with WAY-100635 in the DRN.
A. I/V plots obtained from a DRN neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM). The DRN neurone hyperpolarised from a resting
membrane potential of -64 mV (circles) to -75 mV. This was accompanied by a
decrease in cell input resistance from 334.9 MQ to 157.4 MQ. The I/V plots
intersected at -87 mV.
B. I/V plots obtained from the same DR neurone before (circles) and after (squares)
bath-application of 5-HT (100 pM) while in the presence of WAY-100635 (100 nM).
The DR neurone depolarised from a resting membrane potential of -65 mV to -60 mV.
This was accompanied by a decrease in cell input resistance from 308.5 MQ to 272.2
MQ, measured over the linear portion of the I/V plot in the range -90 mV to -120
mV. The I/V plots did not intersect over the measured range.
74
5-HT (100 pM) (n=l 6 of 29). In cells showing a clear point of intersection I/V plots
showed a reversal potential of -47 ±1.9 mV (n=16 of 29).
Actions of the channel blocker TTX in the DRN
The importance of synaptic activity in the generation of the 5-HT-evoked
depolarisation was investigated using the sodium channel blocker TTX, which
prevents initiation of sodium action potentials. The depolarisation persisted in the
presence ofTTX (3 pM, n=2). One cell treated with WAY-10063 5 (100 nM)
demonstrated a depolarisation due to bath-application of 5-HT (100 pM) from a
resting membrane potential of -64 mV to -59 mV, a change of approximately 5 mV
(Figure 3.7A). This was accompanied by a decrease in cell input resistance from
344.1 MQ to 303.9 MQ. In the presence ofTTX (3 pM) the cell depolarised
following an application of 5-HT (100 pM) from -65 mV to -61 mV, this was
accompanied by a change in input resistance from 330.8 MQ to 307.4 MQ (Figure
3.7B). This indicates that the 5-HT-evoked depolarisation is independent of synaptic
activity.
A non-5-HTiA-evoked hyperpolarisation in the DRN
Another example of a 5-HT-evoked membrane change, in this case a 5-HT-evoked
hyperpolarisation, was observed in a small number of cells following blockade of the
5-HTiA-mediated hyperpolarisation. In one cell a small 5-HT (100 pM) evoked
hyperpolarisation (3mV) was revealed in the presence ofWAY-100635 (100 nM)
and methysergide (100 pM). This DRN neurone which had been treated with WAY-
100635 (100 nM) depolarised with 5-HT (100 pM) from a resting membrane
potential of -60 mV to -56 mV, a change of approximately 4 mV (Figure 3.8A). This
was accompanied by a slight increase in cell input resistance from 163.9
MQ to 169.9 MQ. While in the presence ofmethysergide (100 pM) and WAY-
100635 the same cell showed a 5-HT-evoked hyperpolarisation from -60 mV to -63

























Figure 3.7. 5-HT evoked a depolarisation in the presence of TTX in the DRN.
A. I/V plots obtained from a DRN neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM). The DRN neurone depolarised from a resting
membrane potential of -64 mV to -59 mV. This was accompanied by a decrease in
input resistance from 344.1 MQ to 303.9 Mfi.
B. In the presence ofTTX (3 pM) the cell depolarised following an application of
5-HT from -65 mV to -61 mV. This was accompanied by a change in input resistance
from 330.8 MQ to 307.4 MQ.
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Figure 3.8. 5-HT-evoked hyperpolarisation with WAY-100635 and methysergide
in the DRN.
A. I/V plots obtained from a DRN neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM). The DR neurone depolarised from a resting membrane
potential of -60 mV to -56 mV, a change of approximately 4 mV. This was
accompanied by a slight increase in cell input resistance from 163.9 MQ to 169.9
MO.
B. While in the presence ofmethysergide bath-application of 5-HT (100 pM) evoked
a membrane hyperpolarisation, from a resting membrane potential of -60 mV to -63
mV with 5-HT, there was also a decrease in cell input resistance from 174.9 MQ to
140.6 MQ.
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A 5-HT evoked membrane hyperpolarisation was observed in three cells following
the bath-application of 5-HT while in the presence ofmCPP, a 5-HT2B/2C agonist that
also has some 5-HT2 antagonist activity, and WAY-100635. A typical cell that had
demonstrated a 5-HT (100 pM) depolarisation with WAY-100635 (100 nM) (Figure
3.9A). Then in the continued presence ofWAY-100635 (100 nM) with mCPP (100
pM) bath-application of 5-HT (100 pM) evoked a membrane hyperpolarisation from
a resting membrane potential of -64 mV to -76 mV with 5-HT (Figure 3.9B). There
was also an associated decrease in cell input resistance from 343.1 Mfl to 174.6 MQ.
Study of WAY-100635 in the hippocampus
A study was also made in the hippocampus, a brain region where 5-HTia antagonists
can have different activity to that in the DRN (Artigas et al 1994). First the passive
and active membrane properties were established and then the 5-HTiA-mediated
hyperpolarisation characterised. WAY-100635 was applied to test its ability to block
the 5-HTiA-mediated hyperpolarisation and for any agonist activity.
Passive and active properties of the hippocampal neurone
Data was obtained from ten stable intracellular recordings from pyramidal cells of
the CA1 area of the hippocampus. The neurones all had overshooting action
potentials and showed resting membrane potentials ranging from -58 mV to -69 mV
with a mean value of -63.2 ± 2.8 mV (n=10). Membrane voltage responses to
hyperpolarising current commands showed a linear relationship (Figure 3.10). No
inward rectification was observed in voltage deflections as negative as -100 mV. The
current-voltage relationships in the linear portion of the curve gave an apparent input
resistance of 154.6 ±35.4 MQ, and ranged from 127.3 MQ to 203.6 MQ.
The 5-HTiA-mediated hyperpolarisation in the hippocampus
Data was obtained from a typical pyramidal neurone of the CA1 region of the
hippocampus before and after bath-application of 5-HT (100 pM).
The pyramidal neurone hyperpolarised from a resting membrane potential of -63 mV
to -69 mV, a change of approximately 6 mV with 5-HT (100 pM) (Figure 3.10A).
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Figure 3.9. 5-HT evoked hyperpolarisation with WAY-100635 and mCPP in the
DRN.
A. In the presence ofWAY-100635 (100 nM) the cell underwent a 5-HT-evoked
depolarisation from -63 mV to -58 mV. This was accompanied by a change in input
resistance from 325.1 MQ to 333.1 MQ.
B. In the presence ofmCPP (100 pM) the cell hyperpolarised following bath-
application of 5-HT from -64 mV to -76 mV. This was accompanied by a change in
input resistance from 343.1 MQ to 174.6 MQ.
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Figure 3.10. 5-HT-evoked two responses in the hippocampus.
I/V plots obtained from a pyramidal neurone of the CA1 region of the hippocampus.
A. Before (circles) and during (squares) bath-application of 5-HT (100 pM). The
pyramidal neurone hyperpolarised from a resting membrane potential of -63 mV
(circles) to -69 mV with a decrease in cell input resistance from 163.2 MQ to 108.9
MQ. The I/V plots intersected at -81 mV. 5-HT washout returned the cell to resting
values of -62 mV and 150.1 MQ.
B. Before (circles) and after (squares) bath-application of WAY-100635 (100 pM).
The neurone slightly depolarised from a resting membrane potential of -63 mV to -62
mV. There was a slight decrease in input resistance from 150.1 MQ to 144.1 MQ,
measured over the linear portion of the plot in the range -70 mV to -90 mV.
C. Before (circles) and after (squares) bath-application of 5-HT (100 pM) while in the
presence ofWAY-100635. The neurone depolarised from a resting membrane
potential of -65 mV to -58 mV, a change of approximately 7 mV, with an increase in
cell input resistance from 136.5 MQ to 176.6 MQ, over the linear portion of the plot
and showed a point of intersection at 87 mV. 5-HT washout returned the cell to its
resting values of -65 mV and 139.4 MQ.
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This was accompanied by a decrease in cell input resistance from 163.2 Mfi to 108.9
MQ. The I/V plots intersected at -81 mV. Following 5-HT washout the cell returned
to its resting values of -62 mV and 150.1 MQ. Pooled data showed a 5-HT (100 pM)
evoked a hyperpolarisation from a resting membrane potential of -63.2 ± 2.8 mV to a
peak of -73.1 ± 3.9 mV (n=10). This was accompanied by an input resistance
decrease from 154.6 ± 35.4 MQ to 98.7 ± 35.6 MQ. The mean reversal potential was
found to be -84 ±3.2 mV, indicating the involvement of a potassium conductance.
WAY-100635 in the hippocampus
Following bath-application of 5-HT (100 pM) while in the presence ofWAY-
100635 (100 nM), six of eight cells showed a complete block of the 5-HT (100 pM)
evoked hyperpolarisation. The group of six cells had a resting membrane potential of
-61.3 ± 1.5 mV and input resistance of 147.3 ± 23.2 MQ. WAY-100635 was applied
to hippocampal at a range of concentrations, namely 100 pM, 10 pM and 100 nM
Following pre-treatment with WAY-100635 at all the concentrations tested bath-
application of 5-HT (100 pM) caused no change in the membrane potential at -62.3 ±
1.6 mV and in input resistance at 147.8 ± 20.8 MQ.
WAY-100635 did not have any partial agonist activity; the same neurone as above
showed a slight change from its resting membrane potential of -62 mV following a
bath-application ofWAY-100635 (100 nM) (Figure 3.10B). There was a slight
change from a resting input resistance of 150.1 MQ to 144.1 MQ; this was measured
over the linear portion of the I/V plot in the range -70 mV to -90 mV. WAY-100635
(100 nM) was found to have no partial agonist activity in seven cells when applied
for up to 20 minutes. There was little change in the membrane potential from the
resting membrane potential of -63.3 ±1.6 mV to -61.5 ± 1.8 mV following the
application ofWAY-100635 at any of the drug concentrations. This was also true of
the input resistance, with a control value of 156.3 ± 35.2 MQ and 158.1 ± 24.9 MQ
when exposed to WAY-100635.
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A 5-HT-evoked depolarisation in the hippocampus
In two of eight WAY-10063 5 (100 nM) treated cells there was a depolarisation
following bath-application of 5-HT (100 pM). In one of these cells the membrane
showed depolarisation from a resting membrane potential of -65 mV to -58 mV
following the bath-application of 5-HT (100 pM), a change of 7 mV (Figure 3.10C).
This was accompanied by an increase in cell input resistance from 136.5 MD to
176.6 MQ, measured over the linear portion of the I/V plot in the range -70 mV to -
85 mV. Control and 5-HT I/V plots intersected at -87 mV. Following 5-HT washout
the cell returned to its resting values of -65 mV and 139.4 MQ. When the data from
both experiments was pooled there was a 5-HT (100 pM) evoked depolarisation in
membrane potential from -64.5 ± 2.1 mV to -58.9 ±1.8 mV with an accompanying
increase in input resistance from 159.2 ± 50.5 MQ to 201.6 ± 63.9 MQ. The 5-HT-
evoked depolarisation was accompanied by an increase in cell excitability observed
as an increase in the firing rate of the neurones. The increase in input resistance
indicates a closure of ion channels in the cell membrane. The point of response
reversal (approximately -90 mV) indicates the involvement of potassium channels.
This agrees with the work of Colino and Halliwell (1987) who concluded that a 5-
HT-evoked depolarisation in the CA1 region of the hippocampus was due to a
decrease in potassium conductance.
Summary
5-HTiA-evoked hyperpolarisation in the DRN
The present study has found that the principal action of bath-application of 5-HT to
the serotonergic neurones of the DRN is inhibitory. This inhibitory action of 5-HT is
due to an evoked membrane hyperpolarisation, making the cell less likely to fire an
action potential. This action is associated with a decrease in input resistance.
Analysis of I/V plots showed that the response reversed at around -90 mV, the value
expected for potassium mediated events and in agreement with other studies where
the hyperpolarisation has been shown to be dependent on external potassium
concentration (Aghajanian and Lakoski 1984). This indicates that the 5-HT-evoked
hyperpolarisation is due to the opening of a potassium channel.
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WAY-100635 in the DRN
The present study has shown, in agreement with current literature, that WAY-100635
blocks 5-HTiA-mediated events in the DRN (Fletcher et al 1996). WAY-100635,
following a 15 minute exposure, was found to block the 5-HT-evoked
hyperpolarisation in all cells tested.
WAY-100635 Selectivity in the DRN
WAY-10063 5 did not block the depolarisation associated with bath-applied
phenylephrine and noradrenaline suggesting that WAY-100635 has no ai-
adrenoceptor antagonistic activity. In both cases the membrane ai-adrenorecptor -
mediated depolarisation was accompanied with an increase in input resistance
indicating the closure of ion channels in the cell membrane. Also in each case
reversal values could be extrapolated and were both found to be approximately -90
mV, close to that predicted for potassium-mediated events. This is indicative of a
membrane depolarisation that is mediated only by the closure of potassium channels.
Is WAY-100635 truly silent in the DRN?
When applied to the DRN neurone for up to 45 minutes WAY-10063 5 was found to
have no effect on the resting membrane potential or input resistance indicating that it
has no agonist activity at the 5-HTiA receptor. This is in contrast to a number of
compounds previously claimed to be "silent" antagonists, where partial agonist
properties have been subsequently revealed (Meller et al 1990). However, while
under the influence ofWAY-10063 5 for longer time periods some cells did tend to
show a membrane potential drift in a depolarising direction, leading to an increase in
firing rate. This may be due to the blockade of the tonic inhibition exerted by
endogenously released 5-HT in the DRN (Craven et al 1994; Forster et al 1995), or
may be due to an excitatory action of endogenously released 5-HT. Alternatively, it
could be that WAY-100635 is acting by blocking ion channels involved in
maintaining the resting membrane potential.
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A 5-HT-evoked depolarisation in the DRN
Blockade of the 5-HTiA-evoked response with a long application (30-45 mins) of
WAY-100635 revealed a slow 5-HT-evoked membrane depolarisation. The 5-HT-
evoked depolarisation appears to be a separate phenomenon to the membrane
depolarisation observed with the possible blockade of tonic inhibition with WAY-
100635. The depolarisation closely follows the application of 5-HT and reverses with
5-HT wash out, making it appear that the application of 5-HT evokes the
depolarisation.
The 5-HT-evoked depolarisation was observed in a large number of cells (n=29 of
35). In some cells the depolarisation was associated with a decrease in input
resistance when under the influence of 5-HT. In some cells there appeared to be no
net change in input resistance. I/V analysis showed that in some cells the 5-HT-
evoked depolarisation reversed at approximately -50 mV (n=8) a value not associated
with the potassium channel. The 5-HT-evoked hyperpolarisation in these cells
reversed at approximately -90 mV, as consistent with a potassium-mediated event.
The 5-HT-evoked depolarisation revealed by 5-HTia blockade in the DRN does not
seem to be mediated by the closure of potassium channels. There is no reversal in the
range from -120 mV to -70 mV and no significant increase in input resistance, so the
5-HT-evoked depolarisation it is not solely due to the closure of potassium channels
and so is unlike the depolarisation that follows the application of phenylephrine and
noradrenaline.
TTX and the 5-HT-evoked depolarisation in the DRN
The 5-HT-evoked depolarisation could be demonstrated in the presence ofTTX, a
known sodium channel blocker. This indicates that the response is independent of the
action potential dependent synaptic events involved in networks and so must be
postsynaptic. 5-HT binding to the target cell changes the activity of that cell by
causing a membrane depolarisation leading to an increase in neuronal excitability.
This data points to the 5-HT-evoked depolarisation not being dependent on network
connections. This means that 5-HT can evoke a depolarisation in serotonergic cells
independent of inputs from other neurones.
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Non-5-HTiA-evoked hyperpolarisation in the DRN
In the DRN there was not only a 5-HT-evoked depolarisation revealed with WAY-
100635 but also a 5-HT-evoked hyperpolarisation in the presence of the compounds
mCPP and methysergide. The continued application of WAY-100635 together with
methysergide in one cell and mCPP in three cells revealed a non-5-HTiA-evoked
membrane hyperpolarisation. This hyperpolarisation was associated with a decrease
in input resistance, indicating the opening of ion channels. The response was
observed to reverse at approximately -90 mV, indicating the involvement of
potassium channels. The hyperpolarisation was also associated with a decrease in
excitability. This observation could reflect the electrophysiological activity of one of
the other 5-HT receptors described in the DRN.
5-HTiA-evoked hyperpolarisation in the hippocampus
The present study has shown that 5-HT-evokes a hyperpolarisation associated with a
decrease in input resistance and I/V analysis showed the response to reverse at
approximately the value that would be expected for a potassium mediated event. The
decrease in input resistance also indicates the opening of channels. This is typical of
the 5-HT iA-mediated hyperpolarisation well described in the hippocampus (Andrade
and Nicoll 1987).
WAY-100635 in the hippocampus
WAY-100635 was shown to block the 5-HTiA-mediated hyperpolarisation. This is
also consistent with that observed in the present study in the DRN. Also, WAY-
100635 blocked the 5-HT)A-mediated hyperpolarisation at the same concentration
(100 nM) and with the same exposure time (15 mins) in the DRN and the
hippocampus. As with other studies WAY-100635 was found to have no partial
agonist activity in the hippocampus (Fletcher et al 1996).
5-HT-evoked depolarisation in the hippocampus
Following the blockade of the 5-HTiA-mediated hyperpolarisation by WAY-100635
a 5-HT-evoked depolarisation was revealed. The 5-HT-evoked depolarisation was
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associated with an increase in input resistance and I/V analysis showed a reversal
value in the region of that expected for a potassium mediated event. This has been
previously reported in the hippocampus and is thought to be due to the closure of
potassium channels. The characteristics of the hippocampal 5-HT-evoked
depolarisation appear to be different to that observed in the DRN. The I/V data
suggests the hippocampal 5-HT-evoked depolarisation is due to the closure of




A 5-HT-evoked depolarisation in the DRN
Introduction
Serotonergic neurones of the DRN respond to exogenously applied 5-HT by a
membrane hyperpolarisation and a decrease in input resistance (Aghajanian and
VanderMaelen 1982b) this is mediated by the 5-HTiA autoreceptor (Sprouse and
Aghajanian 1987) the activation of which leads to the inhibition of cell firing.
However, there are known to be a number of 5-HT receptors other than the 5-HTia
receptor found in the DRN. It is also known that throughout the CNS a multiplicity
of 5-HT-evoked actions can coexist within the same neurone. For example, in the
medial pontine reticular formation 5-HT acts on 5-HTi and 5-HT2 receptors evoking
a membrane hyperpolarisation and depolarisation respectively, due to opposing
actions on different potassium conductances (Stevens et al 1992). 5-HT-evoked
effects with similar characteristics have also been observed in the nucleus prepositus
hypoglossi (Bobker and Williams 1995) and the cerebrocortical neurones (Araneda
and Andrade 1991; Davies et al 1987). In the hippocampus the 5-HTia receptor
mediates the hyperpolarisation but the depolarisation is mediated by 5-HT/t-like
receptors (Andrade and Nicoll 1987; Andrade and Chaput 1991), these effects are
due to opposing actions on the same potassium conductance. The present study has
used the 5-HTia antagonist WAY-100635 to look for similar multiple actions of 5-
HT coexisting within the DRN. This chapter will present evidence for the receptor
classification of the 5-HT-evoked depolarisation in the DRN.
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Results
A 5-HT-evoked depolarisation in the DRN
Following bath-application of 5-HT (100 pM) a typical cell hyperpolarised from a
resting membrane potential of -61 mV to -73 mV, a change of 12 mV (Figure 4.0 Ai,
Bi). This was accompanied by a decrease in input resistance from a resting value of
292.2 MQ to 121.7 MQ with 5-HT. The control and 5-HT I/V relationships
intersected at -88 mV. Following pre-application of WAY-100635 (100 nM), bath-
application of 5-HT (100 pM) evoked a membrane depolarisation from a resting
value of -61 mV to -57 mV (Figure 4.0 Aii, Bii). This was accompanied by a slight
decrease in input resistance from 298.2 MQ to 292.7 MQ. Following the
identification of the 5-HT-evoked depolarisation a pharmacological characterisation
was performed.
A Pharmacological Characterisation
To characterise the receptor involved in the 5-HT-evoked depolarisation in the DRN
the effects of different agonists and antagonists were investigated in the presence of
WAY-100635.
DOI mimics the depolarising action of 5-HT
The 5-HT2 receptor subtypes are commonly associated with 5-HT-evoked
depolarisation and so made a sensible starting point for investigation. The 5-HT2
agonist DOI (10 pM) evoked a depolarisation with similar properties to that of the 5-
HT-evoked depolarisation. In a typical WAY-100635 (100 nM) treated cell, 5-HT
(100 pM) evoked a depolarisation from a resting membrane potential of -63 mV to
-59 mV, a decrease of 4 mV (Figure 4.1Ai, Bi). This was accompanied by a decrease
in cell input resistance from 235.1 MQ to 222.7 MQ. In the same neurone a
subsequent application ofDOI (10 pM) depolarised the cell from -63 mV to -59 mV,
which was accompanied by a slight decrease in input resistance from 233.2 MQ to
225.9 MQ (Figure 4.1 Aii, Bii). Pooled data gave an average DOI (10 pM) evoked
depolarisation from a resting membrane potential of -62.4 ± 2.4
88
i) Control 5-HT (100 pM)
-61 mV
ii) WAY-100635 (100 nM) 5-HT (100 pM) + WAY-100635 (100 nM)
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Figure 4.0. Different actions of 5-HT in the DRN.
A. Voltage traces made in response to injected current pulses of 500 ms and
increments of 50 pA of a cell before and after the application of 5-HT (100 pM).
i) 5-HT (100 pM) evoked a hyperpolarisation.
ii) 5-HT (100 pM) evoked a depolarisation followingWAY-100635 (100 nM) treated.
B. Current-voltage relationships were obtained by measuring at the point t after
injecting a series of depolarising and hyperpolarising current pulses into the cell. The
cell had a resting membrane potential of -61 mV and an input resistance of 292.2
MQ.
i) Following bath-application of 5-HT (100 pM) the cell hyperpolarised to -73 mV.
This was accompanied by a decrease in input resistance to 121.7 MQ. The control and
5-HT I/V relationships intersected at -88 mV.
ii) Following pre-application ofWAY-100635 (lOOnM), bath-application of 5-HT
evoked a membrane depolarisation to -57 mV. This was accompanied by a slight











































Figure 4.1. DOI evoked a depolarisation with WAY-100635 in the DRN.
A. Voltage traces of cells in response to injected current pulses of 500 ms duration
and increments of 50 pA.
i) A depolarisation with 5-HT (100 pM).
ii) A depolarisation with DOI (10 pM).
B. Current-voltage relationships were obtained by measuring at the point T after
injecting a series of depolarising and hyperpolarising current pulses in the cell. I/V
plots obtained from a DRN neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM).
i) The DR neurone depolarised from a resting membrane potential of -63 mV to -59
mV. This was accompanied by a decrease in cell input resistance from 235.1 MO to
222.7 MO.
ii) I/V plots obtained from the same DR neurone before (circles) and after (triangles)
bath-application ofDOI (10 pM) while in the presence ofWAY-100635. The DRN
neurone depolarised from -63 mV to -59 mV following an application ofDOI (10
pM). This was accompanied by a decrease in input resistance from 233.2 MO to
225.9 MO.
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mV to -59.1 ± 3.2 mV, which was accompanied by a decrease in input resistance
from the resting level of 267.3 ± 10.3 MQ to 241.2 ± 15.2 MQ (n=3). Statistical
analysis with the t-test showed that DOI caused a significant membrane
depolarisation to a confidence interval of 95%.
mCPP did not evoke a depolarisation
The 5-HT2B/2c partial agonist mCPP (100 pM) did not evoke any response in WAY-
100635 (100 nM) treated cells at the concentration tested. In a typical neurone pre-
treated with WAY-10063 5 (100 nM) bath-application of 5-HT (100 pM) evoked a
depolarisation from a resting membrane potential of -60 mV to -56 mV, a change of
4 mV (Figure 4.2A). This was accompanied by a slight increase in cell input
resistance from 165.8 MQ to 172.7 MQ. Application ofmCPP (100 pM) to the same
cell in the presence ofWAY-10063 5 (lOOnM) did not evoke a change in membrane
potential from its resting value. There was, however, a slight decrease in cell input
resistance from 167.8 MQ to 157.2 MQ (Figure 4.2B). Averaged data for a group of
cells, that demonstrated a 5-HT (100 pM) evoked depolarisation with WAY-100635
(100 nM) treatment, showed no change with mCPP (100 pM). At rest the neurones
had a mean membrane potential of -60.1 ±2.1 mV and -61.5 ± 1.9 mV while in the
presence ofmCPP (n=3, 100 pM).
CP 93129 did not evoke a depolarisation
The 5-HTib agonist CP 93129 was administered to a cell with a resting membrane
potential of -64 mV and an input resistance of 344.2 MQ in the presence ofWAY-
100635 (100 nM). The cell showed a 5-HT (100 pM) evoked depolarisation in the
presence ofWAY-100635 (100 nM) to -59 mV and 303.9 MQ (Figure 4.3A).
Following bath-application ofCP 93129 (10 pM) the cell showed no change with a
membrane potential of -63 mV and an input resistance of 344.4 MQ (Figure 4.3B).
Pooled data (n=3) also showed CP 93129 had no effect on resting membrane









































Figure 4.2. mCPP with WAY-100635 did not change a DRN neurone.
A. I/V plots obtained from a DRN neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM). The DRN neurone depolarised from a resting
membrane potential of -60 mV to -56 mV, a change of approximately 4 mV. This was
accompanied by an increase in cell input resistance from 165.8 MQ to 172.7 MQ.
B. I/V plots obtained from the same DRN neurone before (circles) and after (squares)
bath-application ofmCPP (100 pM) while in the presence ofWAY-100635. The DRN
neurone did not change its membrane potential, -58 mV at rest and -58 mV with




Figure 4.3. CP 93129 with WAY-100635 did not change a DRN neurone.
A. I/V plots from a WAY-100635 treated cell (100 nM) with a resting membrane
potential of -64 mV and an input resistance of 344.2 MQ (circles) shows a 5-HT (100
pM) evoked depolarisation to -59 mV and input resistance of 303.2 MQ (squares).
B. In the same cell in the continued presence ofWAY-100635, bath-application of CP
93129 (10 pM) the cell, showed no change with a membrane potential of -63 mV and
an input resistance of 344.4 MQ (squares).
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Methysergide blocked the 5-HT-evoked depolarisation
To further characterise the receptor involved in the 5-HT-evoked depolarisation
antagonists were used to block the response. Application of the broad spectrum
5-HT antagonist methysergide (100 pM) blocked the depolarisation in five cells
confirming the serotonergic nature of the depolarisation. In a typical cell exposed to
WAY-100635 (100 nM) 5-HT (100 pM) evoked a depolarisation from a resting
membrane potential of -65 mV to -61 mV, a change of approximately 4 mV (Figure
4.4A). This was accompanied by a decrease in cell input resistance from 323.4 MQ
to 264.4 MQ. Following application ofmethysergide (100 pM) to the same WAY-
100635 (100 nM) treated cell the depolarisation was blocked (Figure 4.4B).
Bath-application ofmethysergide (n=8 of 8) (100 pM) had no effect on membrane
potentials from -64 ± 2.6 mV at rest to -65 ±1.9 mV with methysergide, a slight
input resistance increase was observed from resting a value of 313.1 ± 1.6 MQ to
320.1 ± 2.6 MQ. Prior to methysergide application 5-HT (100 pM) evoked a
depolarisation in the presence ofWAY-100635 (100 nM) from a resting value of
-63.6 ± 2.2 mV to -59.9 ± 1.6 mV during 5-HT (100 pM) application (n=8 of 8), a
significant depolarisation when statistically analysed with the t-test. There was an
associated input resistance decrease from 279.6 ± 61.7 MQ to 234.6 ± 52.7 MQ.
Pooled data from methysergide (100 pM) treated cells showed a blockade of the
effects of 5-HT (100 pM) with a slight membrane potential change from -63.6 ± 0.6
mV at rest to -62.9 ± 1.4 mV with 5-HT. The associated input resistance change was
also blocked, from 300.8 ± 88.1 MQ at rest to 296.6 ± 84.5 MQ with 5-HT (n=6 of
8). Statistical analysis showed, to a confidence interval of 95%, that 5-HT no longer
significantly changed the membrane potential in cells treated with methysergide.
The membrane potential and input resistance changes during the course of a typical
experiment are displayed in Figure 4.5. This figure first shows the action of bath-
application of 5-HT (100 pM) with the characteristic membrane hyperpolarisation






























Figure 4.4. Methysergide blocked the 5-HT-evoked depolarisation in the DRN.
A. I/V plots obtained from a DR neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM). The DR neurone depolarised from a resting membrane
potential of -65 mV to -61 mV, a change of approximately 4 mV. This was
accompanied by a decrease in cell input resistance from 323.4 MQ to 264.4 MQ.
B. Application of methysergide (100 pM) while in the presence ofWAY-100635
completely abolished the depolarisation, from a resting membrane potential, -63 mV
at rest and -63 mV with 5-HT, there was also with no change in cell input resistance
from 385.9 MQ to 398.3 MQ.
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Figure 4.5. Changes in a DRN neurone with three 5-HT applications.
A typical cell showed a demonstrated a 5-HTiA-mediated hyperpolarisation with bath-
application of 5-HT (100 pM), it hyperpolarised from -63 mV to -69 mV, with an
associated decrease in input resistance, from 219.9 MQ to 122.2 MQ. The cell
recovered to resting values following 5-HT washout. The addition ofWAY-100635
(100 nM) to the bath aCSF had no effect on membrane potential and input resistance.
A subsequent application of 5-HT (100 pM) while in the presence ofWAY-100635
(100 nM) no longer evoked a hyperpolarisation due to the blockade of the 5-HTiA
receptor by WAY-100635. The blockade with WAY-100635 revealed a 5-HT (100
pM) evoked a membrane depolarisation, from -63 mV to -59 mV, with a decrease in
input resistance, from 209.6 MQ to 177.4 MQ. Methysergide (100 pM) was then
bath-applied to the cell and was found to have no intrinsic activity in WAY-100635
(100 nM) treated cells. While in the presence of WAY-100635 (100 nM) and
methysergide (100 pM) bath-application of 5-HT (100 pM) had no effect on the
membrane potential, from -63 mV at rest to -63 mV with 5-HT. This was also
observed in the input resistance from a value of 209.1 MQ at rest to 210.6 MQ with
5-HT. Methysergide blocked the 5-HT-evoked depolarisation.
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The neurone changed in membrane potential from -63 mV to -69 mV and in input
resistance from 219.9 MQ to 122.2 MQ while in the presence of 5-HT (100 pM) and
showed recovery values with 5-HT wash out. The addition of WAY-100635 (100
nM) to the bath-aCSF is shown to have no effect on membrane potential and input
resistance. A subsequent bath-application of 5-HT (100 pM), in the continued
presence ofWAY-100635 (100 nM), no longer showed the 5-HTia- evoked
hyperpolarisation due to the blockade of the 5-HTia receptor by WAY-100635. The
blockade with WAY-100635 (100 nM) revealed a 5-HT (100 pM) evoked membrane
depolarisation, from -63 mV to -59 mV, and decrease in input resistance, from 209.6
MQ to 177.4 MQ. The analysis of the I/V data showed the 5-HT-evoked
depolarisation did not reverse in the range -120 mV to -60 mV (for an example see
Figure 4.0B). Methysergide (100 pM) was then bath-applied to the cell and was
found to have no intrinsic activity in WAY-100635 (100 nM) treated cells. While in
the presence ofWAY-100635 (100 nM) and methysergide (100 pM) an application
of 5-HT (100 pM) had no effect on the membrane potential. Methysergide blocked
the 5-HT-evoked depolarisation.
Methysergide, however, did not block the depolarisation in another two cells at lower
drug concentrations. In a typical cell from this group a control application of 5-HT
(100 pM) evoked a depolarisation in the presence ofWAY-100635 (100 nM) from a
resting membrane potential of -61 mV to -58 mV, a change of approximately 3 mV
(Figure 4.6A). This was accompanied by a decrease in cell input resistance from
306.4 MQ to 280.3 MQ. Following the application of methysergide (30 pM) in the
continued presence ofWAY-100635 (100 nM) 5-HT (100 pM) could still evoke a
depolarisation from -64 mV to -60 mV; this was accompanied by a decrease in input
resistance from 306.4 MQ to 280.3 MQ (Figure 4.6B).
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Current pA
Figure 4.6. Methysergide did not block the 5-HT-evoked depolarisation at lower
concentrations.
A. I/V plots obtained from a DR neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM). The DR neurone depolarised from a resting membrane
potential of -61 mV to -58 mV, a change of approximately 3 mV. This was
accompanied by a decrease in cell input resistance from 306.4 MQ to 280.3 MQ.
B. Following bath-application of methysergide (30 pM) 5-HT could still evoke a
depolarisation from -64 mV to -60 mV; this was accompanied by a decrease in input
resistance from 306.4 MQ to 280.3 MQ.
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Methysergide blocked the DOI-evoked depolarisation
Methysergide also blocked the depolarising action of DOI (n=2). A cell that had
already shown a 5-HT (100 pM) evoked depolarisation in the presence ofWAY-
100635 (100 nM) was treated with a bath-application ofDOI (10 pM) and a
depolarisation was evoked, this was performed in the continued presence ofWAY-
100635 (100 nM). The neurone depolarised from a resting membrane potential of -68
mV to -63 mV with DOI, a change of approximately 5 mV. This was accompanied
by a decrease in cell input resistance from 196.2 MQ to 128.1 MQ (Figure 4.7A).
Application ofmethysergide (100 pM) completely abolished the DOI (10 pM)
evoked depolarisation, with the membrane potential remaining unchanged at -67 mV
during DOI (10 pM) application in the continued presence ofWAY-10063 5 (100
nM). There was also little change in cell input resistance from 184.4 MQ to 192.1
MQ (Figure 4.7B).
Ketanserin blocked the 5-HT-evoked depolarisation
Application of the non-specific 5-HT2 receptor antagonist ketanserin (100 nM, n=3)
blocked the 5-HT-evoked depolarisation. A WAY-100635 (100 nM) treated cell
from this group depolarised in response to control application of 5-HT (100 pM)
from a resting membrane potential of -68 mV to -64 mV, a change of approximately
4 mV. This was accompanied by a decrease in cell input resistance from 257.5 MQ
to 246.6 MQ (Figure 4.8A). In the same cell the 5-HT (100 pM) evoked
depolarisation was blocked following the addition of ketanserin (100 nM) to the
bath-aCSF (Figure 4.8B). Figure 4.8B also shows that the I/V plots of the 5-HT-
evoked depolarisation reverse at approximately -50 mV. Pooled data showed that in
the presence ofWAY-100635 (100 nM) the cells depolarised on average from -67 ±
1.1 mV to -64 ±2.1 mV and showed an input resistance change with 5-HT (100 pM)
from 260.1 ± 36.5 MQ to 245.3 ± 23.9 MQ (n=3). The 5-HT-evoked depolarisation
was blocked completely by ketanserin (100 nM) from resting values of -66 ± 2.1 mV
and 255.1 ± 14.0 MQ to -65 ± 2.4 mV and 258.1 ± 22.3 MQ with 5-HT.
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Figure 4.7. Methysergide blocked the DOI-evoked depolarisation in the DRN.
A. I/V plots obtained from a DR neurone before (circles) and after (squares) bath-
application of DOI (10 pM). The DR neurone depolarised from a resting membrane
potential of -68 mV to -63 mV, a change of approximately 5 mV. This was
accompanied by a decrease in cell input resistance from 196.2 MQ to 128.1 Mfi.
B. Application of methysergide (100 pM) completely abolished the depolarisation,
with the membrane potential staying constant at -67 mV before and during DOI (10
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Figure 4.8. Ketanserin blocked the 5-HT-evoked depolarisation in a DRN cell.
A. Voltage traces in response to injected current pulses of 500 ms and increments of
25 pA inWAY-100635 treated cells (100 nM).
i) A 5-HT (100 pM) evoked depolarisation.
ii) Ketanserin (100 nM) blocked the 5-HT (100 pM) evoked depolarisation.
B. Current-voltage relationships were obtained by measuring at the point T after
injecting a series of depolarising and hyperpolarising current pulses in the cell. The
cell had a resting membrane potential of -69 mV and an input resistance of 257.5 MQ.
i) I/V plots obtained from a DR neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM). The DR neurone depolarised to -63 mV. This was
accompanied by a decrease in cell input resistance to 246.6 MQ.
ii) The 5-HT-evoked depolarisation was then blocked following the addition of the
5-HT2 antagonist ketanserin (100 nM) to the bath-aCSF.
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SB 200646 partially blocked the 5-HT-evoked depolarisation
The 5-HT2b/2C receptor antagonist SB 200646 (1 mM, n=3) partially blocked the 5-
HT-evoked depolarisation. This group of cells is typified by the WAY-100635 (100
nM) treated neurone illustrated in Figure 4.9 which shows a control depolarisation
with 5-HT (100 pM) from a resting membrane potential of -65 mV to -62 mV, a
change of 3 mV. This was accompanied by a decrease in cell input resistance from
152.1 MQ to 134.3 MQ. Following the application of SB 200646 (1 mM) 5-HT (100
pM) evoked a reduced depolarisation from -64 mV to -62 mV, a change of 2 mV,
with a change in input resistance from 156.3 MQ to 136.2 MQ. Pooled data for a
group ofWAY-100635 (100 nM) treated cells showing a 5-HT (100 pM) evoked
depolarisation from -63 ± 2.9 mV to -59 ± 1.9 mV, with an input resistance decrease
from 165.1 ± 32.7 MQ to 152 ± 42.6 MQ (n=3). In the same cells exposed to SB
200646 (1 mM) in the continued presence ofWAY-100635 (100 nM) a membrane
potential depolarisation was observed with 5-HT (100 pM) from -63 ± 4.1 mV to -60
±1.9 mV, with an associated input resistance decrease from 159 ± 38.8 MQ to 142 +
22.1 MQ. This may show that SB 200646 can partially block the 5-HT-evoked
depolarisation at the concentration tested.
MDL, 100 907 completely blocked the 5-HT-evoked depolarisation
The 5-HT2a antagonist MDL 100, 907 completely blocked the 5-HT-evoked
depolarisation (100 pM, n=3). A typical neurone from this group following pre-
treatment with WAY-100635 (100 nM) showed a control depolarisation with 5-HT
(100 pM) from a resting membrane potential of -66 mV to -62 mV, a change of 4
mV (Figure 4.1 OA). This was accompanied by a decrease in cell input resistance
from 210.1 MQ to 201.2 MQ. Following bath-application ofMDL 100, 907 (100
pM) while still in the presence ofWAY-100635 (100 nM) a subsequent application
of 5-HT (100 pM) did not evoke a depolarisation. The cell membrane potential
remained unchanged at -66 mV with 5-HT. The input resistance also showed little
change following incubation with MDL 100, 907, from 219.5 MQ at rest to 222.9
MQ with 5-HT (100 pM) (Figure 4.10A). This is a total block of the 5-HT-evoked
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Figure 4.9. SB 200646 partially blocked the 5-HT-evoked depolarisation in a
DRN cell.
A. Voltage traces in response to injected current pulses of 500 ms duration and
increments of 50 pA in WAY-100635 (100 nM) treated cells.
i) A 5-HT (100 pM) evoked depolarisation.
ii) SB 200646 (1 mM) partially blocked the 5-HT (100 pM) evoked depolarisation.
B. Current-voltage relationships were obtained by measuring at point T after injecting
a series of depolarising and hyperpolarising current pulses into the cell. The cell had a
resting membrane potential of -65 mV and resting input resistance of 153.4 MD.
i) I/V plots obtained from a DR neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM) show a depolarisation to -62 mV, accompanied by a
decrease in cell input resistance to 131.8 MQ.
ii) Following bath-application of SB 200646 (1 mM) 5-HT (100 pM) evoked a much






































Figure 4.10. MDL 100, 907 blocked the 5-HT-evoked depolarisation in the DRN.
A. I/V plots obtained from a DR neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM). The DR neurone depolarised from a resting membrane
potential of -66 mV to -62 mV, a change of approximately 4 mV. This was
accompanied by a decrease in cell input resistance from 210.1 MQ to 201.2 MQ.
B. Application ofMDL 100, 907 (100 pM) while in the presence ofWAY-100635
completely abolished the depolarisation, from a membrane potential of -66 mV at rest
and -66 mV with 5-HT (100 pM), there was also little change in cell input resistance
from 219.5 MQ to 222.9 MQ.
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depolarisation and is indicative of an effect mediated by the 5-HT2A receptor. This
was repeated in a further two cells with similar effects. Pooled data showed that with
WAY-100635 (100 nM) cells depolarised in response to 5-HT (100 pM) from -65 ±
2.1 mV to -61 ± 1.2 mV and showed an input resistance change from 220.1 ± 26.3
MQ at rest to 203.2 ± 29.1 MQ with 5-HT. The 5-HT-evoked depolarisation was
blocked completely by MDL 100, 907 (100 pM) from resting values of -65 ±1.9 mV
and 225.1 ±22.9 MQ to -64 ± 31.5 mV and 218.1 ± 28.1 MQ with 5-HT (100 pM).
Pindolol did not block the 5-HT-evoked depolarisation
The 5-HTia/ib antagonist pindolol (1 mM) failed to block the depolarisation (n=3) at
the concentration tested. A typical neurone pre-treated with WAY-100635 (100 nM)
depolarised with 5-HT (100 pM) from a resting membrane potential of -62 mV to -
58 mV, a change of approximately 4 mV (Figure 4.11A). This was accompanied by a
decrease in cell input resistance from 250.1 MQ to 235.2 MQ. Pooled showed that in
the presence ofWAY-100635 (100 nM) and pindolol (1 mM) the cell still
depolarised following an application of 5-HT from -63 mV to -59 mV (Figure
4.1 IB). This was also accompanied by a decrease in input resistance from 239.1 MQ
to 226.5 MQ. This was repeated in a further two cells with similar effects. In the
presence ofWAY-100635 (100 nM) the cells depolarised in response to 5-HT (100
pM) from -63 ±1.1 mV to -59 ± 2.0 mV and showed an input resistance change from
249.1 ± 22.3 MQ to 229.2 ± 41.5 MQ with 5-HT. The 5-HT (100 pM) evoked
depolarisation was not blocked by pindolol (1 mM) with the group showing a
depolarisation from resting values of -62 ±2.3 mV and 255.1 ±34.1 MQ to -62 ±2.5








































Figure 4.11. Pindolol did not block the 5-HT evoked depolarisation in the DRN.
A. I/V plots obtained from a DR neurone before (circles) and after (squares) bath-
application of 5-HT (100 pM). The DR neurone depolarised from a resting membrane
potential of -62 mV to -58 mV, a change of approximately 4 mV. This was
accompanied by a decrease in cell input resistance from 250.1 MQ to 235.2 MQ.
B. In the presence of pindolol (1 mM) the cell still depolarised following an
application of 5-HT (100 pM) from -63 mV to -59 mV. This was accompanied by a
decrease in input resistance from 239.1 MQ to 226.5 MQ.
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Summary
To discover which of the many 5-HT receptors was mediating the 5-HT-evoked
depolarisation a number of agonists (Table 4.0) and antagonists (Table 4.1) were
used. The agonists and antagonists were applied to WAY-100635 treated cells.
Agonists
Following the bath-application ofDOI, selective for 5-HT2 receptors, a membrane
depolarisation was observed with the same characteristics as the 5-HT-evoked
depolarisation. This points to the involvement of the 5-HT2 receptor subtypes in the
5-HT-evoked depolarisation. Bath-application ofmCPP, selective for the 5-HT2B/2C
receptors, did not have any effect on membrane potential or input resistance in
WAY-100635 treated cells at the concentration tested. This not only indicates that
the 5-HT2b/2c receptor subtypes do not mediate the 5-HT-evoked depolarisation, but
also that there is unlikely to be any electrophysiologically observable 5-HT2b/2c
receptor mediated events in the DRN under the present experimental conditions.
Agonist Site of Action Effect on WAY-100635 treated cells
DOI (10 pM, n=3) 5-HT2 Mimicked depolarisation
mCPP (100 pM, n=3) 5-HT2b/2c None
CP 93129 (10 pM, n=3) 5-HT,b None
Table 4.0. Actions of 5-HT agonists on the 5-HT-evoked depolarisation.
Following the bath-application of CP 93129, selective for 5-HT]B receptors, to
WAY-100635 treated cells there was no change to the membrane potential or input
resistance. This rules out the 5-HTib receptor subtype as mediating the 5-HT-evoked
depolarisation. This also indicates that any 5-HTib receptors in the DRN (Voigt et al
1991) have no electrophysiologically observable response under these conditions.
The 5-HTib receptor subtype has been shown to have autoreceptor properties
(Limberger et al 1991) and would be predicted to cause a membrane
107
hyperpolarisation. This study has found that the 5-HTib agonist used has no effect on
the excitability of serotonergic neurones in the DRN at the concentration tested. The
data suggests the involvement of 5-HT2 receptors in the mediation of the 5-HT-
evoked depolarisation in the DRN. It also indicates that the 5-HT2A receptor is most
likely to be involved as the lack of action ofmCPP rules out the 5-HT2B/2C receptor
subtypes. Confirmation of the involvement of 5-HT2 receptors in the 5-HT-evoked
depolarisation could only be made using antagonists.
Antagonists
The broad spectrum 5-HT antagonist methysergide was found to have no effect on
the membrane potential or input resistance. Pre-application ofmethysergide to a
number of cells showing the 5-HT-evoked depolarisation blocked the 5-HT-evoked
depolarisation (n=6 of 8). This suggests that the response is mediated by a 5-HT
receptor. Pre-application of methysergide also blocked the action of DOI confirming
that methysergide has antagonistic actions at the 5-HT2 receptor subtype.
Methysergide at lower concentrations did however fail to block the depolarisation in
another two cells. In one cell, while under the influence ofWAY-100635 and
methysergide, a hyperpolarisation was seen with 5-HT. This is a 5-HT-evoked
hyperpolarisation not mediated by the 5-HTiA receptor subtype providing further
evidence that other receptor subtypes found in the DRN are physiologically active.
Antagonist Site of Action Effect on Depolarisation
Methysergide (100 pM, n=8) 5"HTbroad spectrum Abolished
Ketanserin (100 nM, n=3) 5-HT2 Abolished
MDL 100, 907 (100 pM, n=3) 5-HT2A Abolished
mCPP (100 pM, n=3) 5-HT2B/2c No effect
SB 200646(1 mM, n=3) 5-HT2b/2c Possible partial blockade
Pindolol (ImM, n=3) 5-HTja/ib No effect
Table 4.1. Actions of 5-HT antagonists on the 5-HT-evoked depolarisation.
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The 5-HT2 receptor antagonist ketanserin has been shown to have binding sites
within the DRN (Pazos and Palacios 1985). Ketanserin was found to have no effect
on the membrane potential and input resistance ofDRN cells following treatment
with WAY-100635. Ketanserin blocked the 5-HT-evoked depolarisation, this
indicates that 5-HT2 receptors are involved in the 5-HT-evoked depolarisation. This
also confirms that some of the ketanserin binding sites observed in the DRN are due
to binding to 5-HT2 receptor subtypes. When applied to WAY-100635 treated cells
the 5-HT2b/2c receptor antagonist SB 200646 was found to have no effect on
membrane potential or input resistance. SB 200646 possibly showed a partial
blocked the 5-HT-evoked depolarisation at the concentration tested. The cells
showed a slight change in membrane potential, but still showed a decrease in input
resistance. This could be evidence that more than one receptor is involved in
mediating the 5-HT-evoked depolarisation, or it could be that SB 200646 is acting at
a limited number of 5-HT2a receptors. Bath-application of the 5-HT2A antagonist
MDL 100, 907 had no effect on membrane potential or input resistance and so has no
agonist activity on WAY-100635 treated cells. Pre-application with MDL 100, 907
resulted in blockade of the 5-HT-evoked depolarisation pointing to the probable
involvement of the 5-HT2A receptor subtype. Finally the 5-HTia/ib antagonist
pindolol was used and did not block the 5-HT-evoked depolarisation at the
concentration tested. This strongly suggests that the 5-HT2A receptor subtype
mediates the 5-HT-evoked depolarisation in the DRN.
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CHAPTER 5
Regulation of firing in the DRN neurone
Introduction
The firing pattern of neurones in the DRN is governed by a number of different
membrane properties and ion conductances. Burlhis and Aghajanian (1987) first
described the pacemaker potential as an intrinsic mechanism that allows a neurone to
follow a repeating cycle ofmembrane changes resulting in a regular firing pattern.
Each stage of the pacemaker potential is independently open to influence. Further to
direct changes to the intrinsic conductances of each stage of the pacemaker potential,
the pacemaker potential can only operate within tight membrane potential ranges.
For example, when the membrane in hyperpolarised by the presence of 5-HT the first
and initiating stage of the pacemaker potential is inoperative and firing is switched
off. Likewise, when the membrane in depolarised by the presence of noradrenaline
only a slight membrane change is needed to trigger an action potential and this
increases the rate of neuronal firing.
This chapter will investigate the conductances involved in regulating the firing
pattern of neurones in the DRN. This will be carried using the potassium channel
blockers tetraethylammonium (TEA) and apamin. TEA is a non-specific potassium
channel blocker at, for example, the delayed rectifier channel, the large conductance
calcium-activated potassium channel and voltage-sensitive potassium channels
(Stanfield 1983). Apamin, a toxin taken from honey bee venom, selectively blocks
small conductance calcium-activated potassium channels (Hugues et al 1982). These
compounds have a profound effect on neuronal firing, such as delaying repolarisation
following the action potential and blocking the AHP (Scroggs and Anderson 1990;
Yarom et al 1985). The role of 5-HT in regulating the firing properties ofDRN
neurones will also be investigated to discover if the 5-HT released with each action
potential can feedback to modulate further firing and 5-HT release.
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Results
Actions of TEA on the action potential and the AHP
A short (3 ms) depolarising current step (0.25 nA) was injected into a typical cell
generating an action potential overshooting to +38 mV, which was 5 ms in length at
its broadest point, followed by an AHP of 9 mV (Figure 5.OA). Following the
application ofTEA (3 mM) the cell generated an action potential overshooting by
+35 mV, which was much longer in duration, 50 ms, took longer to repolarise and
reduced the amplitude of the AHP to 5 mV (Figure 5.OB). It seems likely that TEA is
acting by blocking potassium conductances involved in action potential
repolarisation and the generation of the AHP. The extended action potential allows
more calcium to enter the cell. This extra calcium does not appear to affect the AHP.
This may be due to TEA blocking the fast component of the AHP, which governs the
peak amplitude. Also shown in Figure 5.OB the slow AHP was shorter in duration in
the presence of TEA from 150 ms to 20 ms. This was observed in a further two cells.
Action of apamin on the AHP
To investigate which of the many potassium channels was involved in the AHP
apamin was applied to the cell. In a typical cell at its resting membrane potential a
short (5 ms) depolarising pulse (0.2 nA) was injected and an all-or-nothing action
potential was evoked, followed by an AHP with a peak of 10 mV after approximately
5 ms (Figure 5.1). Following bath-application of apamin (100 nM) there was a long
lasting inhibition of the AHP. The AHP only reached 8 mV and was much shorter in
duration; this did not recover after extensive apamin washout. This indicated that the
duration of the AHP in the DRN cell is determined by the activity of an apamin-
sensitive conductance suggesting that small conductance calcium-activated
potassium (SK) channels mediate this late phase. These SK channels are activated
either as calcium enters the cell or is released from internal stores during the action
potential. The amount of calcium that enters the cell could depend on the duration of
the spike and if so the AHP would end when most of the extra calcium had been
removed. A similar blockade of the late component of the AHP was observed in a
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Figure 5.0. Action of TEA on the action potential and AHP in the DRN.
A. A short (3 ms) depolarising current step (0.25 nA) was injected into a cell
generating an overshooting action potential of +38 mV which was 3 ms in duration
and was followed by an AHP of 9 mV.
B. Following the application of TEA (3 mM) the cell generated an overshooting
action potential of +35 mV, which was much longer in duration, 50 ms, took much
longer to repolarise and has a reduced AHP of 5 mV following injection of the same
current step. The membrane potential was clamped to the resting membrane potential








Figure 5.1. Action of apamin on the AHP in the DRN.
When at a resting membrane potential of -62 mV a short (5 ms) depolarising pulse
(0.2 nA) was injected and an all-or-nothing action potential was evoked. This was
followed by an AHP. The AHP reached a peak of 14 mV after approximately 5 ms.
Following bath-application of apamin (100 nM) there was a long lasting inhibition of
the AHP. The AHP only reached 11 mV in the presence of apamin and had a shorter
duration; this did not recover after extensive apamin washout. The membrane
potential was clamped to the resting membrane potential by the manual injection of
current.
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component of the AHP, termed the slow AHP, highlights the remaining early, TEA-
sensitive component, termed the fast AHP.
Action of TEA on spike firing
The role of the TEA-sensitive conductance of the action potential and AHP in the
regulation of cell firing was investigated. In one neurone at its resting membrane
potential a long (1000 ms) depolarising current pulse (0.2 nA) evoked three regular,
all-or-nothing action potentials followed by an AHP of 5 mV (Figure 5.2A).
Following bath-application ofTEA (3 mM) there was an increase in spike firing
frequency to five spikes where each successive spike was shorter in duration and the
cell showed adaptation (Figure 5.2B). Adaptation was characterised by a gradually
slowing spike frequency until the cell could no longer reach its firing threshold and
firing was switched off (Hille 1992). The AHP had a much longer duration possibly
due to increased calcium influx. The AHP following a single spike does not appear to
be the same as an AHP following a train of spikes; this is highlighted in the lack of
blockade by TEA of the early component of the AHP following a train of spikes.
Action of apamin on spike firing
The ability of the DRN cell to show spike frequency adaptation was investigated
using apamin. DRN cells showed a regular firing pattern following the injection of a
long depolarising current step. In a typical cell at its resting membrane potential of
-63 mV a long (1000 ms) depolarising pulse (0.2 nA) evoked a series of 9 regular,
all-or-nothing action potentials forming a train of spikes along the whole length of
the pulse, followed by an AHP of 12 mV (Figure 5.3A).
Following bath-application of apamin (100 nM) there was a long lasting inhibition of
this regular firing pattern, any change in membrane potential was compensated for by
manual injection of current to return the cell to the resting membrane potential. There
was an increase in firing rate with apamin; the cell fired twenty-two high frequency
action potentials in response to the same amplitude current pulse when under the





Figure 5.2. Action of TEA on the firing pattern in the DRN.
A. When at a resting membrane potential of -58 mV a long (1000 ms) depolarising
pulse (0.2 nA) evoked a series of regular, all-or-nothing action potentials followed by
an AHP of 5mV.
B. Following bath-application ofTEA (3 mM) there was an increase in spike firing
frequency with a long lasting inhibition of spike accommodation. The action potential
was followed an AHP of 7 mV, with a longer lasting late component. This did not
recover after extensive washout. The membrane potential was clamped to the resting











Figure 5.3. Action of apamin on spike firing in the DRN.
A. When at a resting membrane potential of -63 mV a long (1000 ms) depolarising
pulse (0.2 nA) evoked a series of regular, all-or-nothing action potentials followed by
an AHP of 12 mV.
B. Following bath-application of apamin (100 nM) there was a long lasting inhibition
of spike accommodation and an increase in firing rate. The AHP was reduced to 4 mV
in the presence of apamin; this did not recover after extensive apamin washout. The
membrane potential was clamped to the resting membrane potential by the manual
injection of current.
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firing accommodation. There was also an overall decrease in spike height throughout
the spike train and the cell showed adaptation (Figure 5.3B). The AHP was reduced
to 7 mV despite the increase in the number of spikes; this did not recover after
extensive apamin washout. The duration of the AHP is completely inhibited by
apamin, this may indicate that the AHP following a train of spikes is completely
made up of the activity of SK channels. When under the influence of apamin the cell
showed spike adaptation pointing to the involvement of the SK channels in the
generation of the spike and the regulation of spike frequency.
Action of TEA on membrane properties
Examination of any change in membrane potential and cell input resistance gave a
guide to what conductances were involved in the action TEA has on a cell. In a
typical experiment the cell had a control membrane potential of -65 mV and an input
resistance of 276.5 MQ. Following bath-application of TEA (3 mM) the cell retained
its resting membrane potential of -65 mV, but showed an increase in input resistance
to 362.9 MQ (Figure 5.4A). This showed the cell was undergoing channel blockade
under the influence of TEA. TEA was found to increase input resistance in a further
three cells from 281.1 ± 10.2 MQ to 351 ± 15.2 MQ.
Action of apamin on membrane properties
Examination of any change in membrane potential and cell input resistance gave a
guide to what conductances are involved in the action of apamin on a cell. In a
typical experiment the cell had a control membrane potential -66 mV and an input
resistance of 260.1 MQ (Figure 5.4B). Following bath-application of apamin (100
nM) the cell showed a membrane depolarisation to -62 mV, with an associated
increase in input resistance to 332.8 MQ and a reversal value of -90 mV. Thus
apamin blocks channels that are open at the resting membrane potential. Similar
changes were observed in another two cells with an average membrane
depolarisation from -67 ±3.9 mV to -63.3 ± 2.6 mV, an average increase in input
resistance from 278.5 + 10.4 MQ to 321 ± 8.9 MQ and an average reversal value of
-91 ± 1.9 mV, close to that expected for a potassium-mediated event.
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Figure 5.4. Action of TEA and apamin on membrane properties in the DRN.
A. Following bath-application of TEA (3 mM) a cell with a resting membrane
potential of -65 mV and an input resistance of 276.5 MQ (circles) retained its resting
membrane potential of -65 mV, but showed an increase in input resistance to 362.9
MQ (squares).
B. Following bath-application of apamin (100 nM) a cell with a resting membrane
potential of -66 mV and an input resistance of 260.1 MQ (circles) depolarised to -62
mV, with an associated increase in input resistance to 332.8 MQ (squares). The I/V
plots reversed at -90 mV.
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Action of 5-HT on spike width
In typical cell at a resting membrane potential of -66 mV a short (3 ms) depolarising
pulse (0.1 nA) evoked an all-or-nothing action potential followed by an AHP.
Following bath-application of 5-HT (100 pM) the spike width was reduced from
4.0 ms to 3.5 ms, measured at its broadest point. The spike height was slightly
reduced. The decreased spike width may be due to a reduction in the amount of
calcium entering the cell leading to a smaller AHP (Figure 5.5A). Bath-application of
WAY-100635 (100 nM) reduced the spike width in a similar way to 5-HT, from
4.3 ms to 4.0 ms at its broadest point (Figure 5.5B). Following the application of
WAY-100635, 5-HT continued to have a slight effect on spike width suggesting that
5-HT may modulate spike width through non-5-HTiA receptors (Figure 5.5C).
Similar affects on the spike width were observed in a further eight cells where on
average 5-HT reduced the spike width from 4.0 ± 0.2 ms to 3.4 ± 0.1 ms (n=9 of 15).
Action of 5-HT on the AHP
5-HT is known to inhibit a calcium channel (Penington et al 1991), the role this
channel has on the action potential and AHP was investigated. The 5-HTiA receptor
is negatively coupled to calcium influx, where the application of 5-HT reduces
calcium conductance (Penington et al 1991). By blocking the 5-HTiA-mediated effect
using the 5-HTiA antagonist WAY-100635 the actions of 5-HT on the calcium
current could be investigated indirectly by examining AHP amplitude and duration.
In a neurone at its resting membrane potential a short (5 ms) depolarising pulse (0.2
nA) evoked an all-or-nothing action potential followed by an AHP (Figure 5.6A). As
the membrane potential hyperpolarisation and decrease in input resistance evoked by
5-HT can affect the size of the AHP, the cell was manually held at the resting level
by applying a depolarising current to the cell. The AHP reached a peak of 9 mV after
approximately 5 ms. Following bath-application of 5-HT (100 pM) the peak of the
AHP reduced to 7 mV. The duration of the AHP is reduced under the influence of
5-HT so that the AHP returned to the resting membrane potential more quickly.
Following an incubation in WAY-100635 (100 nM) the AHP reached the same peak







Figure 5.5. Action of 5-HT on spike width in the DRN.
A. Superimposed traces in the same cell before and during an application of 5-HT. At
a resting membrane potential of -66 mV a short (3 ms) depolarising pulse (0.1 nA)
evoked an all-or-nothing action potential followed by an AHP. Following bath-
application of 5-HT (100 pM) the spike width was reduced from 4.0 ms to 3.5 ms
when measured at it broadest point. This resulted in a decrease in the AHP. The spike
height was slightly reduced.
B. Bath-application ofWAY-10063 5 (100 nM) reduced the spike width from 4.3 ms
to 4.0 ms.
C. Following the application ofWAY-100635 5-HT continues to have a slight effect
on the spike, the width was reduced from 4.3 ms to 4.1 ms. The membrane potential
was clamped to the resting membrane potential by the manual injection of current.
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Figure 5.6. Action of 5-HT on the AHP in the DRN.
A. At a resting membrane potential of -66 mV a short (5 ms) depolarising pulse (0.2
nA) evoked an all-or-nothing action potential followed by an AHP. The AHP reached
a peak of 9 mV after approximately 5 ms. Following bath-application of 5-HT (100
pM) there was an inhibition of the AHP, it reached a peak of 7 mV. The AHP
decreased more quickly under the influence of 5-HT.
B. In the same cell bath-application of WAY-10063 5 (100 nM) the AHP was similar
in size, it reached a peak of 9 mV, but the AHP did reduce more quickly.
C. Following pre-application of WAY-100635 (100 nM) bath-application of 5-HT
(100 pM) only slightly reduced the duration of the AHP. The membrane potential was
clamped to the resting membrane potential by the manual injection of current.
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application of WAY-10063 5 (100 nM) bath-application of 5-HT (100 pM) no longer
inhibited the AHP (Figure 5.6C). This may indicate the involvement of the 5-HT]A
receptor and the calcium conductance modulated by 5-HTiA in the regulation of cell
firing via its inhibition of the AHP. However, 5-HT may be acting directly on
potassium channels. The blockade of the 5-HT-evoked reduction of the duration of
the AHP was observed in a further five cells (n=6 of 15).
Action of 5-HT on spike frequency
5-HT also has a role in spike firing frequency regulation that may be the
consequence of the actions of 5-HT on the action potential and the AHP. In a typical
cell at rest a long (1000 ms) depolarising pulse (0.1 nA) evoked a series of six
regular, all-or-nothing action potentials followed by an AHP (Figure 5.7A).
Following bath-application of 5-HT (100 pM) there was an inhibition of the AHP
from 11 mV to 5 mV where the duration of the AHP was reduced (Figure 5.7B).
There was also an increase in the spike-firing rate; the cell now fired seven action
potentials. In the presence ofWAY-100635 (100 nM) the AHP was still small at 6
mV, following an application of 5-HT, but there was recovery of the spike-firing
rate, the cell fired five action potentials (Figure 5.7C). A similar 5-HT-induced
increase in spike firing rate was observed in a further 4 cells and may indicate the
involvement of the 5-HT )A receptor in regulating spike frequency.
Action of CP 93129 on the AHP
The 5-HTib agonist CP 93129 (10 pM) was tested on WAY-100635 (100 nM)
treated cells that had already demonstrated a 5-HT modulated decrease in the AHP.
In one cell at a resting membrane potential of -64 mV a short (3 ms) depolarising
pulse (0.5 nA) evoked an all-or-nothing action potential followed by an AHP of 15
mV (Figure 5.8A). Bath-application of 5-HT (100 pM) resulted in an AHP with the
same peak, but a reduced duration. In the same cell bath-application of CP 93129 (10
pM) did not change the peak of the AHP, but the duration of the AHP was slightly
reduced (Figure 5.8B). CP 93129 did not change the spike width or height of the

















Figure 5.7. Action of 5-HT on spike frequency in the DRN.
A. When at a resting membrane potential of -68 mV a long (1000 ms) depolarising
pulse (0.1 nA) evoked a series of regular, all-or-nothing action potentials followed by
an AHP of 11 mV.
B. Following bath-application of 5-HT (100 pM) there was a slight inhibition of the
AHP to 5 mV where the AHP duration was reduced. There was also an increase in the
spike-firing rate.
C. In the presence ofWAY-100635 (100 nM) the AHP was still small, 6 mV,
following an application of 5-HT (100 pM), but the spike-firing rate was restored.
The membrane potential was clamped to the resting membrane potential by the
manual injection of current.
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Figure 5.8. CP 93129 does not change the AHP in the DRN.
A. At a resting membrane potential of -64 mV a short (3 ms) depolarising pulse (0.5
nA) evoked an all-or-nothing action potential followed by an AHP of 15 mV. Bath-
application of 5-HT (100 pM) resulted in an AHP with the same peak, but a reduced
duration.
B. In the same cell bath-application of CP 93129 (10 pM) did not change the peak of
the AHP, but the duration of the AHP was only slightly reduced. The membrane





The present study has shown that the DRN exhibits evidence of two independent
conductances being involved in the generation and maintenance of the AHP. The
AHP shows a reversal level of approximately -90 mV; the predicted reversal value of
potassium mediated events. The first conductance is made up of a fast TEA-sensitive
conductance activated during the action potential and is involved in the cell
repolarisation and controls the size of the peak of the AHP. The second conductance
is a later slow conductance that governs how quickly the cell returns to the resting
membrane potential. Bath-application of apamin to the cell resulted in the AHP being
shorter duration; therefore SK channels are responsible for maintaining the duration
of the AHP in the DRN. The SK channels are activated following the increase in
calcium concentration during the action potential.
Firing Frequency, Accommodation and Adaptation
DRN neurones typically fire single action potentials in a regular pattern. DRN
neurones also do not typically show spike accommodation, adaptation or burst firing;
properties that might be consistent with pacemaker activity. Following the
application of TEA the firing rate of the neurone increased and the cell showed
adaptation where the AHP gradually slows the spike frequency until the train of
spikes is halted. This shows that the TEA-sensitive conductance is important in
regulating spike frequency.
Following the addition of apamin, DRN cells showed an increase in firing frequency,
firing accommodation and adaptation. Cells fired a rapid, high frequency train of
action potentials where each spike is consistently smaller in amplitude with a
gradually increasing interspike interval. This is firing accommodation. The cells also
show adaptation. The pattern of firing now resembles burst firing. There is also a
reduction in the AHP. This shows that SK channels are involved in preventing the
DRN cell showing a burst firing pattern and allowing the cell to show pacemaker
activity. This indicates that not only do DRN neurones possess the conductances
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needed to maintain pacemaker activity it also shows that these conductances can be
altered by ion channel activation. It may be that these ion channels can be switched
on and off to change the firing pattern of the neurone. Therefore, neurones of the
DRN may be able to switch from firing either a single regular action potential, which
is most commonly observed, to firing a burst, which may give a cell certain
advantages such as the ability to release extra quantities of 5-HT or change the
pattern of 5-HT release.
5-HT-evoked Spike Narrowing
Following the application of 5-HT the duration of the action potential was reduced.
This may be the result of the inhibition of the calcium component of the action
potential. 5-HT is known to modulate a calcium channel via activation of the 5-HTiA
receptor (Penington and Kelly 1990) where the application of 5-HT reduces the
calcium current. WAY-10063 5 itself reduced the spike width and may be acting as a
partial agonist. Alternatively WAY-10063 5 could be acting directly by blocking
potassium or calcium channels. IfWAY-100635 does have 5-HT]A agonist
properties it is impossible to know if WAY-100635 is blocking 5-HT-evoked spike
narrowing, because the spike is already reduced in duration by the action ofWAY-
100635. The work ofNooney and Kelly (1998) has shown that WAY-100635
antagonises the 5-HT-evoked modulation of calcium channels in the isolated channel
preparation. This may mean either that the 5-HT-evoked spike narrowing is due to
modulation of calcium channels not linked to the 5-HTiA receptor or that 5-HT is
acting at other ion channels, such as potassium ion channels, activated during the
action potential. This may also be true of the action ofWAY-100635 on the duration
of the action potential.
The AHP and 5-HT
Following bath-application of 5-HT the peak of the AHP is similar, however the
duration of the AHP is reduced. This effect is seen in conjunction with the 5-HT-
evoked spike, but may not be linked. As SK channels are calcium-sensitive it may be
that if less calcium enters the cell then less channels will be activated. If so the
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calcium channel mediated by the 5-HTia receptor may have a role in the generation
of the AHP. However, 5-HT may also be acting directly on the apamin-sensitive SK
channels that generate the later component of the AHP. Penington et al (1991) have
shown that 5-HT-evoked modulation of calcium channels is linked to the activation
of an outward calcium-sensitive potassium current.
WAY-100635 was also found to reduce the AHP. Again this is an example ofWAY-
100635 showing agonist activity and may be related to the effect WAY-100635 was
having on spike width or could be due to the modulation of apamin-sensitive SK
channels. Due to the action ofWAY-100635 it was impossible to discover if the 5-
HTia receptor subtype mediated the 5-HT-evoked reduction in the AHP.
Firing frequency and 5-HT
Bath-application of 5-HT may have increased the firing rate of the cell, resulting in
more action potentials being generated by the same size current step. Firing
frequency is regulated in a number ofways. It is partly regulated by the AHP. The
AHP delays return to the resting membrane potential and in turn the threshold
potential. 5-HT increases the rate of decay of the AHP. Following the addition of
WAY-100635 to the bath-aCSF, 5-HT application no longer changed the firing rate,
but the AHP was still small. This indicates that the 5-HTja receptors may in some
way modulate the firing rate ofDRN neurones. However, the AHP following a train
of spikes seems to be unaffected by the 5-HTia receptor activation. This means that
the calcium influx due to the calcium channels modulated by the 5-HTia receptor
have either only a minor or no role in the calcium influx that occurs during a train of
action potentials. The SK channels appear to have a role in the regulation of firing
frequency so 5-HT could be acting directly on SK channels to increase firing rate.
However, the work with apamin revealed a very distinctive firing pattern that was
not observed with 5-HT. This may indicate that 5-HT is changing the firing rate of




This chapter will review some of the points raised in the result chapters. Firstly, there
will be discussion of the 5-HTiA-mediated hyperpolarisation and its blockade by
WAY-10063 5 and the actions of WAY-100635 in the DRN and hippocampus.
Secondly, the chapter will review and discuss the actions of 5-HT as revealed by
WAY-100635. This section pays particular attention to the 5-HT-evoked
depolarisation revealed in the DRN following the application ofWAY-100635,
including data on the ionic mechanism and receptor classification. Thirdly, this
chapter will review the ionic mechanisms that control the firing pattern ofDRN
neurones and the actions of 5-HT on this firing pattern.
Actions of 5-HT on the DRN neurone
The present study has shown that 5-HT can regulate cell firing in the DRN by
manipulating the membrane potential. In agreement with other reports (Aghajanian
and VanderMaelen 1982) 5-HT evokes an inhibitory response via activation of 5-
HTia receptors. This study tested the new 5-HTiA selective antagonist WAY-100635
on this well characterised response.
The 5-HT1A-evoked hyperpolarisation
The principal action of bath-application of 5-HT on neurones of the DRN is
inhibitory. This inhibitory action is the result of an evoked membrane
hyperpolarisation making the cell less likely to fire an action potential by holding its
membrane potential at a level below the firing threshold membrane potential. The
action is associated with a decrease in input resistance. I/V analysis showed that the
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response reversed at around -90 mV, indicative of the 5-HT-evoked
hyperpolarisation following the opening of potassium channels.
The receptor mediating the 5-HT-evoked membrane hyperpolarisation has been
termed the somatodendritic autoreceptor. Somatodendritic refers to the receptors
being located on the soma and dendrites on serotonergic cells. The term autoreceptor
derives from the fact that serotonergic cells of the DRN release 5-HT into the
extracellular space and when the concentration of this released 5-HT has reached a
certain level further 5-HT release is inhibited by the membrane hyperpolarisation,
making the cell less excitable. Early work showed that LSD inhibited DRN cell
firing in a similar way to 5-HT (Aghajanian et al 1968). Using the brain slice
preparation it was shown that the ionic basis of the response to 5-HT was potassium
mediated and involved the opening of potassium channels (Aghajanian and Lakoski
1984). The potassium channels involved were further characterised and found to be
inwardly rectifying (Williams et al 1988). This 5-HT-mediated opening of inwardly
rectifying potassium channels has also been characterised in acutely isolated
(Penington et al 1993a) and individually microcultured (Johnson 1994) DRN
neurones. Further to this, Penington et al (1993b) showed that the 5-HT induced
increase in the potassium current results from a greater probability of opening of
unitary resting potassium channel activity. The data of the present study is consistent
with these previously reported results.
The inhibitory 5-HTiA receptor mediated hyperpolarisation has been observed in a
number of neuronal cell types and many different areas of the brain. The neurones of
the CA1 region of the hippocampus show a 5-HT-evoked, dose-dependent membrane
hyperpolarisation, which is associated with a decrease in input resistance as a result
of the opening of inwardly rectifying potassium channels (Andrade and Nicoll 1987),
characteristics in common with the observations in the DRN. These characteristics
are also true of the 5-HTiA receptor mediated hyperpolarisation in the medial pontine
nucleus (Stevens et al 1992), the rat association cortex (Araneda and Andrade 1991),
the lateral septal neurones (Joels et al 1987), the neurones of the midbrain
periaqueductel grey region (Behbehani et al 1993) and in rat ventromedial
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hypothalamic neurones (Newberry 1992). Roberts and Straughan (1967) observed in
vivo that 5-HT inhibits firing in cortical neurones. This inhibition has also been
observed in the somatosensory cortex (Davies et al 1987) and the cerebral cortex
(Bradshaw et al 1983).
It is now widely accepted that the 5-HTiA receptor subtype mediated this inhibitory
effect. However, this was assumed from the use of 5-HTiA agonists, such as 8-OH-
DPAT or non-selective antagonists, such as spiperone. Used in vivo the 5-HTiA
agonist 8-OH-DPAT potently inhibits cell firing in a dose dependent manner (Pan et
al 1993; Sprouse and Aghajanian 1987). In the brain slice 8-OH-DPAT produced a
membrane hyperpolarisation and a decrease in input resistance (Sprouse and
Aghajanian 1987) mimicking the action of 5-HT. However, the lack of compounds
with purely antagonist activity has prevented the characterisation of this action with
antagonists. In this study the recently developed 5-HTiA antagonist WAY-100635
was tested by its ability to block the 5-HT-evoked hyperpolarisation.
WAY-100635 in the DRN and the hippocampus
WAY-100635 has been reported as a selective 5-HTiA antagonist (Fletcher et al
1996) in the rat brain, with the binding characteristics of a 5-HTiA radioligand in the
rat CNS (Khawaja et al 1995). It is reported as having no agonist activity at the 5-
HTiA receptor in the DRN neurone, when studied extracellularly (Corradetti et al
1996), or the pyramidal cells of the CA1 region of the hippocampus. Studies
performed in vivo showed WAY-100635 to have no partial agonist activity in many
physiological and behavioural models including the isolated guinea pig ileum
preparation and the 8-OH-DPAT induced behaviour syndrome (Forster et al 1995).
WAY-100635 can block the 5-HTiA-evoked membrane hyperpolarisation observed
in the CA1 region of the hippocampus where WAY-100635 can also block the 5-HT
induced decrease in excitatory neurotransmission (Corradetti et al 1996). WAY-
100635 antagonises the decrease in the amplitude of the NMDA receptor-mediated
component of the EPSP's induced by 5-HT (Corradetti et al 1998). It also blocks the
5-HT and 5-HTiA agonist induced inhibition of cell firing in the DRN (Craven et al
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1994; Fletcher et al 1993; Forster et al 1995). WAY-100635 application performed in
vivo leads to an increase in the firing rate of serotonergic cells of the DRN in the
anaesthetised cat (Fornal et al 1994), increasing 5-HT release. WAY-100635
reverses the partial agonist activity of pindolol in the DRN, where pindolol inhibits
cell firing, and in the frontal cortex, where pindolol reduces 5-HT release (Clifford et
al 1998). WAY-100635 shows competitive antagonism with 8-OH-DPAT in the
guinea pig DRN (Mundey et al 1996). This study also showed that WAY-100635
application in vivo can increase neuronal firing. Mundey et al (1996) concluded that
this is probably because of the blockade of a 5-HTiA-mediated inhibitor tone acting
on serotonergic neurones resulting in an increase in 5-HT release and 5-HT2
receptor-mediated effects. WAY-100635 has been widely used as an in vivo
radioligand and has been shown to have heterogeneity of signal consistent with the
known localisation of the 5-HTia receptor subtype (Hume et al 1994).
The present study agreed with the findings that WAY-100635 has no action on
membrane potential or input resistance and blocks 5-HTiA-mediated events. When
applied to the DRN neurone for up to 30 minutes WAY-100635 was found to have
no effect on resting membrane potential or input resistance indicating that it has no
agonist activity at the 5-HT)A receptor. This is in contrast to a number of compounds
previously claimed to have purely antagonist activity. For example, NAN-190 has
been found to have partial agonist activity in the DRN (Hodgkiss et al 1992). This
study showed that application ofNAN-190 alone frequently caused a membrane
hyperpolarisation associated with a decrease in input resistance. BMY 7378, SDZ-
216-525 and WAY-100135 also have partial agonist activity (Fletcher et al 1993).
The problem of partial agonist activity in the DRN may be the result of the DRN
neurones having a large receptor reserve for the 5-HTia receptor (Meller et al 1990).
Compounds that have previously been described as 5-HTia receptor antagonists have
been found to be either non-selective or partial agonists or a combination of both.
Spiperone is a 5-HTia antagonist (Schoeffter and Hoyer 1990) but is non-selective,
for example it has activity at the 5-HT2 receptor subtypes (Leysen et al 1981). A
number of P-adrenoceptor antagonists, such as propanolol and pindolol, have 5-HTiA
antagonistic activity (Tricklebank 1985; Sprouse and Aghajanian 1987) but are also
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5-HTib receptor antagonists. The more recently developed compounds are more
selective but cannot be described as "silent". The compounds BMY 7378 (Yocca et
al 1987) and NAN-190 (Glennon et al 1988) block many of the reported 5-HTja-
evoked responses (Yocca et al 1987). However, they have also been described as
partial agonists at the 5-HTiA receptor (VanderMaelen et al 1987; Hodgkiss et al
1992). The recent compound SDZ 216-525 was originally described as "silent" and
has antagonist activity at a number of known 5-HTiA-evoked responses (Hoyer et al
1992; Boddeke et al 1992). However, this too has been found to have partial agonist
activity at the 5-HTja autoreceptor (Sharp et al 1997) where it can inhibit cell firing.
The compound WAY-100135 (Fletcher et al 1993; Lanfumey et al 1993b) has 5-
HTia antagonist activity, but also has 5-HTja partial agonist actions, for example, it
can induce an inhibition in cell firing in the DRN (Fletcher et al 1993). WAY-
100635 is the latest candidate for a silent 5-HTia antagonist and all studies so far
have shown much evidence to support this.
However, in the present study, while under the long term influence ofWAY-100635
some cells showed a slight membrane potential drift in a depolarising direction,
leading to an increase in firing rate. This depolarisation is not consistent with partial
agonist activity, which would be observed as a hyperpolarisation. The depolarisation
following long term application of WAY-10063 5 may be a consequence of the
blockade of the tonic inhibition exerted by 5-HT in the DRN (Craven et al 1994;
Forster et al 1995), or may result from an excitatory action of endogenously released
5-HT. Another possibility is that WAY-100635 is blocking the potassium channels
involved in maintaining the resting membrane potential in the DRN neurone. If this
were true then the depolarising membrane potential drift would be associated with an
increase in input resistance and indeed a slight increase in input resistance is
observed in some cells. To investigate if WAY-100635 is acting by blocking a
potassium current then this may be investigated by performing a voltage clamp
experiment to follow the activity of the potassium current maintaining the membrane
potential.
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The membrane potential changes more commonly observed in the DRN following
long-term recordings are the result of the loss of the excitatory action of
noradrenaline (Baraban and Aghajanian 1980a). Noradrenaline acts at the ai-
adrenoceptor to drive cell firing. In the brain slice preparation noradrenaline is
washed away leading to a loss of firing and a drift in membrane potential in the
hyperpolarising direction. This observation suggests that the depolarising effect of
WAY-10063 5 may be an active phenomenon.
WAY-10063 5 was also applied to pyramidal neurones of the CA1 region of the
hippocampus. WAY-100635 had no partial agonist activity in cells in the
hippocampus as has been previously reported by Fletcher et al (1995). Therefore
WAY-100635 is silent at the postsynaptic 5-HTiA receptor. WAY-100635 was also
shown to block the 5-HTiA-evoked membrane hyperpolarisation in the neurones of
the hippocampus, again in agreement with the previous study of Fletcher et al (1995).
Blockade of the 5-HTiA-evoked hyperpolarisation revealed a 5-HT-evoked
depolarisation. This was associated with an increase in input resistance and therefore
assumed to be the depolarisation described by Andrade and Nicoll (1987) later
characterised as being mediated by the 5-HT4 receptor (Andrade and Chaput 1991).
WAY-100635 blocks the actions of 5-HT at the 5-HTia receptor in both the
hippocampus and DRN. This may indicate that the somatodendritic 5-HTiA
autoreceptor in the DRN and the postsynaptic 5-HT]A receptor in the hippocampus
are, pharmacologically at least, identical. It has been hypothesised that these
receptors are pharmacologically different. This follows from the work with (+/-)-
pindolol and (-)-pindolol, (3-adrenoceptor antagonists with high affinity for the 5-
HTia receptor subtype. Some groups have reported, using electrophysiological
techniques, that these compounds can block the action of 5-HT at the
somatodendritic 5-HT)A autoreceptor while having no effect at the postsynaptic 5-
HTja receptor (Artigas et al 1994; Romero et al 1996). However, there is also much
conflicting data to suggest that pindolol shows no preference for 5-HTiA receptors.
There are reports of pindolol blocking hormonal and behavioural responses to
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postsynaptic 5-HTia receptor stimulation (Scott et al 1994; Ybema et al 1994; Levy
et al 1995). A more recent study has shown electrophysiologically that (-)-pindolol
does indeed block the 5-HTiA-mediated hyperpolarisation in the CA1 region of the
hippocampus (Corradetti et al 1998). This is an example of (-)-pindolol acting at
postsynaptic 5-HTja receptors. The present study adds supports the identical
pharmacological nature of somatodendritic autoreceptors and postsynaptic 5-HTia
receptors by showing that WAY-100635 can block the 5-HTiA-mediated
hyperpolarisation in both the hippocampus and the DRN at the same concentration
while showing no partial agonist activity in the hippocampus. WAY-10063 5 is
highly selective at the 5-HTiA receptor subtype and so could be assumed to identify
any pharmacological differences between any proposed different 5-HTia receptor
types. This does not rule out differences in the way that 5-HTia receptors couple to
second messenger systems, which could account for the many reported differences
between the postsynaptic and autoreceptors of the hippocampus and DRN
In addition, WAY-100635 did not block the ai-adrenoceptor-mediated
depolarisation evoked by the application of noradrenaline and phenylephrine. This
indicates that WAY-10063 5 does not block actions mediated by the
ai-adrenoceptor. The ai-adrenoceptor-mediated depolarisation, as has been widely
reported (Baraban and Aghajanian 1980a), is associated with an increase in input
resistance and when analysed using I/V plots shows a reversal at a value
approximately that expected for a potassium mediated event. The ai-adrenoceptor-
mediated depolarisation is due to the closure of potassium channels.
In the DRN, long-term application ofWAY-100635 revealed a 5-HT-evoked
depolarisation. This 5-HT-evoked depolarisation could only be observed in the
presence ofWAY-100635 and did not have a consistent input resistance increase
more commonly associated with membrane depolarisations, such as that described
above for noradrenaline and phenylephrine. A 5-HT-evoked hyperpolarisation was
observed in WAY-100635 treated cells also exposed to methysergide and mCPP.
This hyperpolarisation is associated with a decrease in input resistance and reverses
134
at approximately the value expected for a potassium event. These are two examples
of 5-HT having actions hidden by the dominant effect of the 5-HT (A receptor,
showing that 5-HT can have a multiplicity of actions in the DRN once the 5-HTia
receptor is blocked.
A 5-HT-evoked depolarisation was also observed in WAY-100635 treated cells in
the hippocampus. This depolarisation was associated with an increase in input
resistance and reversed at approximately the value expected for a potassium-
mediated event. These are characteristics are not consistent with the 5-HT-evoked
depolarisation observed in the DRN which does not show a consistent input
resistance increase and does not reverse at the value expected for a potassium
mediated event.
In summary this study has shown that WAY-100635 does not appear to have partial
agonist activity at the somatodendritic autoreceptor in the DRN or the postsynaptic
receptor in the hippocampus. However, long-term application ofWAY-100635 in the
DRN does appear to have some effect on the resting membrane potential. WAY-
100635 can block the 5-HTiA-mediated hyperpolarisation in the hippocampus and




Following the discovery of a 5-HT-evoked depolarisation the 5-HT receptor subtype
mediating the depolarisation was investigated. The observation of a 5-HT-evoked
depolarising response associated with an increase in cell firing implies that 5-HT also
has a role in increasing cell excitability as well as the more traditional role of
inhibition. This section will discuss possible ionic mechanisms underlying the 5-HT-
evoked membrane depolarisation.
Characteristics of the 5-HT-evoked depolarisation
The 5-HT-evoked depolarisation was observed in the majority of cells. In most cells
demonstrating the 5-HT-evoked depolarisation there was no net change in input
resistance. In a sub-population of cells the depolarisation was associated with a slight
decrease in input resistance and in a smaller population of cells there was a slight
increase in input resistance. In most cells showing a change in input resistance I/V
analysis revealed that the depolarising response did not show a reversal level in the
range -120 to -60 mV. However, in a few of those cells I/V plots obtained during the
5-HT-evoked depolarisation in control conditions reversed at approximately -50 mV
(n=5). This may point to the depolarising response being made up of a change in a
number of conductances with different reversal values. If this is so then the relative
dominance of any component in generating the response may vary in different cells,
resulting in the variation in overall resistance observed. The response could include a
component due to the closure of potassium channels, which would make the reversal
value move towards that expected for a potassium-mediated event. Given that in
some cases the 5-HT-evoked depolarisation is associated with a decrease in input
resistance the other component may be due to the opening of another channel. This
second component would have a positive reversal value and could be made up of
either a non-voltage activated sodium channel, for example, or possibly a non¬
selective cation channel. Also, the voltage responses to injected depolarising current
pulses in the cells of the DRN commonly showed rectification. This rectification
could be observed as a non-linearity in the input resistance. The I/V plots of the 5-
HT-evoked depolarisation against a control show rectification and reversal in the
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region of -45 mV, which is inconsistent with the 5-HT-evoked depolarisation being
due only to the closure of potassium channels.
The 5-HT-evoked depolarisation was only observed following pre-treatment with
WAY-100635. The inability to observe any non-5-HTiA mediated events in the
absence of WAY-100635 could be because of 5-HT released within the slice acting
at the 5-HTia receptors masking any other 5-HT-evoked actions. A tonic effect of 5-
HT as it accumulates in the in vitro slice could artificially hold a neurone at a
hyperpolarised membrane potential. If this were so then the application ofWAY-
100635 would lead to a membrane depolarisation, as the tonic action of 5-HT is
blocked by the 5-HTia receptor antagonist. This depolarisation could either appear as
a gradual membrane drift in the depolarising direction or as a more pronounced
membrane change due to the action of endogenously released 5-HT on the receptor
subtype mediating the 5-HT-evoked depolarisation. A slow drift in the membrane
potential was observed in a number of cells while in the presence ofWAY-100635,
consistent with the first theory and could be indicative of endogenous 5-HT acting on
neurones in the in vitro slice preparation to keep the membrane potential at an
artificially hyperpolarised level and inhibiting cell firing. A drift in the membrane
potential could also be due to the blockade of potassium channels involved in
holding the cell at its resting membrane potential. The observation ofmembrane
changes during the recording of cells adds to the problems associated with working
in the in vitro brain slice. As this shows it is difficult to completely maintain the
properties of neurones in the in vivo brain slice environment.
The 5-HT-evoked depolarisation could be demonstrated in the presence of TTX,
known to block the sodium channel involved in generating the action potential. This
implies that the response is independent of the action potential dependent
transynaptic events involved in networks. 5-HT must be acting postsynaptically,
where 5-HT binding to the target cell changes the activity of that cell by causing a
membrane depolarisation leading to an increase in excitability.
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The first reported 5-HT-evoked excitation was observed by Roberts and Straughan
(1967). They looked at the excitatory effects of 5-HT on cells of the cerebral cortex
in the anaesthetised cat. There are now many reported 5-HT-evoked excitations or
membrane depolarisations. These responses have been associated with a number of
ionic mechanisms and receptor subtypes. In the motorneurone a number of studies
have reported 5-HT-evoked membrane depolarisation. Intracellular studies in vitro,
with the facial motorneurone, have shown that 5-HT induces a slow, sub-threshold
depolarisation associated with an increase in input resistance, indicating a decrease in
resting potassium conductance (Larkman et al 1989). This has also been seen in the
medullary repiratory neurones (Lalley et al 1995) and spinal motorneurones (White
and Fung 1989; Yamazki et al 1992). A 5-HT-evoked depolarisation due to the
closure of potassium channels has also been seen in neurones of the medial pontine
reticular (Stevens et al 1992), of the substantia nigra (Rick et al 1995) and of the
olivary nucleus (Sugihara et al 1995). The neurones of the nucleus accumbens
depolarise and are induced to fire action potentials by the application of 5-HT in
association with an increase in input resistance due to the reduction of an inwardly
rectifying potassium conductance (North and Uchimura 1989). GABAergic neurones
of the nucleus reticularis thalami and medial septal nucleus depolarise in response to
5-HT due to the decrease in a potassium conductance (McCormick and Wang 1991;
Alreja 1996). There are also reports of 5-HT evoking a depolarisation due to a
decrease in a potassium conductance in areas of the cortex, for example, in the
cerebral cortex (Araneda and Andrade 1991; Davies et al 1987) and in the pyramidal
cells of the piriform cortex (Sheldon and Aghajanian 1990). In the prefrontal cortex
the application of 5-HT evokes a delayed membrane depolarisation, there is also the
appearance of a slow depolarising afterpotential following an action potential
(Araneda and Andrade 1991), it is not associated with an increase in input resistance.
However, this response undergoes desensitisation upon repeated agonist
administration and the ionic nature of this has so far been difficult to elucidate. The
ionic mechanism underlying these responses are inconsistent with the results of this
study, where the depolarisation is associated with either no or small changes in input
resistance.
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5-HT has also been shown to depolarise a number of central neurones by
augmentation of a hyperpolarisation-activated, time-dependent, non-selective and
inwardly rectifying cation current, termed Ih (Bobker and Williams 1989; Pape and
McCormick 1989). There is little evidence for the DRN neurone having the Ih
current. One of the characteristics of the Ih current is a depolarising "sag" observed in
hyperpolarising current steps where the cell attempts to repolarise to the resting
membrane potential before the end of the negative current pulse. In the DRN
hyperpolarising current steps up to -120 mV show no evidence of this repolarising
sag. This indicates that the 5-HT-evoked depolarisation is unlikely to be due to the
activation of the Ih channels. The action of 5-HT in the facial motorneurone is an
example of 5-HT acting at more than one ion channel. Larkman and Kelly (1992)
showed that 5-HT can have a dual effect by depolarising facial motorneurones by a
combination ofmechanisms. This depolarisation is in part due to decrease of a
potassium conductance and the enhancement of Ih. This shows that 5-HT not only
modulates non-selective ion channels, but can also activate a combination of
channels to evoke a membrane depolarisation.
The 5-HT3 receptor also mediates depolarising responses. Activation of this receptor
has a very different mechanism to that of the other 5-HT-evoked depolarisations and
is due to the direct activation of a cation channel. Evidence for an
electrophysiologically observable response due to 5-HT interacting with the 5-HT3
receptor was first observed in cultured mouse hippocampal and striatal neurones. It
was characterised as a membrane depolarisation with a rapid onset, which is also
rapid to desensitise (Yakel and Jackson 1988; Yakel et al 1990, 1991). These features
are typical of ligand-gated ion channels and not receptors coupled to a G-protein. 5-
HT3 mediated depolarisations have also been observed in the brain slice preparation.
In the lateral nucleus of the amygdala 5-HT3 mediated fast-excitatory synaptic
responses follow focal electrical stimulation and can only be demonstrated when
glutamate receptors are blocked (Sugita et al 1992), this response also shows rapid
desensitisation. In the hippocampal slice 5-HT can increase spontaneous GABAergic
IPSP's through a 5-HT3 mediated receptor excitation of inhibitory neurones (Ropert
1988; Ropert and Guy 1991), this response also shows fast desensitisation. Most 5-
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HT3 mediated events have so far been characterised as fast to inactivate, but there has
been a 5-HT3 mediated depolarisation observed in neurones of the dorsal root
ganglion that is fast in onset but non-inactivating (Todorovic and Anderson 1990).
The features of rapid onset and rapid desensitisation are not consistent with that of
the 5-HT-evoked depolarisation in DRN neurones, which is slow to activate and slow
to reverse. These features are more consistent with a mechanism involving a G-
protein coupled receptor and probably rules out the 5-HT3 receptor as the receptor
mediating the 5-HT-evoked depolarisation in the DRN.
From the study of hippocampal pyramidal neurones discussed in this thesis, blockade
of the 5-HTjA-mediated hyperpolarisation with WAY-100635 revealed a 5-HT-
evoked membrane depolarisation. This was associated with an increase in input
resistance. This observation agrees with the work of Andrade and Nicoll (1987) and
Colino and Halliwell (1987) who describe a 5-HT-evoked depolarisation associated
with an increase in cell input resistance, the result of a decrease in a potassium
conductance, this has more recently been reported by Corradetti et al (1996).
The 5-HT-evoked depolarisation revealed by the blockade of the 5-HTia receptor
subtype in the DRN does not seem to be mediated solely by the closure of potassium
channels. Craven et al (1997) described a 5-HT-evoked depolarisation in the guinea
pig DRN. They reported that the response was in part associated with a slight
increase in input resistance. Voltage-clamp experiments revealed a 5-HT-evoked
inward current with a decrease in conductance. However, they also found that the
response did not reverse in the range normally associated with potassium mediated
events and concluded that the response must also involve another current. In the
present study an increase in resistance was observed in some cells, but I/V analysis
did not show a point of intersection in the range normally associated with potassium
mediated events, where reversal was found it was in a more positive direction. This
suggests the involvement of another current. A similar voltage-clamp study could be
carried out to investigate the currents involved in the 5-HT-evoked depolarisation in
the rat DRN.
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The mechanism of action of this 5-HT-evoked depolarisation is therefore different to
that typically associated with 5-HT, where the effect is solely mediated by a
reduction in a potassium conductance or an increase in Ih- The input resistance data
from the present study indicates that the depolarising response could be made up of a
number of different components that can vary in importance with each cell. This
accounts for some cells showing a change in input resistance and others not. Where
cells did show a change in input resistance the response reversed at a level
significantly more positive than that predicted for a potassium mediated event. This
implies the response could be made up by an ionic conductance change in potassium
channels and a change in an ion channel conductance with a positive reversal value
such as sodium ions. Also given the small size of the response only a slight change in
the conductance of a sodium or non-selective ion channel would be needed to
mediate the response. The data reported in the guinea pig DRN points to the 5-HT-
evoked depolarising response being mediated by more than one conductance. Craven
et al (1998) conclude that the 5-HT-evoked depolarisation observed in the guinea pig
DRN partly results from a closure of potassium channels. These works also
concluded that the 5-HT-evoked depolarisation is probably also due to an increase in
another conductance that is due to the opening of a cation channel that is either
selective for sodium ions or non-selective for sodium or potassium ions.
There are a number of examples of neurotransmitters modulating a voltage-
independent non-selective cation conductance. In rat locus coeruleus neurones
muscarine can activate voltage-independent and voltage-dependent non-selective
cation conductances, this together with a decrease in potassium conductance results
in an increase in excitability (Shen and North 1992). In bullfrog ganglion cells a
combined potassium conductance decrease and cation conductance increase has been
suggested to account for the slow excitatory effects ofmuscarine (Kuba and Koketsu
1978; Tsuji and Kuba 1988). This kind of mixed conductance change is also thought
to underlie the excitatory effects of substance P on guinea pig inferior ganglion cells
(Dun and Minota 1981). The same mechanism has also been reported to account for
the actions of 5-HT, substance P, muscarine, vasoactive intestinal polypeptide,
forskolin and slow excitatory synaptic transmission in guinea pig submucosal
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neurones (Shen and Surprenant 1993). Many slow depolarising effects have been
associated with neurotransmitters and a number are thought to be mediated by a
combination of ionic mechanisms, these include the action of neurotensin on
tegmental neurones (Jiang et al 1994) and carbachol on rat hippocampal neurones
(Colino and Halliwell 1993).
There is a well characterised membrane depolarisation described in the DRN
neurone. Noradrenaline and the ai-adrenoceptor agonist phenylephrine have been
described as evoking a membrane depolarisation accompanied by an increase in cell
excitability (VanderMaelen and Aghajanian 1983). Data from the present study
shows the phenylephrine-evoked membrane depolarisation is associated with an
increase in input resistance consistent with previously reported data (Baraban and
Aghajanian 1980a). I/V analysis shows the depolarisation reversed at approximately
-90 mV indicating that the response is due to the closure of potassium channels.
It may be that this 5-HT-evoked depolarising response in the DRN is only in part the
result of the closure of potassium channels. This could be investigated using voltage-
clamp conditions, which would allow the measurement of the currents underlying the
5-HT-evoked depolarisation. The opening of sodium or non-selective channels may
also contribute to the response. These two components possibly make up the 5-HT-
evoked depolarisation to a different degree in each example. There are many
examples of neurotransmitters evoking an increase in excitability due to this type of
mechanism.
A study performed in rostral ventromedial medulla neurones by Hwang and Dun
(1999) investigated a 5-HT-evoked depolarisation with similar properties to those
discussed in this thesis. They described a mechanism involving the combination of a
potassium conductance decrease and a caesium-insensitive, non-selective cation
conductance increase to account for the variable conductance associated with the 5-
HT-evoked depolarisation. This reported mechanism could account for the varying
conductances associated with the 5-HT-evoked depolarisation discussed in this
thesis. However, Hwang and Dun had not determined whether a single class of 5-
142
HT2 receptor mediates the 5-HT-evoked depolarisation by coupling to different ion
channels or if each channel is linked to different subclasses of 5-HT2 receptor.
Pharmacology of the 5-HT-evoked depolarisation
There are many reported examples of 5-HT2 receptors mediating depolarising
responses and there is also evidence of 5-HT2 receptors being found in the DRN
(Leysen et al 1982; Davies et al 1988). There are no examples of 5-HT2 agonists
having any action on control DRN neurones. This study found 5-HT hyperpolarised
neurones in every case and only showed the depolarising response following pre-
treatment with WAY-10063 5. This may be explained by the lack of selectivity of the
agonists available for the 5-HT receptor subtypes. Even though DOI, for example,
has pECso values for 5-HT2a receptors of 7.6 and for 5-HT2c receptors of 7.0, it still
shows some binding to the 5-HTia receptor. As the 5-HTiA-evoked hyperpolarisation
appears to be dominant over the 5-HT-evoked depolarisation then even some binding
at the 5-HTia receptor may result in the membrane hyperpolarisation. This is also
compounded by the action of endogenously released 5-HT acting on 5-HTia
receptors masking any other 5-HT-evoked membrane changes.
Action of agonists
The 5-HT2 agonist DOI was found to mimic the 5-HT-evoked depolarisation when
applied to WAY-100635 treated neurones showing that the 5-HT2 receptor may be
involved in the depolarisation. DOI has been used extensively in behavioural studies
to investigate the role of the 5-HT2 receptor subtypes in anxiety (for review see
Griebel 1995). DOI has similar affinities for each of the 5-HT2 receptor subtypes
showing little selectivity, but has been used to selectively identify the 5-HT2A
mediated component of the inhibition of glutamate release from the rat cerebellum, a
5-HTi-like receptors make up the other component of this effect (Maura et al 1988).
Due to the lack ofDOI selectivity this data does not distinguish between the three
known 5-HT2 receptors, but does show they are involved.
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Bath-application ofmCPP (pEC50 = 6.9), a partial agonist more selective for 5-HT2c
receptors (Groteweil et al 1994) did not have any effect on membrane potential or
input resistance on WAY-100635 treated cells in the DRN. mCPP is known to
induce hypophagia and hypolocomotion (Curzon and Kennett 1990) via its 5-HT2c
activity. The 5-HT2c receptor activation is also thought to account for the anxiogenic
and panic precipitating properties induced by mCPP in behavioural studies (Trail et
al 1995). In rodents mCPP can cause hypoactivity, hypophagia, oral dyskinesia,
penile erection and hyperthermia. In the DRN neurone the lack ofmembrane changes
following the application ofmCPP indicates that not only is the 5-HT-evoked
depolarisation not mediated by the 5-HT2c receptor subtype, but also that the 5-HT2c
receptor may not mediate electrophysiologically observable events in the DRN.







DOI 5-HT2 Mimicked depolarisation 5-HT2 mediated.
mCPP 5-HT2b/c No effect Not mediated by 5-HT2b/c
CP 93129 5-HT1b No effect Not mediated by 5-HTib
Table 6.0 Summary of the results derived from 5-HT agonists.
The 5-HTib agonist CP 93129 (PEC50 = 7.8) had no action on membrane potential or
input resistance. CP 93129 has been shown to cause a reduction in 5-HT release from
the hippocampus in anaesthetised rats (Hjorth and Tao 1991). The present study
indicates that any 5-HTib receptors present in the DRN do not mediate direct
electrophysiologically observable responses in serotonergic neurones in the brain
slice preparation. The 5-HTib receptor subtype has been shown to have autoreceptor
properties (Limberger et al 1991). A report in the caudal raphe nucleus describes a
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mechanism of autoinhibition of neuronal activity by 5-HT]B receptor-mediated
inhibition of glutamatergic inputs, where the 5-HT]B receptor is acting via a
presynaptic inhibitory effect (Li and Bayliss 1998). The present study has found that
the 5-HTiB receptors have no direct effect on the excitability of serotonergic
neurones in the DRN.
This agonist derived data suggests the involvement of the 5-HT2 receptors in the
generation of the 5-HT-evoked depolarisation in the DRN. It also indicates that the
5-HT2A receptor is more likely to be involved, as the lack of action ofmCPP rules
out the 5-HT2C receptor.
Action of Antagonists
The broad spectrum 5-HT antagonist methysergide was applied to a number of
WAY-10063 5 treated cells and found to have no effect on the membrane potential or
input resistance. Methysergide has been reported as having agonist activity at some
receptor subtypes and acts as an antagonist at a wide range of 5-HT receptor
subtypes. It is also reported as having a 1-adrenergic receptor affinity where it acts as
an antagonist. Pre-application of methysergide to cells showing the 5-HT-evoked
depolarisation blocked the 5-HT-evoked depolarisation in six of eight cells. This
confirms the response is mediated by a 5-HT receptor. Pre-application of
methysergide also blocked the action ofDOI confirming methysergide has
antagonistic actions at the 5-HT2 receptor subtypes in the DRN. Methysergide did
not block the depolarisation in another three cells at lower drug concentrations.
Methysergide has been characterised as a partial agonist in a number of preparations.
For example, in the dog and rabbit saphenous vein methysergide evokes contraction.
Methysergide also binds to the 5-ht5 receptor and 5-HT7 receptor subtypes. 5-htse
receptors have been detected in the DRN (Erlander et al 1993) and may have a role
in involvement of the DRN in depression, anxiety and feeding (Plassat et al 1992;
Wilkinson and Dourish 1991). Activation of this receptor could account for the
inability to observe the blockade of the 5-HT-evoked depolarisation due to the
activation of a hyperpolarisation mediated by the 5-ht5B receptor.
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Ketanserin, the well characterised 5-HT2 antagonist, has been shown to have a
number of binding sites within the DRN and cannot be used conclusively to
distinguish between the 5-HT2A and 5-HT2C receptor subtypes (Pazos and Palacios
1985). Ketanserin was found to have no effect on the membrane potential and input
resistance of cells of the DRN following treatment with WAY-10063 5. Ketanserin
has been found to inhibit firing in the DRN by observing extracellular measurements
of the single unit activity in the anaesthetised rat (Lakoski and Aghajanian 1985).
This was attributed to ketanserin antagonising the effects of noradrenaline at the cti-
adrenergic receptor, well known to drive firing in the DRN. Ketanserin was also
noted to neither attenuate nor potentiate any responses to 5-HT. This was attributed
to the low number of 5-HT2 binding sites in the DRN. Ketanserin blocked the 5-HT-
evoked depolarisation, confirming the result indicated by the DOI experiments that
5-HT2 receptors are involved. This also confirms that some of the ketanserin binding
sites in the DRN are the result of binding to the 5-HT2 receptor subtypes.
SB 200646 (ED50 > 10 at the 5-HT2A receptor), selective for the 5-HT2b/2C receptor
subtypes over the 5-HT2A receptor subtype (Schreiber et al 1994), was applied to
WAY-10063 5 treated cells and had no effect on membrane potential or input
resistance. This compound may be partially blocking the 5-HT-evoked
depolarisation. WAY-100635 and SB 200646 treated cells showed a slight change in
membrane potential and a decrease in input resistance in response to the application
of 5-HT. This could mean that the 5-HT-evoked depolarisation is the result of 5-HT
interacting with a number of 5-HT2 receptor subtypes. If this were true then the
remaining response would be the result of the 5-HT2A receptor portion of the 5-HT-
evoked depolarisation. However, the partial blockade could also be the result of SB
200646 acting at a small number of 5-HT2A receptors resulting in an incomplete
block of the 5-HT-evoked depolarisation. The results observed with mCPP, where
application does not cause a membrane potential change, point to the second theory.
The 5-HT2A selective compound MDL 100, 907 (ED50 = 0.0006 at the 5-HT2A
receptor) had no action on WAY-100635 treated cells (Schreiber et al 1994). MDL
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100, 907 completely blocked the 5-HT-evoked depolarisation. This points to the
involvement of the 5-HT2A receptor subtype. MDL 100, 907 has been recently
characterised as an antagonist selective for the 5-HT2A receptor, it is 300-fold more
selective for the 5-HT2A receptor over the 5-HT2C receptor subtype. It has been found
to block the 5-HT-evoked excitation of interneurones in the piriform nucleus when
looking at the firing rate in the extracellular in vitro preparation (Marek and
Aghajanian 1994).
Antagonist Site of Action Effect on
Depolarisation
Conclusion
Methysergide 5-HTbroad spectrum Blockade 5-HT mediated.
Ketanserin 5-HT2 Blockade 5-HT2 mediated
MDL 100, 907 5-HT2A Blockade 5-HT2A mediated
SB200646 5-HT2b/2c Partial Blockade Not 5-HT2B/2cmediated
Pindolol 5-HTia/ib No effect Not 5-HTiB mediated
Table 6.1 Summary of the results derived from antagonists.
Finally the 5-HTia/ib antagonist pindolol did not affect the membrane potential of
WAY-100635 treated cells. It also did not block the 5-HT-evoked depolarisation.
This rules out the 5-HTiB receptor being the receptor mediating the 5-HT-evoked
depolarisation. The antagonist data has suggested that the 5-HT-evoked
depolarisation is mediated by the 5-HT2A receptor subtype (Table 6.1).
At first sight the concentration of agonists and antagonists used throughout this study
may seem high and hence be thought to show little receptor selectivity. However,
this does not take into account the problems associated with the use of the interface
chamber in supporting the viability of the brain slice for electrophysiology. Although
the drug concentration in the chamber can accurately reach the desired level it is
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much more difficult to predicate the drug concentration reaching the cell under study.
It can be assumed that the concentration at the cell membrane of a drug is lower than
that in the chamber due to the difficulty in diffusing through the brain slice. Using
high drug concentrations ensures that the drug is reaching the cell membrane and so
will have the predicated effect.
Using the isolated DR cell preparation Nooney and Kelly (1998) found that pre-
application ofWAY-10063 5 blocked the actions of 5-HT at the 5-HTja receptor.
However, further 5-HT-evoked responses were not observed in the isolated cell. It
can be surmised from this that the 5-HT2A receptor mediating the response seen in
DRN slices may be located on the cell dendrites. The process of tissue trituration
involved in preparing the isolated cell tends to result in dendrite damage or removal
from the cell body. A remote receptor site could also account for the small size of the
response because of the effect of electrotonic distance. If the site of action of the
receptor is remote from the site of electrode impalement at the cell body electrotonic
decay will lead to a misleadingly smaller response being recorded. The membrane
change at the point of 5-HT2A action may be larger than the membrane change
around the electrode at the cell body. The receptor being sited remotely from the
electrode could also account for the lack of significant data on cell input resistance
changes. It could be that in some cells the electrode is too remote from the site of the
5-HT effect to detect any input resistance changes whereas in some cases the
electrode is closer and can pick up some resistance change. However, the membrane
depolarisation is associated with an increase in cell excitability and so has the power
to change the cell's activity. Also, if the depolarisation is being underestimated due
to the electrotonic distance then it would probably trigger an action potential, which
does not, although there is an increase in excitability. Alternatively, there is a low
density of 5-HT2A receptor sites in the DRN, which could account for the small
voltage change of the membrane depolarisation.
The problems with the current clamp method limit the information that can be drawn
form this experimental procedure. The problem of space clamp is the result of a
neurone having long dendrites and axons. The electrode can only inject enough
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current to clamp the cell body and the area of dendrites and axons immediately
surrounding it. Therefore the complete cell membrane cannot be completely clamped
throughout the neurone and its processes. This can affect the voltage response of the
neurone where the receptor site and the site of membrane change are remote from the
electrode. This would mean that the input resistance might not be a true reflection of
the membrane activity at that remote site.
The 5-HT-evoked depolarisation appears to be mediated by the 5-HT2a receptor. The
size of the response has made it difficult to explore the molecular mechanism
underlying the cellular effects signalled by activation of the 5-HT2A receptor and the
5-HT-evoked depolarisation. If the 5-HT-evoked depolarisation is the result of
changes in two ion channels as has been discussed, then the 5-HT2A receptor must be
linked to multiple ion channels. The 5-HT2A receptor is a Gq-coupled receptor and
there are a number of different receptors that show similar effects upon activation.
For example, in the association and prefrontal cortex muscarinic and a i-adrenergic
receptors show a robust membrane depolarisation on chronic agonist exposure
(Andrade 1991; Araneda and Andrade 1991). The ionic mechanisms underlying
these responses have been more thoroughly investigated and the resulting
information could be extrapolated for other Gq-coupled receptors. In these examples
the membrane depolarisation resulted from the activation of non-selective cationic
channels (Haj-Dahmane and Andrade 1996). This is consistent with the
characteristics of the 5-HT-evoked depolarisation in the present study and it seems
likely that a similar or even identical mechanism could mediate this 5-HT2A-evoked
depolarisation in the DRN.
The study of cortical neurones by Szabadi et al (1977) reported that the probability of
observing an excitatory or inhibitory response to 5-HT was related to the firing rate
of the neurone. A greater number of cells are excited by 5-HT when the cell has a
low resting firing rate. In the DRN slice, cells with a high resting membrane potential
showed a small inhibitory response to application of 5-HT. Likewise, with the 5-HT-
evoked depolarisation, where the cell has a hyperpolarised resting membrane
potential, it exhibited a larger membrane depolarisation.
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There are a number of examples of 5-HT having opposing responses in many
different regions of the brain. For example, in the medial pontine reticular formation
5-FIT acts on 5-HTi and 5-HT2 receptors by evoking a membrane hyperpolarisation
and depolarisation respectively. This is due to opposing actions on different
potassium conductances. These opposing responses are observed on separate
populations of neurones where each cell is only able to show one response and
blockade of one response does not reveal the other (Stevens et al 1992). Similarly in
the nucleus prepositus hypoglossi and the rat association cortex 5-HT-evokes a
hyperpolarisation, mediated by the 5-HTia receptor, and a depolarisation, mediated
by the 5-HT2 receptor (Bobker and Williams 1995; Araneda and Andrade 1991).
These opposite effects are due to the manipulation of the different potassium
conductances. Roberts et al (1967) observed that 5-HT could increase cell firing by
an excitatory response or decrease cell firing in an inhibitory response. This has also
been observed in cortical neurones where all neurones are capable of showing both
hyperpolarising and depolarising responses to 5-HT (Davies et al 1987). The 5-HT-
evoked depolarisation was the most commonly observed. The responses could be
observed on all cells and blockade of one with an antagonist revealed the other. In
the hippocampus the 5-HTia receptor mediates a hyperpolarisation with an
associated decrease in input resistance and an inhibition of cell firing. Following
blockade of the hyperpolarising response it is possible to observe the depolarisation,
which is associated with an increase in resistance and is mediated by 5-HT4-like
receptors (Colino and Halliwell 1987). These effects are again due to opposing
actions on different potassium conductances. The 5-HT4 receptor also acts to reduce
the AHP by modulating the calcium-activated potassium channels. The presence of
opposing 5-HT-evoked responses in the brain either on all neurones within a brain
region or separate populations of neurones within the same region is gradually
becoming more commonly described. With the development ofmore selective
antagonists the incidence of a multiplicity of 5-HT-evoked responses mediated by
many 5-HT receptor subtypes in the same brain region will become widespread. The
DRN now has two 5-HT-evoked actions, hyperpolarising and depolarising.
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There are reports of behavioural evidence for a functional interaction between 5-
HTia and 5-HT2 receptors. A number of 5-HT2 antagonists, ritanserin, ICI 170, 809
and ketanserin have been observed to enhance 5-HTiA agonist-induced behaviour
through blockade of an inhibitory 5-HT2 receptor that regulates or is coupled to 5-
HTia receptor-mediated function (Backus et al 1990). This could be explained by
endogenous 5-HT exerting an inhibitory response on 5-HTia receptor function via 5-
HT2 receptors and that blockade of these receptors releases 5-HTia receptors from
this inhibitory influence. There is also electrophysiological evidence of the functional
relationship between 5-HTia and 5-HT2 receptors (Lakoski and Aghajanian 1985).
Therefore, it is not unusual for 5-HT to have opposing actions in the same cell
population. A functional reason for a 5-HT-evoked depolarisation could be to
counteract the inhibitory action of the 5-HTiA-mediated hyperpolarisation and so fine
tune the membrane potential to control which synaptic events the DRN neurone can
respond to. This allows a neurone to integrate incoming synaptic inputs and only
transmit the true synaptic input.
Ionic mechanism of the 5-HT-evoked depolarisation
The 5-HT2A-evoked depolarisation was extensively investigated pharmacologically
to determine the receptor mediating the response. However, the ionic mechanism
underlying the response is still in doubt. Investigations performed so far indicate that
the response has variable changes in input resistance. Whereas the majority of
neurones showing the 5-HT2A-evoked depolarisation showed a slight decrease in
input resistance some showed no input resistance change and a small group of cells
showed slight increases in input resistance. In the cells showing an input resistance
change the response was observed to reverse in the region of -50 mV. Two possible
theories to explain these observations are:
1) The 5-HT2A-evoked depolarisation is due to the activation of a non-selective ion
channel that allows the flow of sodium ions and the closure of a potassium
channel;
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2) The receptors mediating the depolarisation are found remotely from the cell
body, on the dendrite for example, so that the electrode recording the membrane
changes does not detect the complete response. In this case the remote site of the
receptor will result in the recording electrode only detecting a small voltage
change and would also indicate that the electrode is not detecting the true input
resistance changes associated with the response.
The best way to determine which of these possible theories is correct is to perform a
series of ion substitute experiments where the external ion concentrations of those
thought to be involved in the response are manipulated. In this case the important
ions are potassium and sodium. One way to perform the potassium substitute
experiment is to increase the external levels to observe if this has any effect on the
response. With sodium there is a large concentration of sodium ions found in the
aCSF, therefore reducing the ion concentration would be the best way to observe any
change to the 5-HT-evoked response.
A 5-HT-evoked hyperpolarisation
The 5-HT-evoked depolarising response was in some cases replaced by a 5-HT-
evoked hyperpolarisation. Firstly, in a cell treated with WAY-100635 and
methysergide where subsequent applications of 5-HT evoked a membrane
hyperpolarisation. Secondly, in cells treated with WAY-10063 5 and mCPP,
applications of 5-HT could evoke a membrane hyperpolarisation. This membrane
hyperpolarisation was associated with a decrease in membrane potential and I/V
analysis found that the response reversed at around -90 mV. This 5-HT-evoked
hyperpolarisation could be explained in two ways, either by an incomplete block of
the 5-HTia response, or it could be due to 5-HT interacting with another receptor
subtype. WAY-100635 has a high potency at the 5-HTia receptor subtype and the
inability to observe the return of the 5-HTia response following wash out ofWAY-
100635 makes the possibility of an incomplete blockade of 5-HTia receptors seem
unlikely. It seems more probable that the response is due to an as yet uncharacterised
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receptor. There are a number of candidates for the receptor mediating the non-5-
HTiA-mediated hyperpolarisation.
There have been reports of the presence ofmRNA for the 5-HTib receptor in the
DRN (Voigt et al 1991). Many studies have established that terminal receptors of the
rat cortex are of the 5-HTib receptor subtype. There is also a significant correlation
between the affinity of a drug's potency for the rat autoreceptor and its affinity for
the 5-HTib receptor (Middlemiss et al 1984, 1985, 1986; Limberger et al 1991). A
recent study has found that 5-HTiB receptors modulate excitatory glutamatergic
inputs into the caudal raphe via a presynaptic inhibitory effect (Li and Bayliss 1998).
This study recorded from EPSP's in caudal raphe neurones following local electrical
stimulation in the neonatal rat brainstem slice. They stimulated one neuronal cell and
measured the resulting EPSP in a neighbouring neurone. This was later shown to be
serotonergic using immounohistochemical staining of tryptophan hydroxylase. It is
not certain if the cell targeted in stimulation is the source of the synaptic inputs and
may mean that the 5-HTib receptor is found on interneurones rather than
serotonergic neurones. Results from a study performed by Sprouse and Aghajanian
(1987) showed that the 5-EITib agonist CP 93129 did not have any activity in the
DRN. Results from the present study showed that CP 93129 had no activity in WAY-
100635 treated cells. This seems to imply that the 5-HT-evoked hyperpolarisation
observed in WAY-100635 treated cells is not mediated by the 5-EITib receptor.
The 5-HT2, 5-HT3 and 5-HT4 receptor subtypes are more commonly associated with
depolarising responses and are unlikely to mediate a 5-HT-evoked hyperpolarisation.
The 5-ht5 receptor subtypes have been difficult to characterise and study due to the
lack of selective agonists and antagonists. 5-htsA may act as a terminal autoreceptor in
the mouse frontal cortex (Pineyro et al 1995), but little as yet is known about 5-htsB.
5-ht5B receptors have, however, been detected in the DRN (Erlander et al 1993). The
5-htsa receptors are negatively coupled to adenylyl cyclase via the G; G-protein, this
is in common with the 5-HTi receptor subtypes which are also negatively coupled to
adenylyl cyclase, but by the Gj and G0 G-proteins. This makes the 5-ht5A and the 5-
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htsB receptor subtypes good candidates for mediating the 5-HT-evoked
hyperpolarisation.
The 5-ht6 receptor subtype has so far proven difficult to study, it is however
positively coupled to adenylyl cyclase via the Gs G-protein making it unlikely to
mediate a hyperpolarising response.
The 5-HT7 receptor seems to be highly expressed in the rat hypothalamus and
thalamus and other forebrain regions and to a lesser extent, brain regions including
the dorsal raphe nucleus and the CA3 region of the hippocampus (Lovenberg et al
1993a). It is positively coupled to adenylyl cyclase via the Gs G-protein. The 5-HT7
receptor has been associated with a number of excitatory responses. For example, a
5-HT-like response has been characterised in many smooth muscle preparations,
including the 5-HT-induced relaxation of the rabbit femoral vein, cat saphenous vein,
cynomolgous monkey and dog jugular vein (Eglen et al 1997). This makes it unlikely
that the 5-HT7 receptor subtype would mediate an inhibitory response in the DRN.
This may indicate that the new 5-HT-evoked hyperpolarisation is mediated by one of
the 5-ht5 receptor subtypes. The response was only observed in a small number of
experiments and the lack of useful agonists and antagonists makes it difficult to
conclusively characterise the nature of the receptor mediating the hyperpolarisation.
Also it may be that the 5-HT-evoked hyperpolarisation is a transynaptic event, due to
inputs from the local network of neurones. This can be investigated using compounds
that block synaptic transmission, such as TTX, a sodium channel blocker, and
bicculine and picrotoxin which block GABAergic transmission from interneurones.
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Regulation of the firing pattern in the DRN neurone
5-HT can modulate the excitability of a cell by hyperpolarising or depolarising its
membrane potential. 5-HT can also more directly modulate excitability by changing
the firing pattern of a cell. This is brought about by the regulation of the action
potential and AHP and in turn the firing frequency. This section will discuss the ionic
mechanisms that regulate the spike, AHP and firing frequency and will then go onto
discuss the role of 5-HT in the regulation of firing in the DRN.
The duration of the action potential
The generation of the action potential in the DRN is a well described phenomenon
and involves a number of different conductances. In the DRN the action potential is
the result of the activation of sodium channels, which cause a membrane
depolarisation. The present study blocked the action potential with TTX, a known
sodium channel blocker. This rapid depolarisation then activates a TEA-sensitive
current, which causes membrane repolarisation. This is most probably due to the
activity of voltage-activated potassium channels. These potassium channels would be
activated with the sodium channels, but open more slowly so their effects are only
dominant once the sodium channels inactivate. In the DRN the duration of the action
potential can be simplified to the balance between two different ion channel
conductances. The balance is between a TEA-sensitive potassium current and a
voltage-activated calcium channel (Penington et al 1991). Bath-application of TEA
greatly increases the duration of the action potential. This is the result of the
blockade of channels that produce cell repolarisation following the action potential.
This allows an extension of the calcium shoulder of the action potential.
Channel types that may contribute to cell repolarisation and the early part of the AHP
include voltage-activated potassium channels and large conductance calcium-
activated potassium channels, termed BK channels. TEA blocks many of the known
potassium channels and it is only possible to differentiate between each channel type
by gating characteristics. Voltage-activated potassium channels are a likely candidate
for cell repolarisation as BK channels need high levels of calcium for activation,
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which would only happen during the action potential. However, a role of the BK
channel in repolarisation has been previously described in vertebrate sympathetic
neurones (Adams et al 1982). The channels that mediate repolarisation allow the
efflux of potassium ions lowering cystolic potassium levels making the cell more
negative, this effect may contribute to the repolarising phase of the action potential.
Blockade of a voltage-sensitive potassium current with TEA would be observed as
an extension of the calcium dominated phase of the action potential slowing
repolarisation. TEA has been observed to increase action potential duration in a
number of neuronal cell types. In rat supraoptic neurones TEA increases action
potential duration as it does in the acutely dissociated chick ciliary-ganglion
neurones and rat locus coeruleus neurones (Kirkpatrick and Bourque 1996; Dryer et
al 1991; Osmanovic and Shefner 1992).
Spike Narrowing
Narrowing of the action potential can result either from an increase in the activation
of the potassium currents involved in repolarisation, from a reduction in the amount
of calcium entering the cell, or a combination of both. Bath-application of TEA
extended the action potential allowing more calcium to enter the cell. However, the
AHP was also blocked by TEA despite the extra calcium entry.
Actions of 5-HT on the spike
In normal aCSF this study found that bath-application of 5-HT resulted in a reduction
of the duration of the action potential. The narrowing may be because of a reduction
of the calcium component of the action potential. 5-HT is known to inhibit calcium
channels in isolated DRN neurones via activation of the 5-HTia receptor (Penington
and Kelly 1990). It could be that spike narrowing is the result of reduced calcium
entry. It could also be because of an increase in the activity of the TEA-sensitive
potassium current which repolarises the cell. Similar actions of 5-HT have been
reported in two other neuronal cell types. Ropert (1988) noted that 5-HT reduced the
duration of the calcium spike in pyramidal cells of the CA1 region of the
hippocampus. Scroggs and Anderson (1990) observed a 5-HTia receptor mediated
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narrowing of the action potential in the bullfrog dorsal root ganglion. Both these
studies concluded that this effect is the result of a 5-HT-evoked modulation of the
calcium component of the action potential. Although the studies looked at the
enhanced calcium component of a spike generated in the presence of TEA, the large
calcium shoulder observed in the cells of the DRN allows a valid comparison with
the present study.
The present study also showed that in the presence ofWAY-100635, a 5-HTiA
antagonist, the effects of 5-HT on spike width were reduced. This is consistent with
the theory of spike narrowing being due to a reduction in calcium channel activation
during the action potential. However, it was also observed that WAY-100635 itself
reduced spike width, although to a lesser extent that 5-HT. Several possibilities exist
to explain the actions ofWAY-100635; it may be acting at either calcium channels
directly or via the 5-HTia receptor. WAY-100635 could be acting at some other
channel including the potassium current involved in repolarising the membrane
potential. IfWAY-100635 is acting at the 5-HTia receptor to give spike narrowing
then it is acting as a partial agonist. If this is so then WAY-100635 is not a truly
"silent" 5-HTia antagonist. However, Nooney and Kelly (1998) have shown in the
isolated cell that WAY-100635 has no effect on calcium channels in the DRN. This
contradicts the possibility that WAY-100635 can act as a partial agonist at the 5-
HTia receptor mediated modulation of calcium channels. It thus seems unlikely that
WAY-100635 is acting at the 5-HTia receptor and that WAY-100635 may be
causing spike narrowing by a different mechanism to 5-HT-evoked spike narrowing.
Regulation of the AHP
The generation of the rhythmical single action potential firing pattern characteristic
of the DRN involves a number of intrinsic conductances. This includes the currents
governing spike width, those involved in generating the AHP and those controlling
AHP duration. The AHP is made up of two conductances; first the conductance
generated by a TEA-sensitive potassium current that governs the amplitude of the
AHP. The duration of the AHP is governed by an apamin-sensitive current, this
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probably represents the activity of SK channels. Evidence for multiple conductance
involvement in AHP's in other neuronal cell types was first uncovered in the
experiments of Pennefather et al (1985), Fowler et al (1985) and Lancaster and
Adams (1986). The present study has shown that in the DRN the AHP following a
single action potential is made up of a fast and slow component.
The fast AHP
The fast AHP governs the amplitude of the AHP and is created as the membrane
undershoots the resting potential due to continued activation of the TEA-sensitive
potassium current. There may also be a contribution by the calcium-activated
potassium channels termed BK. The fast AHP is blocked by TEA where bath-
application blocks the voltage-activated potassium channels that also bring about
repolarisation. This fast AHP may also be due to the action ofBK channels such as
in the hippocampus where the current responsible for the rapid AHP following spike
generation has been termed Ic (Brown and Griffith 1983). The channel is a calcium-
activated potassium channel, with low sensitivity to calcium; it controls the peak size
of the AHP and is inactivated following repolarisation.
The slow AHP
The slow AHP is made up of an apamin-sensitive, calcium-activated potassium
current. Apamin is known to block subtypes of the SK channels (Hugues et al 1982)
suggesting that SK channels are responsible for maintaining the duration of the AHP
in the DRN. The SK channel is activated following the influx of calcium during the
action potential. The calcium source of the SK channel activation is as yet unclear
and may be the result of release from internal calcium stores or the calcium influx
evoked during the action potential. The release of calcium from internal stores can be
triggered by the calcium influx and so it may be difficult to separate the two events.
5-HT modulates a calcium channel via activation of the 5-HTia receptor (Penington
and Kelly 1990) where the application of 5-HT reduces the calcium current. Thus
less calcium entering a cell during an action potential will activate fewer SK
channels leading to a short duration AHP. The role that calcium, which enters the
cell via the channels modulated by activation of the 5-HTia receptors, has in the
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generation of the AHP was investigated. Modulation of this channel may account for
the spike narrowing discussed earlier.
The AHP following a train of spikes
The present study has shown that TEA only blocks the fast AHP following a single
spike, but does not inhibit the AHP following a train of spikes, indeed this AHP is
increased by TEA, probably due to the increase spike duration and the increase in
calcium entry. In contrast, only apamin block the slow AHP following a single spike,
but completely blocks the AHP following a train of spikes. This may indicate that the
AHP following a train of spikes has only one component and is completely due to the
activity of apamin-sensitive SK channels.
Action of 5-HT on the AHP
Following bath-application of 5-HT the peak of the AHP is unchanged, however the
duration is decreased so that the cell returned to its resting membrane potential more
quickly. This effect was observed in-conjunction with the 5-HTiA-mediated spike
narrowing. The SK channels underlying the membrane potential of the late part of
the AHP are calcium activated, if less calcium enters the cell during the action
potential fewer SK channels will be activated. This observation may indicate that the
calcium channel inhibited by the 5-HTia receptor has a role in the generation of the
AHP. In the DRN high-threshold calcium channels (HVA) are activated during the
action potential and allow the influx of calcium (Marrion and Tavalia 1998). 5-HT
has been found to modulate HVA channels via the 5-HTia receptor in the DRN
where the current amplitude is reduced and the current activation is slowed by 5-HT
(Penington and Kelly 1990). As a HVA channel lengthens the action potential and 5-
HT reduces it, these channels may, in part at least, be the same channels. The
apamin-sensitive component of the action potential is very calcium sensitive, so that
only low concentrations of calcium are needed for SK activation. The first part of the
AHP is largely voltage-activated and is much less dependent on calcium for its
activation; this would account for the AHP peak amplitude being unaffected even
though there is less calcium entering the cell.
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Alternatively, 5-HT could be acting directly on the apamin-sensitive SK channels
that generate the later component of the AHP. If this were so then 5-HT-evoked
spike narrowing would be unconnected to the reduction in the duration of the AHP.
WAY-10063 5 was also found to reduce the AHP, but to a lesser extent than 5-HT.
Again this could be an example ofWAY-100635 showing agonist activity at the 5-
HTia receptor making the observation connected to the effect WAY-100635 has on
spike width. The action ofWAY-100635 may also be due to the direct blockade of
apamin-sensitive SK channels and is not associated with WAY-100635-evoked spike
narrowing.
5-HT has been reported as having actions on the AHP in other brain regions. In the
hippocampus 5-HT evokes a 5-HT4 receptor mediated reduction in the AHP, this is
brought about by an inhibition of SK channels (Chaput et al 1990). This reduced
AHP increases neuronal excitation and may have a role in the regulation of
neurotransmitter release and synaptic transmission (Fagni et al 1992).
The calcium source for the maintenance of the AHP
The duration of the AHP is maintained by a calcium-sensitive potassium channel, but
the source of the calcium is as yet unclear in the DRN. The neurones of the DRN
have been observed to have a number of calcium channels namely HVA channels
which can be inhibited by 5-HT, and LVA channels which are unaffected by 5-HT.
Calcium channels modulate the intracellular calcium concentration.
Noradrenaline has been reported to augment the AHP due to the mobilisation of
internal calcium stores (Pan et al 1993). Therefore, neurones of the DRN do possess
intracellular calcium stores that can be triggered to release calcium by
neurotransmitter binding. These intracellular stores are commonly found in the
endoplasmic reticulum and are coupled to the IP3 signal that opens calcium-release
channels. Calcium release can be evoked by second messenger activation, but can
also be observed following an increase in the cystolic calcium concentration through
increased calcium entry across the cell membrane. There is also evidence that 5-HT
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can increase intracellular calcium and the accumulation of cAMP (Ebersole et al
1993) in the cultured vascular smooth muscle cells derived from the basilar artery.
This group found that 5-HT-evokes an increase in intracellular calcium, firstly
because of intracellular release of calcium from internal stores and secondly a
sustained influx of extracellular calcium resulting in muscular contraction. This
appears to be mediated by a 5-HTi-like receptor other than the 5-HTia receptor.
The observations that 5-HT can inhibit the AHP is in contrast to the work with
noradrenaline in the DRN. Application of noradrenaline or the a i-agonist,
phenylephrine, not only caused a membrane depolarisation, but also augmented the
duration of the AHP so that the cell took longer to return to its membrane potential
(Freedman and Aghajanian 1987). Both these effects appear to be due to
enhancement of the apamin-sensitive component of the AHP. The a i-adrenoceptors
are positively coupled to phosphoinositide turnover (Brown et al 1984) which can
lead to a mobilisation of internal calcium stores (Pan et al 1994). This results in the
increase of the concentration of intracellular calcium, which may lead to an
enhancement of the apamin-sensitive, calcium activated SK channels. This may
serve to regulate the activity of neurones during noradrenaline-evoked
depolarisation; this is also mediated by the ai-adrenoceptor (Yoshimura et al 1985).
The neurotransmitter noradrenaline, through the activation of the a i-adrenoceptor,
has been shown to modulate a number of potassium conductances in the DRN (Pan
et al 1993). Noradrenaline acting via ai-adrenoceptors increased the size of the fast
potassium-current, Ic- Noradrenaline can also evoke a membrane depolarisation
associated with an increase in input resistance due to the closure of potassium
channels. This results in an increase in cell firing due to a membrane depolarisation,
but also an inhibition of cell firing frequency due to the increase in size and duration
of the AHP. Pan et al (1993) concluded that the manipulation of the AHP by
noradrenaline might serve to regulate cell activity during the membrane
depolarisation.
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5-HT has the opposite effect to noradrenaline, its causes a membrane
hyperpolarisation and decreases the duration of the AHP by increasing the rate of
decay. This is probably due to the modulation of the calcium channel mediated by 5-
HTia receptors. However, the 5-HT modulation of the SK channels directly cannot
be ruled out. This may serve to regulate the activity of neurones during 5-HTiA-
evoked hyperpolarisation. These opposing actions may be important in maintaining
the rhythmical firing pattern of a cell showing pacemaker activity allowing it to keep
its regular firing pattern.
Firing frequency
The AHP can regulate firing frequency by delaying the return to the threshold
membrane potential, the AHP is modulated by 5-HT and so can modulate firing
frequency. Further to this, 5-HT can modulate firing frequency in other ways. Bath-
application of 5-HT increased the number of action potentials fired during a long
depolarising current step and decreased the AHP. It may be that WAY-100635 can
block the 5-HT-evoked increase in firing rate. However, the AHP was reduced by 5-
HT application. This indicates that the activation of the 5-HT]A receptors modulates
the firing rate ofDR neurones. However, the AHP created following a train of spikes
seems to be unaffected by the 5-HTiA receptor blockade. There is other evidence for
the AHP following a train of action potentials being different from that following a
single spike. This is in contrast to the AHP that follows a single action potential,
which decays more quickly in the presence of 5-HT, the effect is blocked by pre-
application ofWAY-10063 5. This could mean that the calcium channels modulated
by the 5-HTiA receptor have only a minor or no role in the maintenance of the AHP
following a train of action potentials. In conclusion, 5-HT can increase the firing
frequency of a train of action potentials by a 5-HTi A mediated action which may be




DRN neurones do not typically show spike accommodation, adaptation or burst
firing, all properties consistent with a neurone that shows pacemaker activity.
Following bath-application of TEA the firing rate of the neurone increased and the
cell showed adaptation. This shows that a TEA-sensitive potassium current is
important in regulating spike frequency.
Apamin-sensitive SK channels have been identified as important in the regular,
single spike firing pattern characteristic of the pacemaker activity observed in the
cells of the DRN. Blockade of the SK channels with apamin changed the cell-firing
pattern. A DRN neurone normally responds to a long depolarising current step with a
series of regularly spaced action potentials. Following exposure to apamin, DRN
neurones fired a high frequency train of action potentials that resembled a burst. The
train of action potentials had a number of characteristics. Spike height was reduced
in each successive spike. There was also a progressive increase in the interspike
interval. This is accommodation and does not normally occur in the absence of
apamin. DRN neurones also showed adaptation, the cessation of firing during the
injected current pulse, in the presence of apamin. This is characteristic of a burst
firing pattern. A small number ofDRN neurones show burst firing and the SK
channels may act as the switch between the two states. When the SK channels are
active a cell fires a regular firing pattern, when blocked the cells fires action
potentials in a burst. Burst firing may be an important mechanism for increasing the
amount of 5-F1T released, as burst firing is an efficient mechanism to release large
amounts of transmitter.
The ability to show firing accommodation and adaptation was also investigated with
TEA. Following the application of TEA cells showed an increase in cell firing
frequency and firing adaptation, but not accommodation. The late phase of the AHP
was also inhibited so that the cell returned to its resting membrane potential more
quickly. This is in contrast to the observations seen in the single spike. This may
163
indicate that the mechanisms involved in generating the AHP following a single
spike are different to those following a train of spikes.
The interspike period allows the cell time to remove sodium ions, which flood into
the cell during the action potential, and the transport of potassium ions into the cell to
recover the resting ion concentrations. This period also allows time for the sodium
channel to recover from inactivation. This allows the cell to show a repetitive-firing
pattern for long periods of time without rundown, which is also important for
pacemaker activity.
In cells of cultured skeletal muscle a long lasting AHP allows prolonged and regular
repetitive discharge to a constant depolarising current by clamping the membrane to
negative potentials between each action potential, this the allows sodium channels
enough time to recover from inactivation (Barrett et al 1981). By blocking the
opening of SK channels with apamin to give an AHP with a reduced duration the
DRN neurone was observed to no longer demonstrate pacemaker-like activity. The
apamin treated neurone could not generate its typical train of regularly firing action
potentials in response to a long depolarising current step. The DRN neurones fire a
burst of high frequency action potentials and then became silent. The control of
repetitive discharge of spikes has also been described in vitro in bullfrog sympathetic
ganglion cells (Pennefather et al 1985), in guinea pig neurones of the olfactory cortex
(Constanti and Simm 1987), in rat hippocampal neurones (Lancaster and Nicoll
1987) and in the neurones of the sensorimotor cortex of the cat (Schwindt et al
1988). This is similar to that observed in the DRN where the SK channels are
blocked with apamin. This indicates that SK channels are involved in regulating
firing frequency in the DRN as in other neuronal cell types.
There is evidence for a low level of burst firing within the DRN although the single
regular spike associated with pacemaker activity is more commonly observed. An
electrophysiological study performed in vivo by Wang and Aghajanian (1982) using
the extracellular technique found evidence for spike trains in the anaesthetised rat.
They found that these trains were made up of pairs of spikes with a short time
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interval. They assumed this was the result of two closely positioned cells firing in
synchrony. More recent work, also performed in the anaesthetised rat, suggests this
evidence may be due to one cell firing a burst of two action potentials (Hajos et al
1995). They noticed that a sub-population of cells fired two (sometimes three or
four) spikes in quick succession and that each subsequent spike was smaller in
amplitude. They also found that any cell firing trains of spikes did not change to
firing single spike or vice versa. This resembles the cell when under the influence of
apamin indicating that the blockade of apamin-sensitive SK channels may act as a
switch between a cell with a single and regular action potential firing pattern to a cell
with a burst firing pattern. This study has also shown that 5-HT can modulate the SK
channel and so may be part of the switching mechanism.
The importance of the burst firing pattern, the interburst interval and the excitation-
coupled release of neuropeptide has been investigated in the isolated rat neural lobe
(Cazalis et al 1985). They found that the interspike intervals in a burst and the
duration of silent periods between bursts are both important determinants of the
effectiveness of a burst pattern in promoting neuropeptide, in this case vasopressin,
release. Cells firing spikes with an interburst interval released more vasopressin than
when firing a similarly sized burst of spikes with no interburst interval. This means
that the amount of neurotransmitter or hormone released from a cell can be
determined in a number ofways and not just from the number of spikes. The regular
firing of a single action potential gives a tonic release of transmitter from DRN
neurone. Burst firing and the pattern of burst firing may be a mechanism for
releasing extra 5-HT or altering the pattern of 5-HT release. Cazalis et al (1985) also
showed that most neuropeptide is released in the early part of the burst. This
corresponds to the evidence of burst firing in the DRN where each successive action
potential is shorter in amplitude.
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Functional aspects of 5-HT's complexity of actions
5-HT has now been demonstrated to have a range of effects in the DR neurone:
• A 5-HTiA-mediated membrane hyperpolarisation (Aghajanian and VanderMaelen
1982);
• A 5-HTiA.mediated inhibition of calcium currents (Penington and Kelly 1990);
• A 5-HT2A-mediated membrane depolarisation;
• A 5-HT-evoked inhibition of the AHP;
• A 5-HT-evoked enhancement of firing frequency.
However the physiological function of this range of 5-HT-evoked actions is unclear.
A study by Andrade and Nicoll (1987) first highlighted the complex series of actions
of 5-HT in the pyramidal neurone of the CA1 region of the hippocampus. They
noticed 5-HT had multiple effects including a 5-HTiA-mediated hyperpolarisation
leading to a 5-HT-evoked depolarisation, both due to activity at different potassium
channels and a 5-HT-evoked blockade of the AHP. The blockade of the AHP by 5-
HT reduced spike frequency adaptation and counteracted the inhibitory action of the
5-HTiA-mediated hyperpolarisation. From these observations Andrade and Nicoll
came to believe that 5-HT can influence the activity of a neurone in subtle ways
leading to a pattern of activity that is both intensity and time dependent. 5-HT may
be acting to control the way pyramidal neurones integrate incoming synaptic inputs.
In other words the multiple actions of 5-HT allow pyramidal neurones to pass on
only significant synaptic inputs.
In a more recent study by Bayliss et al (1997) the effects of 5-HT on caudal raphe
neurones was investigated paying particular attention to calcium channels and the
AHP. Their data indicated that 5-HT can inhibit N- and P/Q-type calcium currents
mediated by the 5-HT)A receptor via pertussis-sensitive G-proteins. They also
showed that 5-HT could cause a decrease in the spike AHP and an enhancement of
the repetitive firing response to injected current pulses. They concluded that the
physiological significance of the decrease in the AHP and increase in the firing
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response to current inputs evoked by 5-HT would be to enhance the effects of brief
supra-threshold synaptic inputs. They also thought that this effect coupled with the 5-
HTiA-evoked hyperpolarisation, which would gate out smaller synaptic inputs by
moving the cell away from the threshold potential, would be to enhance strong
synaptic inputs and inhibit weak synaptic inputs onto the caudal raphe neurone. In
effect, the actions of 5-HT on the caudal raphe neurone would be to increase the
signal-to-noise ratio of the synaptic input-firing frequency transfer function. The
observations of the actions of 5-HT in the caudal raphe neurone are similar to those
observed in the DRN neurone. The DRN neurone shows a 5-HTiA-mediated
membrane hyperpolarisation and inhibition of calcium currents. There is 5-HT2A-
evoked depolarisation in the DRN neurone. 5-HT can also decrease the duration of
the AHP and increase firing frequency. It maybe that the 5-HTiA-mediations of 5-HT
are not to simply inhibit cell firing, but are indeed to filter out background synaptic
inputs which should generate postsynaptic events. The 5-HT2A-mediated
depolarisation may be acting to enhance the intermediate synaptic event. Overall, the
combined actions of 5-HT ensure to control which synaptic events the DRN




The receptor binding profile ofWAY-100635. Competitive studies were performed
to calculate the Kj values which were displayed as means ± S. E. of at least two
experiments.
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